University of Kentucky

UKnowledge
Theses and Dissertations--Chemistry

Chemistry

2013

Understanding multidrug resistance in Gram-negative bacteria -- A
study of a drug efflux pump AcrB and a periplasmic chaperone
SurA
Meng Zhong
University of Kentucky, meng_raul7@hotmail.com

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Zhong, Meng, "Understanding multidrug resistance in Gram-negative bacteria -- A study of a drug efflux
pump AcrB and a periplasmic chaperone SurA" (2013). Theses and Dissertations--Chemistry. 17.
https://uknowledge.uky.edu/chemistry_etds/17

This Doctoral Dissertation is brought to you for free and open access by the Chemistry at UKnowledge. It has been
accepted for inclusion in Theses and Dissertations--Chemistry by an authorized administrator of UKnowledge. For
more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained and attached hereto needed written
permission statements(s) from the owner(s) of each third-party copyrighted matter to be
included in my work, allowing electronic distribution (if such use is not permitted by the fair use
doctrine).
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive
and make accessible my work in whole or in part in all forms of media, now or hereafter known.
I agree that the document mentioned above may be made available immediately for worldwide
access unless a preapproved embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s dissertation
including all changes required by the advisory committee. The undersigned agree to abide by
the statements above.
Meng Zhong, Student
Dr. Yinan Wei, Major Professor
Dr. John Anthony, Director of Graduate Studies

UNDERSTANDING MULTIDRUG RESISTANCE IN GRAM-NEGATIVE
BACTERIA--A STUDY OF A DRUG EFFLUX PUMP ACRB AND A PERIPLASMIC
CHAPERONE SURA

_____________________________________
THESIS
_____________________________________

A thesis submitted in partial fulfillment of the requirements
for the degree of Doctor of philosophy in the College of
Arts and Sciences at the University of Kentucky

By
Meng Zhong
Lexington, KY
Director: Dr. Yinan Wei, Professor of Chemistry
Lexington, KY
2013
Copy Right © Meng Zhong 2013

ABSTRACT OF THESIS

UNDERSTANDING MULTIDRUG RESISTANCE IN GRAM-NEGATIVE
BACTERIA--A STUDY OF A DRUG EFFLUX PUMP ACRB AND A PERIPLASMIC
CHAPERONE SURA
Multiple drug resistance (MDR) has been a severe issue in treatment and recovery from
infection.Gram-negative bacteria intrinsically exhibit higher drug tolerance than Grampositive microbes. In this thesis, two proteins involved in Gram-negative bacterial MDR
were studied, AcrB and SurA.
Resistance-nodulation-cell division pump AcrAB-TolC is the major MDR efflux system
in Gram-negative bacteria and efficiently extrudes a broad range of substances from the
cells. To study subtle conformational changes of AcrB in vivo, a reporter platform was
designed. Cysteine pairs were introduced into different regions in the periplasmic
domain of the protein, and the extents of disulfide bond formation were examined. Using
this platform, an inactive mutant, AcrB∆loop, was created that existed as a well-folded
monomer in vivo. Next, random mutageneses were performed on a functionally
compromised mutant, AcrBP223G, to identify residues that restored the function loss. The
mechanism of function restoration was examined.
SurA is a periplasmic molecular chaperone for outer membrane biogenesis. Deletion of
SurA decreased outer membrane density and bacterial drug resistance. The dependence of
SurA function on structural flexibility and stability was examined. In addition, the effect
of molecular crowding on SurA interaction with its outer membrane protein substrates
was examined.
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CHAPTER I. INTRODUCTION
1.1 A Brief History of Antibiotics Development
Long before the invention of the word “antibiotic”, application of mold and plant extracts have
been documented in disease treatment in ancient Greek and ancient Egypt.1 In 1928, Alexander
Fleming discovered the bactericidal property of penicillin in a staphylococcus aureus plate,
suggesting that a particular group of compounds extracted from microbes could be used to treat
infection effectively.2 This kind of compounds were later named antibiotic. The urgent need of
antimicrobials in treating wounded soldiers in World War II stimulated the beginning of the
antibiotic era.3 Till 1960s, more than 100 antibiotics became commercially available and were
used extensively in the treatment of infectious disease.4 This period of time was considered as
the golden age of antibiotics.
Based on the mechanism of action, antibiotics are categorized into several classes. Antibiotics
can be bactericidal or bacteriostatic through inhibiting the synthesis of cell wall, DNA, RNA,
and protein, cell growth, and cell division.5-8 Table 1.1 listed major classes of antibiotics and
their working mechanisms.5-10 At the beginning, antibiotics were mostly natural products isolated
from microorganisms. Later compounds derived or synthesized from natural products were used.
Finally, taking advantage of the structures of known natural products, scientists successfully
designed and synthesized a great variety of antibiotics by substituting different functional
groups.11-13 Despite the remarkable success in exploring the natural product scaffolds, the pace of
the advancement of antibiotic development slowed down in 1960s.14, 15 The pre-existed drug
resistance of structurally related antibiotics killed most new antibiotics in the cradle. The partial
to complete failures in the mining of novel antibiotics drove away most pharmaceutical
companies and financial investments.16-18 As a result, no new class of antibiotics was developed
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from 1962 to 2002. Since 2002, only four new classes of antibiotics have been approved and are
available commercially. 19-22
Table 1.1 List of Antibiotics by their classes and mechanisms of action.5-10
Classes

Examples

Mechanism

Aminoglycosides

Gentamicin, Kanamycin,

Bind to ribosome subunits, inhibit protein

Neomycin, Spectinomycin

synthesis, and disrupt bacterial cell membrane

β-lactam

Penicillin, Cephalosporins,

Inhibit bacterial cell wall synthesis

antibiotics

Carbapenems

Glycopeptides

Vancomycin, Teicoplanin

Inhibit peptidoglycan synthesis in bacterial
cell wall

Lincosamides

Lincomycin, Clindamycin

Bind to 50s subunit of ribosome, inhibit
protein synthesis

Lipopeptides

Daptomycin, Polymixin B

Bind to bacterial membrane, inhibit protein,
DNA, and RNA synthesis

Macrolides

Erythromycin,

Bind to 50s subunit of ribosome, inhibit

Azythromycin

protein synthesis

Oxazolidonones

Linezolid, Torezolid

Inhibit protein synthesis

Polypeptides

Bacitracin, Colistin

Alter gram negative bacterial outer membrane
and cytoplasmic membrane permeability

Quinolones

Ciprofloxacin, Levofloxacin

Inhibit DNA replication and transcription

Sulfonamides

Sulfadiazine, Sulfisoxazole

Inhibit folate synthesis

Tetracyclines

Tetracycline, Doxycycline

Bind to 30s subunit of ribosome, inhibit
protein synthesis
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1.2 Current Situation of Multiple Drug Resistances
Since the discovery of penicillin, antibiotics were considered as “magic bullets” in curing
infectious diseases. They have been misused and abused in the clinical treatment. For example,
antibacterial drugs were inappropriately prescribed to patients with viral infection due to
misdiagnosis. Premature cessation of therapy failed to eradicate the pathogens, instead provoking
resistance in the surviving bacteria. Additionally, in some countries, especially developing
countries, antibiotics are sold as over the counter drugs without prescription. Another major
factor that causes drug resistance is the large scale usage of antibiotics in animal farming which
later consumed by human and accumulated in food chain.23-26 Consequently, microbes developed
cross-resistance to a series of structurally and functionally unrelated drugs. In the past decade,
multidrug resistance (MDR) has been found toward all available antibiotics, presenting one of
the biggest threats to public health.
In the pre-antibiotic era, antibiotic resistance was only identified in a very small portion of
bacterial strains that have intrinsic and constitutive high drug tolerance, such as Pseudomonas
aeruginosa.27, 28 Gradually, usage of antibiotics served as an environmental selective pressure to
select for strains with elevated drug tolerance. Mutations may first occur as random errors in
replication. Bacteria with higher drug resistance were able to survive. Those genes who confer
high antibiotic resistance were amplified and accumulated in pathogens under the selection
process.29 The horizontal transfer of genetic materials enables the wide spread of resistance. The
resistant genes can be transferred by naked DNA transformation, phage-mediated transduction
and cell-to-cell conjugation.30 MDR is often found in organisms that acquired plasmids encoding
genes for multidrug resistance.
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Undoubtedly, the prevalence of MDR increased the morbidity, mortality of bacteria infection,
making the treatment more difficult. In 2010, Center of Disease Control reported that bacterial
infection results approximately 30,000 deaths each year in the United States. It is estimated that
annual cost to treat infections of six major bacteria was over $1.87 billion.31 nowadays, the
increasing frequency of communication between countries makes MDR an international
epidemic problem. Every year, species with new antibiotic resistance are identified and spread
all over the world, attracting great public concern. The word “superbug” becomes more and more
prevalent. Methicillin resistant Staphylococcus aureus (MRSA) is one of the most well-known
examples of superbug. Surveys conducted in 2006 estimated more than 53 million people were
carriers of MRSA globally, and the number is increasing each day.32 Another alarming example
is the fast spread of New Delhi metallo-beta-lactamase-1 (NDM-1) gene in a variety of strains of
bacteria. It was first detected in colonies of Klebsiella pneumonia in India. Within a year, it has
been found in more than 30 countries. So far, three years since the detection of the first case,
effective treatment for infections caused by bacteria harboring NDM-1 gene is still lacking.33, 34
Most

recently,

it

is

reported

that

another

deadly

superbug,

carbapenem-resistant

Enterobacteriaceae (CRE) was found in Virginia in December 2012. The mortality of infections
caused by CRE can be as high as 40%.35 These superbugs present great challenge in the
treatment of bacterial infection. Unfortunately, under current medical condition, there is still a
shortage of valid methods to combat superbug infection. Numerous efforts have been devoted in
conquering this problem. Many strategies have been developed targeting different mechanisms
of bacterial drug resistance.

1.3 Mechanisms Of Resistance To Antibacterial Agents
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Multiple biochemical factors contributed to the fast spread of the MDR, presenting tremendous
challenges in the fight against infectious diseases. There are five major mechanisms from which
microbes acquire drug resistant. (Figure 1.1)36 First, an organism can gain resistance to a drug
target via mutation or enzymatic alteration. For example, due to an alteration of the ribosomal
target, Acinetobacter developed resistance to two aminoglycosides: streptomycin and
spectinomycin.37 An additional example is MRSA. Acquisition of mecA gene helped express
penicillin-binding protein 2a which cannot interact with methicillin or other β-lactam antibiotics,
thereby leading to extremely strong drug tolerance.38 Second, some drugs are inactivated by
enzymatic degradation and modifications. The inactivation could be achieved by hydrolysis,
group transfer, and redox mechanism.39 Till now, more than 200 different β-lactamases have
been identified, which is the major reason for resistance of β-lactam group antibiotics.40 Third,
bypass of the inhibited mechanism of antibiotics conferred high drug resistance to certain group
of antibiotics.41 One of the well-studied examples is a glycopeptide, vancomycin. Vancomycin
inhibits cell wall synthesis by binding to the D-Ala-D-Ala in the pentapeptide of peptidoglycan.
Vancomycin-resistant Enterococcus reprograms the synthesis pathway to produce D-Ala-D-Lac,
so that the binding affinity of vancomycin to the peptide is reduced by 1000-fold.42 Fourth,
overexpression of drug targets exhibits titration effects on antibiotics, leading to reduction of
drug efficiency. Fifth, drug penetration can be slowed down or inhibited by certain group of
proteins and cell walls. For instance, multidrug efflux pumps can export a broad spectrum of
compounds, including antibiotics, dyes, detergents, fatty acids, biocides, and organic solvents.43
A low permeability barrier can provide a shield in order to decrease the influx of different
drugs.44 Among these five mechanisms, the first four mechanisms are specific towards a single
drug or drugs with similar structures, while the last mechanism apply more generally. Therefore,
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the latter mechanism is more difficult to target, which is my main research focus in this thesis.
Moreover, microbes may employ more than one mechanism, making it even more challenging to
combat multidrug resistance.

Figure 1.1 Mechanisms confer antibiotic resistance in bacteria.45 Reprinted by permission from
Macmillan Publishers Ltd: Nat. Rev. Drug. Discover., ©2002

1.4 Gram Negative Bacterial Infection vs Gram Positive Bacterial Infection
Bacteria can be grouped into Gram-negative and Gram-positive strains based on Gram staining.
Gram-negative bacteria are those that do not retain crystal violet dye after staining.
6

The

difference between the two groups of bacteria lies in their cell walls (Fig. 1.2).46 Gram-positive
bacteria cells are covered with a thick layer of peptidoglycan, whereas Gram-negative bacteria
have a more complex cell envelope structure. Gram-negative bacterial cell wall contains two
phospholipid membranes, between which lies a thin intermediate layer of peptidoglycan.
Lipopolysaccharide is bound to the outer leaflet of the outer membrane and stablizes the entire
membrane structure. The non-covalent linkage between lipid A and divalent cations is highly
polarized, preventing the entrance of hydrophobic molecules. At the same time, the high
hydrophobicity of the phospholipid bilayer slows down the penetration of hydrophilic
compounds.47 The extra layer provides such a good protection that 90% of antibiotics effective
against Gram-positive bacteria showed much lower activity against Gram-negative bacteria.48
Additionally, a large group of inner and outer membrane proteins embedded in the two
membranes. The majority of outer membrane proteins (OMPs) served as transportation channels
for small hydrophilic substances. Some of the outer membrane proteins assemble together with
inner membrane proteins to selectively pump out a broad range of compounds out of the cells.
Therefore, these proteins could potentially be drug targets in combating MDR in the bacteria.
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Figure 1.2 Cell envelope of Gram-negative (left) and Gram-positive (Right) bacteria.46
Reprinted by permission from Macmillan Publishers Ltd: Nat. Chem. Biol. (1) © 2011

1.5 Bacterial Multidrug Efflux Pump
Based on sequence homology, bacterial efflux system can be grouped into five classes49: a) The
major facilitator (MF) superfamily, also known as uniporter-symporter-antiporter family.
Transporters in the MF family are the dominate substance excluding pumps in Gram-positive
bacteria. They are responsible for transporting small solutes powered by chemiosmotic ion
gradient. b) The ATP-binding cassette (ABC) family. Hydrolysis of adenosine triphosphate
(ATP) provides energy for both the uptake and efflux of small molecules and macromolecules. c)
The small multidrug resistance (SMR) family. These transporters shared a similar structure
containing four transmembrane helices and driven by proton motive force. d) The multidrug and
toxic compound extrusion (MATE) family. The efflux of this group of transporters is mediated
by sodium gradient. e) The resistance-nodulation-division (RND) family, which is the major
contributor to drug resistance in Gram-negative bacteria.50 My research is focused on exploring
structure and assembly of one of the most extensively studied RND pump, AcrAB-TolC.

1.6 AcrAB-TolC Tripartite Efflux Pump
AcrA, TolC in AcrAB-TolC system
AcrAB-TolC is one of the most extensively studied Gram-negative RND pump. In the complex,
AcrA is a membrane fusion protein that facilitates the interaction between AcrB and TolC, and
assembly of the entire pump. The α-helical hairpin domain of AcrA is the TolC binding domain.
The exact interface of AcrA and AcrB remains unknown, but the α-β-barrel domain on AcrA is
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thought to be the AcrB binding domain. AcrA may exist as a trimer or hexamer in vivo, which
remains controversial .51
TolC is the outer membrane component of the pump and the final exit of the substrates. It is a
trimeric protein composed of three 428-residue protomers. TolC trimer forms a long tunnel-like
structure of 140 Å in length, transversing the entire outer membrane and the majority of the
periplasmic space (Fig. 1.3). The transmembrane domain of TolC is consisted of 12 anti-parallel
β-strands. They forms a 40 Å long β-barrel tunnel. The periplasmic part is composed of 12 αhelices, extending about 100 Å into the periplasm. The internal diameter of TolC is 35 Å. When
TolC is recruited by an inner membrane complex, conformational rearrangements in the inner
H7/H8 coiled coils and the outer H3/H4 coiled coils are induced. This opens the tunnel by
approximately 30 Å, allowing the protein to transport molecules as large as full-length proteins.52
Besides its role in the AcrAB-TolC tripartite efflux system, TolC is associated with several other
inner membrane translocase complexes to export a large variety of substrates out of the cell,
including enzymes, metals, antibiotics and toxins.53, 54
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Figure 1.3 A) crystal structure of outer membrane protein TolC. Each protomer of TolC trimer is
marked in different color. The 40 Å β-barrel domain is embedded in the outer membrane, while
the 100 Å α-helical domain inserted into the periplasm. B) Top view of close-state (Top) and
open-state confirmation (bottom) of TolC. Open-state of TolC allows passage of substances.
Crystal structures were obtained from protein data bank. Protein data bank ID of close-state
structure: 1TQQ, open-state structure: 2VDD. Structures created using Pymol.

AcrB in the AcrAB-TolC system
The third component in the AcrAB-TolC efflux pump is the inner membrane protein, AcrB.
AcrB is the engine of the pump. It determines substrate specificity and provides the energy to
drive the pump. So far, the substrates of AcrAB-TolC include antibiotics, detergents, dyes and
organic solvents.55
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The AcrB gene was first discovered during a genomic screen conducted by Nakamura et al. in
1978. Upon its deletion, the cell became hypersensitive to acriflavine. It was the second protein
identified which caused elevated cell sensitivity to acriflavine. This is why the protein was
named AcrB.56 It was not until 1990s that scientists began to realize its crucial role in drug
resistance. Since then, the protein has been studied extensively.
The crystal structure of AcrB was first solved by Yamaguchi and his group in 2002. AcrB is a
trimeric protein, of which each protomer containing 1049 amino acids. The overall shape of
AcrB is like an asymmetric jellyfish. The scheme of the arrangement of secondary structure
elements in a single protomer was shown in Fig 1. 4. 57

Figure 1. 4 Topology of a single protomer of AcrB. Secondary structures were indicated by
cylinder (α-helic) and arrow (β-strand). Pore domain is divided into four regions: PN1, PN2, PC1,
and PC2. TolC docking domain is composed by two subdomains, DN and DC. Two periplasmic
loops lies in between TM1 and TM2, TM7 and TM8, respectively.
from Macmillan Publishers Ltd: Nature (419) ©2002
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57

Reprinted by permission

Each monomer AcrB contains 12 transmembrane (TM) α-helices and two large hydrophilic
periplasmic loops. The two periplasmic loops reside in between TM1 and TM2 and TM7 and
TM8, respectively. The periplasmic region of AcrB can be divided into two parts, the TolC
docking domain and the porter domain, based on proposed functionality. The overall length of
the AcrB periplasmic head piece is approximately 70 Å, of which the porter domain is 40 Å in
length. The two subdomains between TM1 and TM2 were named PN1 and PN2; while the other
two subdomains between TM7 and TM8 were PC1 and PC2. In AcrB trimeric state, PC1 and
PC2 subdomain are at the outside surface. Though how AcrB interacts with AcrA remains
unknown, it is often believed the cleft between PC1 and PC2 is the AcrA association region.
Between PN2 and PC2 subdomains there are open vestibules which are later proven to be the
central cavity for substrate binding. At the top of AcrB structure, 8-stranded β-sheets form TolC
docking domain. In each monomer, an antiparallel β-sheet loop extends approximately 35 Å and
inserted into the neighboring AcrB (Fig 1.5).57 Our group demonstrated that this protruding loop
is essential for the stabilization of AcrB trimer. Deletion of a fragment of the loop led to
dissociation of trimeric AcrB and accumulation of inactive monomer AcrB, resulting in
compromised drug resistance.58 The bottom α-helix-turn-α-helix structure of TolC seems to fit
perfectly with the tip of the TolC docking domain of AcrB through manual fitting.59 The
transmembrane domain is formed by 12 α-helices of 50 Å.59 Asp407, Asp 408, Lys940 were
buried in TM4 and TM10. These charged residues formed ion pairs which were involved in
proton translocation.60
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C)
Figure 1.5 A) Crystal structure of a single AcrB monomer. (Protein data bank ID: 1IWG). B)
Assembly of AcrB trimer. Based on the function and position, AcrB is divided into three
domains: TolC-docking domain (30 Å), Pore domain (40 Å), and Transmembrane domain (50 Å).
Structure was drawn by Pymol from 2GIF in protein data bank. C) Top view of boundaries
between each protomer in AcrB oligomer.56 Reprinted by permission from Macmillan Publisher
Ltd: Nature (419) ©2002

The conformational differences between each protomer were observed in the trimeric AcrB.
From the observation, a three-stage functional rotation mechanism was postulated by two
different groups at approximately the same time.61,

62

Each monomer exhibits different

confirmation upon different substrate activity: Access, Binding and Extrusion, which
corresponding to Loose (L), Tight (T) and Open (O) in the other literature (Fig. 1.6). The
transition of each monomer between different states is driven by proton relay. In the access state,
the vestibule between PN2 and PC2 subdomains is open and accessible to substrates. Substrates
enter the vestibule from periplasm or the groove at the top of TM8 and TM9, and bind loosely to
the protein. In the binding state, the binding pocket expanded so that substrates could further
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move upwards into the extended deep substrates channel. At this stage, the vestibule remains
open and the central α-helix tilted approximately 15° towards the PN2 subdomain, which blocks
the exit pathway. Finally, incline of the central helix in the extrusion state opened the exit and
allowed the substrate to be excluded from the pump. The confirmation change from binding state
to extrusion state required energy, which is generated from proton gradient force. 61, 62

Figure 1.6 Schematic illustrations of substrate and proton pathways in the functionally rotation
mechanism of AcrB.63 When substrate enter AcrB pathway, three states of confirmation is
induced: access, binding, and extrusion. The top views are from the periplasmic region of AcrB.
Substrate and proton uptaken process are noted by dotted lines. Reprinted from Curr Opin Struct

15

Biol 18, Murakami, S. Multidrug efflux transporter, AcrB--the pumping mechanism. 459-465
©2008, with permission from Elsevier.

The pump transports substances from low concentration to high concentration, and hence energy
is needed for the efflux of AcrAB-TolC. Proton motive force is primary energy source. Three
amino acids, Asp407, Asp408, and Lys940 are crucial in the proton translocation pathway.
Substitutions of each of the three residues with alanine lead to complete function loss of the
pump.57, 64 The three residues exhibit different configuration in each state of substrate efflux. In
the access and binding states, Asp407 and Asp408 form a salt bridge with Lys940. When the
protomer shifts to extrusion state, the salt bridge is dissociated and Lys940 forms hydrogen bond
with another highly conserved residue Thr978. At this time, Asp407 and Asp408 are exposed so
that they can interact freely with proton. It was proposed that energy released from twisting in
transmembrane α-helices would lead to further conformational change in porter domains.57
However; the exact mechanism of how the energy induces structural change is still unknown.
Exploration of the interaction between AcrB and its substrates is another active topic of research.
Switching the periplasmic domain of AcrB and AcrD altered the substrate specificity of the two
pumps, indicating the substrate specificity is determined by the periplasmic loop.65 Next,
mutagenesis studies identified a phenylalanine rich hydrophobic binding pocket, containing
Phe178, Phe610, Phe615, Phe617, Phe664 and Phe666.66 The position of the interaction site was
consistent with Murakami and co-workers’ finding by X-ray crystallography. Using Nile Red
efflux assay, AcrB substrates are divided into two groups judging by their interacting sites: cave
binders and groove binders.67 Both sites are located in the binding pocket. This allows the pump
to accommodate two kinds of substrates at the same time. Recently, the Bodipy-FL-maleimide
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labeling assay was used to picture the complete substrate transportation pathway. AcrB
substrates first entered from the lower cleft at TM8/TM9 groove and then bound to the deep
binding pocket (Fig. 1.7).68, 69

Figure 1.7 Substrate pathways in AcrB periplasmic loop. Residues showed positive results in
Bodipy-FL-maleimide labeling or CPM/pyrene-maleimide assay were mapped in the AcrB
protomer as spheres. Deep blue residues are at the exit gate of AcrB, while light blue residues are
in the binding pocket. Orange and purple indicated residues are in the upper and lower region of
cleft, respectively.68 Reprinted from Molecular Microbiology, 78, 320-330 © 2010 by John
Wiley and Sons

Due to the technical difficulty in crystallography, a complete crystallographic structure of the
AcrAB-TolC complex has not been determined. The interactions between each subunit have
been investigated by mutagenesis coupled with drug susceptibility assay, crosslinking, and
computer modeling. An AcrA3-AcrB3-TolC3 model has been proposed.59 The tripartite complex
17

is 610,000 Da, 270 Å long, spanning across the entire cytoplasmic membrane and outer
membrane. The α-hairpin of AcrA is docked with the coiled-coil helices in TolC. AcrA Cterminus (residue 315-397) is involved in interaction with AcrB. It is reported both AcrA and
TolC could interact with AcrB independently with high affinity, which is not affected by the
third component and substrates.51, 59 However, it has been shown that addition of substrates could
help stabilize the whole complex.63

Figure 1. 8 Assembly of TolC3-AcrA3-AcrB3 tripartite efflux pump by computer modeling.59
Positions of outer membrane and inner membrane are indicated. Different colors were used to
differentiate domains of TolC (Orange, yellow, and grey), AcrA (bright green), AcrB (blue, grey,
and green). Figure adapted from Symmons, M. F., et al. The assembled structure of a complete
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tripartite bacterial multidrug efflux pump. Proc Natl Acad Sci U S A 106, 7173-8. Copy right
(2009) National Academy of Sciences, USA.

1.7 Gram-negative Bacterial Outer Membrane Biogenesis
As mentioned in section 1.4, the outer membrane of Gram-negative bacteria offers a better shield
against antibiotics comparing to Gram-positive bacteria. The outer membrane of Gram-negative
bacteria is an asymmetric lipid bilayer with an outer leaflet made of lipopolysaccharide and an
inner leaflet of phospholipid. Integral outer membrane proteins reside in this bilayer structure.
More than sixty OMPs have been identified in Gram-negative bacteria, most of which form
transportation channels called porins. All OM porins share a β-barrel structure motif formed by
multiple β-strands. These β-strands form a hydrophilic pore in the center of the protein, which is
main channel for the translocation of hydrophilic compounds. The hydrophilic pores are very
narrow. For instance, the diameter of OmpF channel is approximately 10 Å. Only molecules
smaller than 600 Da can diffuse across the outer membrane through porins.70
These integral OMPs are first synthesized in cytoplasm with N-terminal signal peptide. Nterminus signal sequence directs the unfolded OMP precursors to the Sec translocon in the
plasma membrane. During or after the completion of the translocation, signal peptide is digested
by signal peptidase.71 Once the OMP precursors enter the periplasm, several chaperones help
stabilize and transport the polypeptides to their final destination. Eventually, these nascent
polypeptide chains fold into functional β-barrel proteins and insert themselves into the cell
envelope.72 Several periplasmic chaperones assist the folding and translocation process. For
instance, DsbA and DsbC catalyze the disulfide bond formation and protein oxidation.73 PPIase
accelerates Proline cis-trans isomerization. Because of the high hydrophobicity of the OMP
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polypeptides, several chaperones that could prevent the OMP polypeptides from aggregation in
the hydrophilic environment of periplasm are recruited. SurA, Skp and DegP have been
identified with this function.74

Figure 1.9 Translocation, folding and assembling of E. coli integral outer membrane protein
in the assistants of periplasmic chaperones, Sec translocon and Bam complex.75 Adapted
from Hagan, C. L. et al. Reconstitution of outer membrane protein assembly from purified
components. Science 328, 890-2. Reprinted with permission from AAAS©2010

The exact roles of these chaperones in OMP biogenesis are still under investigation. One
hypothesis is based on immunoprecipitation studies in SurA, Skp and DegP deficient strains.
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SurA and Skp/DegP are two parallel pathways in assisting OMP biogenesis. SurA is the primary
chaperone in helping the folding of the majority of OMPs. Those who fall off the SurA pathway
are rescued by Skp and DegP.76 Recently, another theory was proposed by Zhao et al. based on
kinetic study of chaperone and unfolded OMP. It is believed SurA and Skp act at the early stage
of the OMP folding while DegP serves as a final quality control role which helps the unfolded
OMP precursors at a later stage.77 DegP not only collaborates with Skp, but also with SurA
which forms a SurA–OMP–DegP ternary complex.

1.8 Periplasmic molecular chaperone SurA
SurA was first identified as an essential gene in Escherichia coli for stationary phase survival. It
is required for cells to tolerate the nutritional starvation phase. SurA is composed of 4 domains
following a signal peptide: an amino terminus domain with the first 150 amino acids, two
peptidylprolylisomerase domains of 100 residues each (P1 and P2 domain), and a carboxyl
terminus domain. Crystallographic structure showed that the N, C-terminal domain and the first
PPIase segment constitute a core module, while the second PPIase segment forms a satellite
domain about 30 Å away in distance (Fig. 1.10).
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Figure 1.10 Structure of SurA. The sequence of SurA was color-coded as signal peptide (white),
N-terminus domain (red), PPIase P1 domain (yellow), P2 domain (blue), C terminus domain
(green). Protein structure was from protein data bank 1M5Y. Structure created using Pymol.

It has been proven that deletion of SurA in E. coli induces the cell stress factor σE. σE factor
regulates the expression of OMPs.78 Recently, in a thorough LC-MS/MS analysis of OMP
abundance, only 8 of the 64 OMPs are negatively affected by SurA deletion. Decreasing levels
of six of the eight OMPs are caused by suppressed mRNA level. Major OMPs such as OmpF is
absent when SurA is knocked out. Expression level of LamB was reduced by 4- to 5- fold, while
the level of OmpC and OmpA dropped by 2- to 3- fold. The abundances of some OMPs, such as,
TolC and BamA, were elevated in the absence of SurA. Surprisingly, although only a small
subset of OMPs has been affected, the overall OM density of the cell is drastically reduced. This
is likely due to the high abundance of OmpF, OmpA, and LamB, which account for a large
fraction of the OM. The LC-MS/MS study further elucidated the role of SurA in outer membrane
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biogenesis. SurA is important to the folding and assembling of the majority of the OMPs. Most
OMPs interact with SurA, DegP and Skp, depending on their availability. But OMPs like LptD
and FhuA can only go through the SurA pathway in the periplasm. Another group of OMPs were
down regulated by SurA in vivo, the mechanism of which remains unknown. 79
SurA was first noticed for its sequence homology with the parvulin domain of PPIase. It was
originally believed to assist protein folding mainly by mediating the cis-trans isomerization of
proline. However, later experiments showed that the chaperone activity of SurA was independent
from its PPIase domains.80 Deletion of either P1 or P2 domain showed no effect on the ability of
cell to survive in the presence of nobobiocin. SurA N-teminus and C-terminus domains (SurA NC) are sufficient to restore membrane functionality and complete SurA activity in vivo.81
Substrate specificity of SurA has also been studied. Mckay et al. used phage display to identify
several peptides that interact tightly with SurA.82 Klappa and his group also selected multiple
peptides by enzyme linked immunosorbent assay (ELISA) screening of cellulose-bound library
peptides representing LamB, OmpF and OmpA.81 All these peptides shared a similar sequence
stereotype Ar-X-Ar. Ar stands for aromatic amino acids, while X can be any amino acids. Since
the frequency of Ar-X-Ar was the highest in OMPs among all E. coli cell surface proteins, there
is no doubt why SurA would preferentially bind with unfolded OMPs. Mckay and coworkers
further studied the interaction of SurA and the two peptides WEYIPNV (pepN) and
NFTLKFWDIFRK (pepC) using isothermal calorimeter (ITC).83 Both peptides interacted with
SurA with a binding affinity in µM range, which is the highest among all peptides tested. Also
the peptides competed with unfolded OmpF and OmpG in binding to the core structural fragment
of SurA. However, the co-crystallization of SurA-peptide showed pepN and pepC only interacted
with the first PPIase segment. Deletion of P1 domain drastically increased the binding affinity
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between SurA and peptide. Because PPIase domains are unrelated to SurA chaperone function,
the peptides bound to P1 domain may not be native substrates of SurA. The competition between
peptides and OMPs could be a result of the steric hindrance effect.
Later researches have linked SurA to different cellular activities. SurA, in collaboration with
BamB, is involved in folding of outer membranes exported not only from Sec pathway, but also
from twin arginine translocation (Tat) pathways.84 The outer membrane biogenesis in different
Gram-negative bacteria and mitochondria outer surface required SurA and its homologue.85
Moreover, SurA is essential in helping outer membrane protein folding in reconstituted OMP
assembling complex.75 Despite of all these progresses in the understanding of the function of
SurA, how SurA selects and interacts with its substrates remains unknown.
Immunoprecipitation studies revealed that SurA is highly related to the correct folding and
assembling of outer membrane proteins. When surA gene is knocked out from E. coli genomic
DNA, the cells are highly sensitive to hydrophobic drugs and membrane perturbants.80 It is
universally believed that this drug tolerance change caused by SurA deletion is affected by the
OMP density. But there is no direct proof that may correlate the two observations. Elucidation of
the relationship between SurA OM integrity and its role in cell permeability may offer a great
target in fighting against drug resistance in Gram-negative bacteria.

1.9 Actions In Response To Slow Down the Spread of Multidrug Resistance
Microbes reproduce at an extreme fast speed, usually with generation times measured in minutes.
This means that once drug resistance gene is generated, it can be transferred among the pathogen
species very quickly. Therefore, effective treatments at the onset of the infection are extremely
important in a clinical setting. The shortage of effective antimicrobials has raised significant
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concerns and attracted comprehensive research interests. Measurements have been adopted from
different aspects to address this global epidemic issue.
Several government agencies are sparing no effort on evoking awareness of the severe situation
of infection caused by antibiotic resistant pathogens, especially in developing countries. One of
the most straight forward approaches is to control the usage of antibiotics, not only in clinical
treatment, but also in farming and aquaculture. Rational use of antibiotics limited the
unnecessary exposure of microorganisms to antibiotics.86 Another important issue is to improve
the hygiene conditions in all affected areas. It has shown millions of dollars could be saved
simply by practicing good hand hygiene by clinicians.
Currently, cases of drug resistance towards all commercially available antibiotics have been
reported. Identification of new class of antibiotics is in urgent need. Historically, the majority of
antibiotics came from natural products extracted from microbes. Because of the limitation of
cultivation conditions, only 1% of bacteria have been studied. DNA samples from soil and
marine habitats have been isolated and sequenced, which opens up great opportunities of
discovering new antibiotics.14 Another direction of genomic hunting is high throughput screening
for essential genes for bacterial survival or targets in the crucial metabolic pathways.14 For
example, the key features in bacterium cell walls have been selected as targets. New
antimicrobial peptides have been tested which bind with lipopolysaccharide (LPS) on the outer
membrane to induce membrane distortion and increase permeability. However, this could only
enhance the influx rate of hydrophobic drugs.87 Furthermore, resistance in compliance with these
antimicrobial peptides has been reported. OMPs are also a group of vital targets in drug
penetration pathway. To increase the permeability of hydrophilic compounds, mutagenesis
studies on OMP channels have been reported, but they are specific to structurally related drugs.88
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In addition, it is impossible to mutate the OMP channels in the pathogen during the treatment.
There is no effective strategy to deal with drug resistance from this perspective.
Vaccines against bacteria have also been developed.89 The advantage of vaccines is there would
not be the resistance problem. However, it is unlikely to have vaccines against all available
disease related bacterial strains, not to mention the evolved second and third generation of
existing microbes. And the effects of different vaccines are still under investigation. Phage
therapy is also an alternative way to treat infection. But the method is relatively expensive since
multiple bacteriophages may be required at the same time. Additionally, the treatment has to be
monitored by physicians to ensure safety.90
As discussed above, my study in this thesis focuses on two proteins, a multidrug transporter and
a periplasmic molecular chaperone. Efflux pump has been served as the target for the design of
inhibitors. New efflux pump inhibitors have been tested as uptake enhancers to elongate the
retention time of drugs within the cells. MC-207, 110 (Phe-Arg-β-naphthylamide, PaβN) is the
first inhibitor of RND pump identified through the collaboration of Microcide Pharmaceuticals
and Daiichi Pharmaceutical Co.91 Because MC-207, 110 is a preferred substrate for the pump, it
will compete with other substrates in interacting with the pump. Therefore, when high
concentration of MC-207, 110 is used, the pump loses its extrusion ability to actively pump out
other desired antibiotics. Derivatives of this compound haven been used as inhibitors to reverse
drug resistance caused by mostly RND pumps, as well as particular efflux pumps in Grampositive bacteria. Antisense DNA and siRNA provide are an alternative therapy in preventing
mRNA translation and gene expression. Antisense phosphorothioate oligonucleotide
encapsulated in novel anion liposome targeting AcrB has successfully restored antibiotic
susceptibility in fluoroquinolone-resistant E. coli.92 In OMP biogenesis, generally OMPs are
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targeted in the fight against MDR. Still, little is known about how SurA and other chaperons
affect cell permeability. As a result, there is no reported inhibitor for OMP biogenesis.

Copyright © Meng Zhong 2013
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CHAPTER II. A REPORTER PLATFORM FOR THE MONITORING OF IN VIVO
CONFORMATIONAL CHANGES IN ACRB
2.1 INTRODUCTION
Despite multiple drug resistant Gram-positive pathogens, such as Methicillin-resistant
Staphylococcus aureus (MRSA), are in the media spotlight, the lack of new and effective
antimicrobials against Gram-negative bacteria is the real concern.93-96One of the major
mechanisms that confer intrinsic drug resistance to Gram-negative bacteria is the active pumping
of drug efflux systems. Genetic modification of the drug efflux pump could change the drug
susceptibility level of the bacteria.97Such an observation spurred the interest in searching for
inhibitors that can block the function of efflux pumps.98-102 A thorough understanding of the
structure and function of this type of pumps is critical for such endeavors.
AcrB is one of the most extensively studied MDR efflux pumps.103-115Strains deficient in AcrB
have been proven to be hyper-sensitive to antimicrobials. AcrB is the inner membrane
component of the tripartite pump complex AcrAB-TolC. This complex spans the distance across
the inner membrane, the outer membrane, and the periplasmic space in between. Crystal
structures of both the apo-AcrB and AcrB-substrate complexes have been determined.61, 62, 116
AcrB functions as a homo-trimer. The observation that the three promoters in the AcrB trimer
have slightly different conformations prompts the proposal that this protein functions through a
mechanism resembling that of a peristaltic pump. 117-120 Each subunit rotates through loose, tight
and open conformations successively. One molecule of substrate is extruded per cycle. The
translocation of protons from the periplasmic space provides the energy for the conformational
change. This mechanism is supported by multiple mutational studies, through which the substrate
binding sites and proton relay pathway have been identified. In addition, disulfide bonds
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engineered at the interface of subdomains reduce protein flexibility and prevent each AcrB
monomer from conformational changing, and consequently blocked the function of AcrB.119
The activity of AcrB can be monitored conveniently with a drug susceptibility assay. The acrB
knockout strain is hyper-sensitive to many drugs that have been identified as AcrB substrates.
This defect can be accommodated by the introduction of a plasmid encoding active AcrB.
Therefore, the effect of mutations on the function of AcrB can be monitored by measuring the
susceptibility to certain drugs using an AcrB-deficient E. coli strain expressing a plasmidencoded AcrB mutant. Although the effect of a mutation that causes the loss of protein function
is easy to identify, it is more difficult to attribute such changes to specific aspects of protein
structure. A mutation may impair the function of AcrB from several different aspects, including
the substrate binding site, disrupting the proton relay pathway, the interaction with AcrA and
TolC, changing the conformation of the subunit (tertiary structure level) or the formation of an
AcrB trimer (quaternary structure level). While extensive mutational studies have been focused
on the first three aspects, there is not yet a convenient method that can identify if the impact of a
detrimental mutation is on the tertiary or quaternary structure levels. In this study, I worked with
Dr. Lu Wei and established a platform to examine the effect of mutations on protein tertiary
structure (Figure 2.1). Briefly, double Cys mutations were introduced into AcrB at positions that
can form disulfide bonds under the native conformation. These Cys pairs serve as reporter for the
examination of the impact of further mutation on protein structure. A sophisticated blocking and
labeling protocol was also developed to keep track of the disulfide bond versus free thiols in the
protein. Although the analysis was performed after protein purification, the results actually
reflected the conformation of AcrB when it was under the native condition in the inner
membrane.
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Figure 2.1 Concept of reporters for protein conformational change. Each AcrB reporter construct
has a single pair of Cys in the periplasmic domain, which form a disulfide bond in the native
conformation. If an additional mutation (red star) causes a change of local conformation, the
extent of disulfide bond formation will be affected. The extent of disulfide bond formation can
be monitored as a reporter for protein conformational change.

2.2 MATERIALS AND METHODS
Construction of plasmids
The DNA coding sequence of AcrB was amplified by PCR from E. coli genomic DNA and then
digested with SphI and BamHI restriction endonucleases. The fragment was inserted in frame
into the expression vector pQE70 between the restriction sites SphI and BglII to create plasmid
pQE70-AcrB. A polyhistidine tag was introduced at the C-terminus to facilitate convenient
protein purification. Plasmid pQE70-AcrB was then used as the template to construct the
cysteine-less AcrB (CLAcrB) using the Quick-change mutagenesis kit following the protocol
provided by the manufacturer (Agilent, Santa Clara, CA). AcrB has two intrinsic Cys, Cys493
and Cys887. To prevent them from interfering with the reporter Cys pairs, these two Cys were
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substituted by Ala to create AcrBC493A/C887A, which was named

CLAcrB

in the rest of this study.

The same protocol was also used to construct all the reporter pairs with CLAcrB as the template.
In each reporter pair, a different pair of Cys was introduced to create

CLAcrBV32C/I390C,

CLAcrBT44C/T91C, CLAcrBM184C/V771C, CLAcrBT199C/T749C, CLAcrBI335C/A995C, CLAcrBQ726C/G812C,
CLAcrBA627C/T574C.

and

To identify the performance of the disulfide trapping protocol developed in

this study, four additional Cys-pair mutants were constructed with the same protocol to create
CLAcrBA627C/G570C, CLAcrBA627C/F572C, CLAcrBA627C/V576C,

and

CLAcrBA627C/L578C.

Protein coding

sequences of all plasmids were confirmed by DNA sequencing.

Drug susceptibility assay
AcrB activity could be monitored conveniently by a drug susceptibility assay. The minimum
inhibitory concentrations (MIC) of different stains were measured as described.109 Briefly, an
acrB deficient E. coli strain (BW25113ΔacrB) was used as the host cell. BW25113ΔacrBstrain
transformed with plasmid-encoded wild type AcrB (WTAcrB) or pQE70 vector were used as the
positive and negative controls, respectively. Plasmids encoding different AcrB mutants were
transformed into BW25113ΔacrB as well. Freshly transformed cells were plated on LB-agarose
plates containing 100 μg/mL ampicillin and 50 μg/mL kanamycin. The same ampicillin and
kanamycin concentrations were used throughout the study when noted. A single colony was
inoculated into a LB media supplemented with ampicillin and kanamycin. The exponential-phase
cultures of different strains were diluted to an OD600nm unit of 0.1 with LB broth. 5 µL of this
culture was used to inoculate 1 mL LB media containing the indicated concentration of
erythromycin or novobiocin. The cultures were incubated under shaking at 37oC for overnight.
The next morning, the OD600nm of each culture was measured. This activity assay was conducted
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under the basal AcrB expression condition, which was not supplemented with inducer. Each
experiment was repeated at least three times.

Protein expression
To avoid potential contamination from genomic AcrB, all AcrB expression plasmids were
transformed into BW25113ΔacrB for expression. A single colony from a freshly transformed
plate was inoculated into 3 mL LB media supplemented with ampicillin and kanamycin and
cultured overnight at 37°C. The overnight culture was used to inoculate 600 mL fresh LB media
containing ampicillin and kanamycin. Then this culture was incubated with shaking at 37°C
overnight. Cells were harvested the next morning by centrifuge. Protein was purified
immediately without freezing the cell pellet.

Protein purification and blockage of free Cys
The cell pellet was suspended in a lysis buffer (30 mM iodoacetamide (IAM), 0.5 mM
phenylmethanesulfonylfluoride (PMSF), 30 mM Tris, 0.5 M NaCl, pH 7.9) and sonicated for 15
minutes in ice/water bath with 5 s on/off intervals. The cell lysate was centrifuged at 15,317×g
under 4oC for 20 min. The pellet was then suspended again in a buffer containing 1.5% Triton,
10 mM IAM, 0.5 mM PMSF, 30 mM Tris, 0.5 M NaCl (pH 7.9) and sonicated gently at low
amplitude for 10 minutes in ice/water bath with 5 s on/off intervals. The mixture was then
incubated on ice and kept shaking for 2 hours, followed by centrifugation at 15,317×g under 4oC
for 20 minutes. The supernatant which contained the detergent solubilized AcrB was collected.
Imidazole was added to a final concentration of 10 mM to reduce the non-specific binding during
purification. The supernatant was mixed with Ni-NTA sepharose resin (Qiagen Inc., Valencia,
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CA) for 40 minutes with rotation at 4°C. The suspension was packed into an empty column and
subsequently washed with a wash buffer (0.5% Triton, 10 mM IAM, 50 mM imidazole, 30 mM
Tris, 0.5 M NaCl, pH 7.9). The target protein was eluted with an elution buffer (0.5 M imidazole,
1% Triton, 10 mM IAM, 30 mM Tris, 0.5 M NaCl, pH 7.9). Compare with the AcrB purification
protocols in literature, I omitted the step of purifying the membrane vesicles. I found that the
additional step of purifying the membrane vesicle did not have a significant improvement on the
purity of the sample under my experimental condition.
After elution, maleimide (MAL) and SDS were immediately added to protein samples to final
concentrations of 50 mM and 4% (w/v), respectively. The high percentage of SDS denatured the
protein and MAL was included to further block any residual free Cys. After incubated for 30
minutes at room temperature, proteins were precipitated using 15% trichloroacetic acid (TCA).
After centrifugation, the precipitate was washed with cold acetone and then re-solubilized in a
buffer containing 4% SDS and 50 mM Tris (pH 8.0). This precipitation and washing step were
used to remove IAM and MAL from the sample. Protein concentration was determined by
measuring the absorbance at 280 nm, with the re-solubilization buffer as blank.

Fluorescent labeling
The protein concentrations of different AcrB mutants were adjusted to the same level by
measuring the absorbance at 280 nm. Labeling was performed as described bellow. First,
dithiothreitol (DTT) was added to the samples to a final concentration of 50 mM. Then the
samples were incubated at 37°C for 1 hour. Second, proteins in these samples were precipitated
using 15% TCA. After centrifugation, the protein precipitate was washed with ice cold acetone.
This step removed the extra DTT from the reduced proteins. Finally, a buffer containing 4% SDS,
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50 mM Tris, pH 8.0, and 5 mM N-(5-fluoresceinyl) maleimide (F-MAL) was added immediately
to the protein pellet to solubilize and label the freshly reduced free thiol groups. The pellet was
resuspended with a pipette tip and incubated at room temperature for 30 minutes. After the
incubation, 10 mM DTT was added to quench the labeling reaction.
The labeled samples were analyzed with SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
on 8% gels. After the extra fluorescence dye migrated out of the gel, the gel was collected and
the fluorescence image was taken using the MiniVisionary gel documentation system
(FOTODYNE Inc., Hartland, WI) under UV light. The same gel was stained with coomassie
blue R250 and the image of the gel was then taken under normal white light.
Note: Construction of plasmids, protein purification, fluorescent labeling, protein expression
level measurement were performed by WL (Dr. Wei Lu) and MZ (Meng Zhong), Drug
susceptibility assay as performed by MZ

2.3 RESULTS AND DISCUSSION
2.3.1 Design and construction of double cysteine reporter pairs
Disulfide bond can not be formed in cytoplasmic proteins, due to the reducing environment in
the bacterial cytosol. However, disulfide bonds are commonly found in periplasmic proteins,
outer membrane proteins and the periplasmic domain of inner membrane proteins.74,

121, 122

Taking advantage of the oxidative environment of periplasm, a series of reporter Cys pairs were
introduced at different locations of the AcrB periplasmic domain. Based on the crystal structure
of AcrB, I have selected seven locations where intra-subunit disulfide bond are likely to form.
The criteria for the selection includes: 1) Residues to be changed need to be far away from
crucial residues that are related to AcrB backbone and function. In other words, mutation and
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formation of disulfide bond should not disturb the structure of AcrB or its function. 2) The
distance between the two Cys residues of each pair should remain constant during the whole
AcrB function cycle. AcrB functions through a rotary mechanism in which the three subunits
rotate through three different stages.61,

62, 119, 120

The distances between the two Cys of each

reporter pair should stay similar in all three states, thus the formation of the disulfide bond is
unlikely to affect function. After examining the three stages of AcrB structures, I selected seven
regions to introduce the reporter pairs that meet the above criteria. Their positions are
highlighted in Figure 2.2 by black circles, T199-T749 (1), Q726-G812 (2), M184-V771 (3),
T574-A627 (4), T44-T91 (5), V32-I390 (6), and I335-A995 (7). All of the reporter residues exist
in the the periplasm, the oxidative environment of which will enable the formation of disulfide
bonds under the natural condition. 119

Figure 2.2 Superposition of the three states of AcrB, open (blue), tight (red) and loose (yellow).
Positions of the reporter pairs were highlighted by green space-filled models with circles. The
three domains of AcrB were labeled on the right.
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Seven reporters were constructed, each containing a Cys pair at the indicated locations on a
CLAcrB

background. Plasmids encoding the reporter AcrB constructs were transformed into

BW25113∆acrB for protein expression as described in the materials and methods section. All
experiments were performed under a basal expression condition without induction. The
expression levels of the reporters were comparable to the wild type AcrB, which were confirmed
by Western blot analysis of membrane vesicles extracted from BW25113∆acrB transformed with
plasmids encoding different AcrB mutants (Figure 2.3).

Figure 2.3 Western blot analysis revealed that the reporter constructs had similar expression
levels as the wild type AcrB. The same numbering system as in Figure 2.1 was used to label the
lanes. Wild type AcrB (WT) was used as a control.

2.3.2 Drug susceptibility assay of AcrB reporters
To meet the criteria as a structural reporter, the mutation to Cys and subsequent formation of
disulfide bonds should not affect the structure and function of AcrB. Plasmids encoding the
reporter genes were transformed into BW25113∆acrB, and the drug susceptibilities of the strains
to erythromycin and novobiocin were examined (Table 2.1). Five of the seven reporters were
fully active. The MICs of two reporters,

CLAcrBV32C/I390C

and

CLAcrBI335C/A995C,

were half of the

value compared with other AcrB constructs. This slightly decreased activity is possibly because
of the limited flexibility caused by the formation of the disulfide bonds.
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Table 2.1 MIC of BW25113∆acrB expressing plasmid encoded acrB mutants.
MIC (µg/ml)
Plasmid or mutant
Erythromycin

Novobiocin

pQE70

4

4

pQE70AcrB

128

128

Cysless

128

128

V32C/I390C

64

64

T44C/T91C

128

128

I335C/A995C

64

64

M184C/V771C

128

128

T199C/T749C

128

128

T574C/A627C

128

128

Q726C/G812C

128

128

Plasmid

Mutation*

*All mutations were constructed using CLAcrB as the background.

The drug transporter activity of

CLAcrB

was examined with a MIC assay as described in the

materials and methods section. As shown in Table 1, plasmid encoded CLAcrB fully restored the
drug resistance of an acrB knockout strain, indicating that the replacement of these two Cys did
not impair the function of AcrB, which is also consistent with results previously reported in
literature.119
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2.3.3 Fluorescein maleimide label and purification of AcrB reporters
CLAcrB

and

WTAcrB

were used as negative controls for the disulfide trapping experiment. The

protocol was derived from a procedure published for soluble proteins.

123

Several important

modifications were described in the materials and methods section, which were critical to make
it useful for membrane proteins. In the first lane, no IAM and MAL were added to block free Cys
(Figure 2.4A). After purification, DTT was added to reduce the eluted protein samples. After the
reduction, any Cys in a protein, either free or existed in a disulfide bond, would become reduced
form and react with F-MAL during the labeling step to generate a bright fluorescent band. In the
second lane, IAM was added during the protein purification procedure to block free Cys (Figure
2.4B). No reduction step was performed afterward. Therefore, no fluorescent labeling was
expected to occur since there would be no free Cys in the protein. Finally, for samples in the
third lane, protein was purified in the presence of IAM to block free Cys (Figure 2.4C). After
purification, the extra IAM and MAL were removed, and the sample was reduced with DTT. If
there was disulfide bond in the protein, the incubation with DTT would generate freshly reduced
free Cys, which would be labeled and yield fluorescent band. In the case of WTAcrB, the pattern
of the three lanes was bright, dark, and dark, indicating the presence of free Cys but no disulfide
bond in this protein, which is consistent with the known structure of AcrB (Figure 2.4D). The
CLAcrB

was used as a negative control. None of the three bands were fluorescent in this case

indicating the absence of Cys in this protein as expected.
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Figure 2.4 Controls for the disulfide trapping experiment. A. Purified protein was first incubated
with DTT, and then labeled using F-MAL. All Cys residues in the protein would be labeled. B.
Protein was purified in the presence of IAM, and then labeled using F-MAL. None of the Cys
could be labeled. C. Protein was purified in the presence of IAM, and then reduced using DTT
and labeled. Free Cys could not be labeled, while Cys protected by a disulfide bond during the
IAM treatment could be labeled. D.

WTAcrB

and

described in A (lane 1), B (lane 2), or C (lane 3).

CLAcrB
WTAcrB

treated according to the procedures
contains two free Cys, while

CLAcrB

contains no Cys. The same amount of protein was loaded in each lane as revealed by Commassie
blue stain.
After expression, the protein purification procedure was performed as descried in materials and
methods section. As shown in Figure 2.5, all reporters formed disulfide bonds was revealed by
the bright, dark, and bright pattern. Samples in lane 1 and lane 2 were served as internal positive
and negative controls in the quantification of the percentage disulfide formation. The
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fluorescence intensities of lane 1 and lane 2 were designated as 100% and 0, respectively. The
intensity of lane 3 was converted to percentage labeling using equation:
labeling % =

F3 − F 2
× 100
F1 − F 2

Where F1, F2 and F3 were fluorescence intensities of the band in lane 1, 2, and 3, respectively.
The calculated percentage labeling for each reporter pair was shown in table 2.2.

Figure 2.5 Labeling results of the Cys pair reporters. Samples in different lanes were treated
similarly as those in Figure 2D. The similar protein amount was loaded in each lane as revealed
by the Commassie blue stain.
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Table 2.2 Percentage disulfide formation in the reporter Cys pairs as revealed by the percentage
of fluorescence labeling.
Reporter construct

Disulfide bond%

V32C/I390C

82.5±6.8

T44C/T91C

100.7±3.0

M184C/V771C

76.2±4.9

T199C/T749C

82.7±2.9

I335C/A995C

51.7±0.8

T574C/A627C

102.9±6.8

Q726C/G812C

97.7±5.0

The extents of disulfide bond formation for different reporter pairs were different. Three pairs
existed as complete disulfide bond, including

CLAcrBT44C/T91C,

CLAcrBT574C/A627C,

and

CLAcrBQ726C/G812C.

CLAcrBV32C/I390C, CLAcrBM184C/V771C,

and

CLAcrBT199C/T749C,

Another three pairs, including

existed approximately 80% in the form of disulfide bond and 20% as free Cys.

The last pair, CLAcrBI335C/A995C, existed with 50% in the form of disulfide bond.

2.3.4 Correlation between fluorescence intensity and the extents of labeling
To figure out the correlation between the fluorescence intensity and extent of labeling while
using the current protocol, the different extent of labeling was mimicked by mixing purified
WTAcrB

and

CLAcrB.

The purified

WTAcrB

and

CLAcrB

samples were adjusted to the same

protein concentration and then mixed with different ratios to generate samples containing 100%,
90%, 80%, 60%, 40%, 20%, 10%, and 0%

WTAcrB.
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In the next step, the samples were reduced

with DTT and then labeled using F-MAL as described in the materials and methods section.
After labeling, samples were analyzed with SDS-PAGE (Figure 2.6). Fluorescent intensities of
different bands were quantified using software ImageJ124, 125 and plotted against the percentage
of

WTAcrB

in the samples. As shown in Figure 2.5, the fluorescence intensities correlated very

well with the percentages of WTAcrB, indicting that the fluorescent intensity did reflect the extent
of labeling, which correlated with the quantity of reactive thiols in the labeling step.

A.

B.

Normalized
Fluorescence

100% 90% 80% 60% 40% 20% 10% 0

1

0.5

0
0

50
WTAcrB

100

%

Figure 2.6 A. SDS-PAGE analysis of fluorescent labeling results of samples containing the
indicated percentage of WTAcrB. B. The fluorescent intensities of each band were plotted against
the percentages of

WTAcrB.

The experiment was performed three times. The average intensities

and standard deviations were shown in the plot.
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These results indicated that all reporter Cys pairs could form disulfide bond, and five out of the
seven pairs did not significantly affect the transport activity of AcrB. These five pairs, which
existed at different locations in the periplasmic domain of AcrB, could be used to monitor local
conformational changes. Purified membrane proteins exist in detergent micelles. Limited by the
size of the protein and bound detergent, in most cases NMR could not be used to study structures
of membrane proteins. If the conformational change in the protein is drastic enough to cause a
change of the secondary structure content or overall stability, then circular dichroism (CD)
spectroscopy and limited protease digestion can be used to monitor the changes. However, more
subtle changes are difficult to identify. The method described in this study has the following
advantages: first, the combined usage of different reporters together could reveal a more detailed
profile of AcrB conformational changes. Second, while most protein structure characterization
methods can only tell information about purified proteins, the current method actually reveals the
conformation of the protein while it is under the native environment in vivo. The presence of
IAM throughout the protein purification process blocked all free Cys and maintained the profile
of different Cys pairs at their native conditions.
The major concern of this study was the potential oxidation of free Cys in the protein purification
process, as it would yield false positive result indicating higher disulfide bond percentage than
the actual number. To keep the percentage of disulfide bond unchanged during the protein
purification process, IAM was added throughout the purification process. IAM is a small
molecule thiol modifier that can penetrate into protein hydrophobic core and react with
membrane proteins.123 In addition, proteins from freshly cultured cell is purifed, to avoid the
possibility that free Cys might form disulfide bond during the freezing and subsequent storage
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period. After sample was eluted from the affinity purification column, SDS and MAL
immediately added into the protein samples. High concentration of SDS denatured AcrB to
prepare it for fluorescent labeling, while MAL further eliminated any residual free Cys that
might survive through the blocking process.

2.3.5 Study of distance sensitivity of the reporters
It is known that the formation of disulfide bond is very sensitive to the distance between the two
Cys residues involved. Such sensitivity was served as the foundation for the reporter platform
described in this study. The distances between the Cα of the involved Cys pairs in 171 disulfide
bonds from 28 randomly chosen protein structures from the protein data bank were
measured(Figure 2.7). According to Figure 2.7, disulfide bond has been observed to occur
between two residues with Cαs less than 7.5 Å apart. While the distances ranging from
approximately 4 to 7.5 Å, the majority clustered at 5 to 6.5 Å. This number is consistent with
values reported in literature, which indicates disulfide bond may form between a pair of residues
that possess a α-carbon to α-carbon distance ranges from 4 to8 Å.126-128
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Figure 2.7 Summary of the distance between the Cα of two Cys in 171 disulfide bonds found in
protein structures randomly chosen from the protein data bank.

To further verify the disulfide trapping protocol, the correlation between the extent of fluorescent
labeling and the the real distance between the involved Cys was examined. Four additional Cys
pairs were created. According to the crystal structure of AcrB, T574 and A627 locate in the
middle of a pair of anti-parellel β-strands that exists in PC1 subdomain (Figure 2.8). Taking
advantage of this intrinsic “ruler”, the extent of disulfide bond formation between A627C, which
located in the center of one strand, with five residues were measured. These five residues
scattered on the other strand, including L578C, V576C, T574C, F572C and G570C. The
distances between the Cα of A627 and the Cα of the five residues on the other strand are
summarized in Table 2.3. These distances were obtained by measuring the corresponding
distances in all independent AcrB crystal structures currently available, including 1IWG, 1OY6,
1T9T, 2HQC, 2GIF, 2DHH, 2RDD, and 3B5D. The average distances and standard deviations
were also listed. The distance between the Cα of T574 and A627 is in the optimum range to form
disulfide bond (which is one of the seven reporters created), while the distance between the Cα
of A627 and F572 or V576 are slightly beyond the disulfide bonding distance. The distances
between the Cα of A627 and G570 or L578 are too long to form the disulfide bond.
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Table 2.3 Summary of the measured Cα distances and percentage of fluorescence intensity.
Res. 1

Res. 2 C

 distFluorescence %

A627C T574C 5.4 ± 0.22

100

A627C G570C 14.3 ± 0.38

7.7 ± 3.4

A627C F572C 8.9 ± 0.25

12.5 ±6.0

A627C V576C 8.1 ± 0.26

65.1 ± 10.4

A627C L578C 14.5 ± 0.28

3.0 ± 2.7

The extents of disulfide bond formation of these five pairs were compared. After overnight
expression, proteins were purified in the presence of IAM, and then reduced with DTT before
labeled using F-Mal. As shown in Figure 2.8B,

CLAcrBA627C/T574C

formed strong disulfide bond.

Assuming the extent of disulfide bond formation in CLAcrBA627C/T574C was 100%, the percentages
of disulfide bond formation in the other four mutants were calculated through comparing their
fluorescent intensities with that of CLAcrBA627C/T574C in Figure 2.8B (Table 2.3). Two interesting
observations were obtained. First, although the measured distances between the Cα in C627C572 and C627-C576 are both longer than the distance normally observed in existing disulfide
bonds, there were still significant levels of disulfide bond formation in both cases. Second, while
the measured Cα distances in C627-C572 and C627-C576 were similar, the extent of disulfide
bond formation was quite different. These observations may indicate that AcrB structure has a
certain degree of flexibility, which involves a slight shift of the relative position between the two
β-strands. The breathing effect of the structure may have temporarily brought the side chains of
C627 and C572 or C576 within the disulfide bond forming distance. In addition, this movement
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is asymmetric relative to the location of A627, which favored the formation of C627-C576
disulfide bond to a greater extent.

Figure 2.8 A. Side chains of 5 pairs of residues that within the β-strands were shown in spacefilled model with labels on the side. B. Labeling results of Cys pairs, CLAcrBG570C/A627C (lane 1),
CLAcrBF572C/A627C
CLAcrBL578C/A627C

(lane 2),

CLAcrBT574C/A627C

(lane 3),

CLAcrBV576C/A627C

(lane 4), and

(lane 5). Protein purification was carried in the presence of IAM, and then

reduced with DTT and labeled using F-MAL. As revealed by the Commassie blue stain, the
protein loading amount in each lane was the same.

To verify if the extent of fluorescent labeling reflects the distance in the reporter Cys pair under
the native condition, the extent of disulfide bond formation of five Cys pairs separated by
different distances was compared. These five Cys pairs locate in two closely spaced anti-parallel
β-strands in AcrB PC1 subdomain. The results not only confirmed that the fluorescent labeling
approach can faithfully reflect the distance between the involved Cys pairs, but also suggested
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that there was certain degree of structural motion in the related region of AcrB. This motion may
reflect the intrinsic structural flexibility of AcrB. However, it should not be critical for the
function of AcrB, as the cross-linking between A627C and one of the other Cys did not affect the
activity of the efflux pump.
Finally, the activity assay for these mutants was performed to confirm that these mutations did
not cause a drastic change of AcrB structure (Table 2.4). CLAcrBT574C/A627C had been shown to be
fully active in earlier experiment. The MICs of the rest four pairs were also similar to that of the
wild type AcrB. The mutations to Cys and formation of disulfide bonds had no negative effect on
the activity of the protein.
Table 2.4 Drug susceptibility of four cysteine pair reporters for distance sensitivity measurement
MIC (µg/ml)
Plasmid or mutant
Erythromycin

Novobiocin

Wild type

128

128

G570C/A627C

128

128

F572C/A627C

128

128

V576C/A627C

128

128

L578 C/A627C

128

128

The disulfide trapping method is an established technique that has been applied successfully in
the detection of conformational change in membrane proteins.126-133 Usually Cys pairs introduced
at strategic positions in the protein are first induced to form disulfide bond with a chemical
catalyst, and then various methods are used to determine the formation of disulfide bond. The
most commonly method used to detect the presence of disulfide bond is SDS-PAGE.134 Under
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reducing or non-reducing conditions, proteins containing disulfide bond may migrate differently
in the gel. Nevertheless, the presence of intra-molecular disulfide bond may not always generate
a detectable shift in migration. Another popular method in the detection and quantification of
disulfide bond and free cysteine is mass spectrometry.135This method is more accurate, but is
also more time consuming, expensive, and requires specific instrumentation. An alternative
method is to use sulfhydryl-specific labeling reagents, including biotin, fluorescence dye, and
radioactive probes.123, 135 These labeling reagents can react with free thiols. However, cysteine in
the form of free thiol may suffer from oxidation by ambient oxygen during the protein
purification process, which may cause artifact in the estimation of the percentage of free cysteine
in the protein. The procedure developed here is more reliable because all cyeteine in the protein
were first blocked to prevent the formation of new disulfide bond during the detergent extraction
and protein purification process. After purification, the protein was denatured in the presence of
the blocking reagent, which could further eliminate residual free thiols that might not be
accessible by the blocking reagent under native state. Finally, disulfide bond that presented in the
protein before the purification process was reduced and immediately labeled with a thiol-reactive
fluorescent probe. The experimental design included internal positive and negative controls,
which could compensate for potential differences in chemical reactivity of Cys placed at
different regions of the protein sequence. Through comparing the fluorescence intensity of the
sample with those of the negative and positive controls, I could estimate the percentage labeling
of the sample, which reflected the portion of the Cys pair that existed in the form of disulfide
bond in the protein. The experimental results were highly reproducible due to these proactive
experimental designs.
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The establishment of multiple reporter Cys pairs in the AcrB periplasmic domain has set the
stage for the investigation of AcrB conformational changes under various experimental
conditions. For example, while the effect of detrimental mutations that disrupt know mechanisms
such as substrate binding or proton relay are easy to interpret, mutations that disrupt AcrB
function through interfering protein structure or folding are more difficult to pin down. Now the
structural impact of such mutations can be assessed by the reporter constructs.

2.4 CONCLUSION
AcrB and its homologues are major players in conferring multidrug resistance to Gram-negative
pathogens. Its structure is strongly connected to its function as an efflux pump. Study of AcrB
conformational changes helps understand which residues are important to the protein activity and
identify potential inhibitors as drugs for clinical treatment. Herein, a disulfide-trapping based
reporter system was developed. Cysteine pair reporters can be labeled by fluorescein maleide to
different extents which is highly related to its distance and local environment. These reporters
could be used as a fast, convenient and sensitive method to probe local conformational changes
in AcrB. Later this method has been used by my group to detect subtle conformational difference
upon further mutagenesis studies. I expect that such a design might be applicable to other
membrane proteins as well.

Copyright © Meng Zhong 2013
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CHAPTER III. STUDY OF ACRB FOLDING AND TRIMERIZATION
3.1 INTRODUCTION
Oligomerization is a common feature in protein structure. The majority of oligomers are homooligomers.136-140 Obligate oligomers exist and function exclusively in one oligomeric state. The
assembly of obligate oligomers is an interesting and yet poorly understood process. Studies with
soluble oligomeric proteins indicated that oligomerization may occur via a two-stage or a threestage pathway.141-144 In the two-stage pathway individual monomers remain unfolded in the
absence of oligomerization, while in the three-stage pathway individual monomers fold into an
independently folded structure, which may be different from the final conformation in the
oligomer.145
It is not well defined how proteins oligomerize in the plasma membrane of a cell. Of all the
proteins encoded in sequenced genomes, approximately 20-30% are predicted to be membrane
proteins, many of which function as oligomers.146 However, the mechanism of the oligomer
assembly in the cell membrane of integral membrane proteins is still not clear, mainly due to the
difficulty of characterizing protein tertiary and quaternary structures separately in the cell
membrane under native condition. The anchoring of the subunits in the membrane restricts the
movement of the subunits to two dimensions, which may increase local concentrations of the
subunits and therefore the chance of encountering among them. Thus, the oligomerization of
membrane-associated proteins may occur more efficiently.
In the case of obligate oligomers, it is not well defined how each subunit exist before they
assemble into the final oligomeric state. In Gram-negative bacteria, the membrane insertion of
inner membrane proteins occurs co-translationally. It is still unclear to what extent each
individual subunit folds before the onset of the assembly. It still remains elusive whether it
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occurs through a two-stage or three-stage pathway. The assemblies of heteropentameric
membrane proteins have been shown to be sequential by several studies. For example, Green and
Claudio studied the sequential folding and assembly of the heteropentameric Acetylcholine
receptor (AChR).147 Taking advantage of the temperature sensitive assembly of Torpedo AchR
subunits in the mouse cell line, they first expressed the subunits at 37oC, and then triggered the
assembly by lower down the temperature to 20oC. With this method, they found that within first
few minutes the αβγ trimer was assembled, followed by the sequential addition of a δ, and finally
a second α subunit. The authors concluded that the subunit folding events contribute to subunit
recognition site formation during assembly. One factor that was not addressed in their study is,
how close are the structure of each individual subunit to their final structure in the functional
heteroligomer.
In this study, the relation between the subunit folding and oligomer assembly in a trimeric
membrane protein, AcrB, was investigated. The rationale is, since the major difference between
the two-stage and three-stage pathway is the existence of well folded, independent monomers
under native condition, the observation of well folded monomeric AcrB in the cell membrane
would support the three-stage pathway. To make this research possible, it is crucial to have a
method to probe the structure of AcrB in the membrane under the native condition, as detergent
extraction and purification may affect the conformation and oligomeric state of AcrB. For this
purpose, a folding reporter platform has been constructed that can be used as a research tool to
reveal the tertiary structure of individual subunits in the cell membrane.148 In the current study, a
well-folded monomeric AcrB mutant, AcrB∆loop, was created. Part of a protruding loop was
deleted in AcrB∆loop (Figure 3.1). Since AcrB is a structural and functional obligate trimer,
monomeric AcrB has not been found in the cell membrane before. AcrB∆loop existed in the cell
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membrane in a folded conformation highly similar to that of the final structure in the obligate
trimer. In other words, the folding of each individual subunit does not need assistance from
neighboring subunits. These results indicated that the trimerization of AcrB may occur through a
three-stage pathway.

Figure 3.1 A. Side view of an AcrB trimer. Different domains were marked. The position of the
inner membrane was marked between the grey bars. B. Head view of an AcrB trimer. The
contour of each subunit was highlighted using a transparent envelope to illustrate the protruding
loop.
3.2 MATERIALS AND METHODS
Cloning, expression and purification of AcrB and its mutants
The pQE70-AcrB plasmid was used as the template to construct the AcrB∆loop Mutant. (13) In
this mutant the N211-G227 was deleted and the Quikchange mutagenesis kit (Agilent
Technologies, Santa Clara, CA) was used to generate this deletion mutation (Figure 3.2).
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Figure 3.2 Structure of a single AcrB subunit. The part of the protruding loop that was removed
in this study was highlighted in green. The structure was created using pdb file 2DHH.

Complementary

primers

used

to

construct

of

AcrB∆loop

are

as

follows:

CATTACCGCCATCAAAGCGCAGCAACAGCTTAACGCCTCTATTATTGC-3’

and

5’5’-

GCAATAATAGAGGCGTTAAGCTGTTGCTGCGCTTTGATGGCGGTAATG-3’.
With the same method, loop deletion mutation was also introduced into AcrB reporter constructs
CLAcrB,

32-390-AcrB, 44-91-AcrB, 184-771-AcrB, 199-749-AcrB and 726-812-AcrB. The

coding sequences of all plasmids used in this study were confirmed by DNA sequencing. AcrB
and all the mutants were expressed in an E. coli strain deficient in gene acrB (BW25113ΔacrB)
and purified as described.148
Drug susceptibility assay of AcrB∆loop mutant
AcrB activity could be measured with a drug resistance assay. The minimum inhibitory
concentrations (MIC) of different strains were measured using the protocol described

54

previously.148 Briefly, E. coli strain deficient in gene acrB (BW25113ΔacrB) was used as the
host cell. The plasmid encoding wild type AcrB (WTAcrB) or empty pQE70 vector was
transformed into the BW25113∆acrB strain separately. These two transformed strains were used
as the positive and negative controls, respectively. Plasmids encoding different AcrB mutants
were also transformed into BW25113∆acrB strain. Freshly transformed cells were plated on LBagarose plates containing 100 μg/mL ampicillin and 50 μg/mL kanamycin. The same ampicillin
and kanamycin concentrations were used throughout the study. A single colony was inoculated
into a LB media containing ampicillin and kanamycin. The strains were cultured to the
exponential-phase and then were diluted to an OD600nm unit of 0.1 using LB broth. 5 µL of this
culture was used to inoculate 1 mL LB media containing the indicated concentration of
erythromycin or novobiocin. The cultures were incubated with shaking under 37oC for overnight.
The OD600nm of each sample was measured the next morning. The activity assay was conducted
under the basal expression condition. Each experiment was repeated in triplicates.

Expression, purification, and labeling of AcrB and its mutants
Labeling of AcrB reporters was performed as described in Chapter II. (13) Briefly, AcrB reporter
mutants freshly expressed in BW25113ΔacrB was treated with iodoacetamide (IAM) and
purified with Ni-Sepharose. IAM could block free thiols in the protein but it would not affect
disulfide bonds. After purification, dithiothreitol (DTT) was added into the protein samples to
reduce disulfide bonds and generate free thiols. These freshly generated thoils were immediately
labeled with 5-Maleimido-fluorescein (Flu-MAL) and analyzed by SDS-PAGE. With this
method, disulfide bonds existing in the protein can be quantified.
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Blue Native PAGE analysis of wild type AcrB and AcrB∆loop
BN-PAGE was performed as previously described.149, 150 Briefly, purified protein samples were
mixed with blue native loading buffer to reach a final concentration of 0.1M 6-aminoocaproic
acid, 6% sucrose, 10mM 2-[bis(2-hydroxyethyl)amino-2-(hydroxymethyl) propane-1,3-diol-HCl,
1% Coomassie brilliant blue G-250, pH 7.0. Protein samples were load to a 4–20% gradient
polyacrylamide gel . The electrophoresis was performed at 60 V in the 4°C refrigerator for 5
hours using a running buffer (25 mM Tris-HCl, 192 mM glycine, 0.01% Coomassie brilliant blue
G-250, pH 8.3) . Then Coomassie Blue stain was used to visualize the protein bands. Band
intensity was quantified with the software ImageJ. (44)

Limited Trypsin digestion of WT-AcrB and AcrB∆loop
Purifed AcrB samples were dialyzed with a reaction buffer containing 20 mM phosphate buffer,
0.1M NaCl, 0.03% n-dodecyl-β-maltoside, 10% glycerol. Then trypsin was added into each
sample at a molar ratio of 1:200. The samples were incubated at room temperature for the
indicated period of time before phenylmethylsulfonyl fluoride (PMSF) (final concentration was 2
mM) and SDS-loading buffer (final concentration was 1X) was added to quench the digestion
reaction. The samples were then heated at 95ºC for 2 minutes and analyzed using SDS-PAGE.

Analysis of expression levels of wild type AcrB and AcrB∆loop by immunoblotting
Freshly transformed colonies of BW25113ΔacrB strain containing plasmid-encoded wild type
AcrB or AcrBDloop were inoculated into LB medium containing ampicillin and kanamycin.
After overnight culture at 37°C, cells were harvested, resuspended in 10 mM HEPES-KOH
buffer (pH 7.5) to an OD600 of 15. Then the cells were ruptured with French Press in the
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presence of PMSF. Unbroken cells of the sonicated suspensions were removed by low-speed
centrifugation and the membrane vesicle was collected by ultracentrifugation at 150,000 g for 1
hour under 4°C. The pellet was resuspended in 10 mM HEPES-KOH (pH 7.5) buffer containing
2% (wt/vol) SDS to solubilize the inner membrane proteins. The solubilization was enhanced by
sonication and then incubated at 37°C for 2 hours. Then SDS-Loading buffer was added and the
samples were separated on 8% SDS-PAGE and transferred to a nitrocellulose membrane
(Millipore, Bedford, MA) for Western blot analysis with polyclonal rabbit anti-AcrB as primary
antibody and an alkaline phosphatase-conjugated anti-rabbit (Abcam, Cambridge, MA) as
secondary antibody. Then the protein-antibody conjugates were visualized with nitroblue
tetrazolium chloride and 5-bromo-4-chloro-3’-indoyl phosphate p-toluidine. (Sigma-Aldrich, St.
Louis, MO).

CD analysis of the structure and heat stability of WT-AcrB and AcrB∆loop
CD analysis was performed on a JASCO J-810 spectrometer (JASCO, United Kingdom) with 1
nm bandwidth. Protein samples were dialyzed overnight against a low salt buffer (10 mM
sodium-phosphate, 50 mM NaCl, 10% glycerol, 0.05% DDM, pH 7.5) before the CD
measurement. Blank scans were performed with the exterior dialysis buffer. For far-UV CD
spectra of secondary structure, samples in 1 mm path length cuvettes were scanned in the
wavelength range 250–190 nm. Spectra were then corrected for background by subtraction of a
blank curve obtained from the dialysis buffer. For the near-UV CD analysis, the scanning was
performed in the wavelength range 350-250 nm using a 1cm path-length cuvette. Protein
concentrations were determined with Bradford assay.
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Chemical crosslinking
The WT-AcrB and AcrB∆loop were freshly expressed in BW25112∆acrB strain and the bacteria
cells were harvested and lysed by sonication in a buffer containing 50 mM phosphate, 0.15M
NaCl and 0.5 mM PMSF (pH 7.5). After sonication the suspensions were centrifuged and the cell
pellets were collected and re-suspended in a buffer containing 50mM phosphate, 0.15M NaCl,
0.5mM DSP (pH=7.5). The suspension was incubated under 37°C for 40 minutes. Tris-HCl (pH
8.0) was added to a final concentration of 50 mM to quench the crosslinking reaction. Then
TritonX-100 was added to a final concentration of 1% to extract the inner membrane proteins
and AcrB was purified as described above.
Purified WT-AcrB and AcrB∆loop samples were analyzed by non-reducing SDS-PAGE. Later,
western blot analysis was performed with polyclonal rabbit anti-AcrB primary antibody and
alkaline phosphatase-conjugated anti-rabbit secondary antibody.
Note: Cloning, expression and purification of AcrB mutants, fluorescence labeling, limited
protease digestion, blue native analysis, CD analysis were performed by Dr. Wei Lu and Meng
Zhong. Drug susceptibility was performed by MZ. Chemical crosslinking was performed by WL.

3. 3 RESULTS AND DISCUSSION
3. 3. 1 Construction of pQE70-AcrB∆loop
The goal of this study is to determine if monomeric AcrB mutant can exist in the cell membrane,
and if so, how does the structure of this mutant compare with that of wild type AcrB. The answer
of this question may shed light on the oligomerization pathway of AcrB. The capability of AcrB
monomer to fold independent from the neighboring subunits in the cell membrane would suggest
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a three-stage oligomerization pathway, which involves well-folded monomer intermediate state.
AcrB is an obligate trimer. No monomeric or dimeric AcrB has ever been observed in cell
membrane. After extracted from the membrane using detergent, AcrB predominantly exists as a
trimer. 61-63 Change of the sample buffer condition or prolonged storage may cause AcrB trimers
to dissociate into monomer, but no evidence has been reported concerning if these monomers
could re-assemble into trimer.151
To create monomeric AcrB in the cell membrane, we predict that the inter-subunit interface
between neighboring subunits would be interrupted while at the same time the intra-subunit
interactions should not be interrupted. Through examination of the AcrB structure, we speculated
that mutations in the protruding loop as revealed in Figure 3.1 might generate monomeric AcrB
mutant. It is far away from the bulk of the protein structure and is not expected to be important
for the overall tertiary structure packing. While at the same time, it should be critical for the
inter-subunit interactions. With the site directed mutagenesis kit, 17 residues were deleted in the
loop which corresponds to half of the overall length of the loop. The loop deletion mutation was
also introduced into five of the AcrB reporters described in Chapter II. The disulfide trapping
method was used to investigate how loop deletion would affect AcrB conformation.

3. 3. 2 Drug susceptibility of AcrB∆loop
The activity of AcrB∆loop was measured by a drug susceptibility assay. Plasmids encoding wild
type AcrB or AcrB∆loop were transformed into BW25112ΔacrB strain. In parallel, vector pQE70
was also transformed into BW25112ΔacrBto serve as a negative control. Minimum inhibitory
concentrations of these strains were measured for two established AcrB substrates, erythromycin
and SDS (Table 3.1). The MIC of the strain containing plasmid-encoded AcrB∆loop was much
59

lower than the plasmid-encoded wild type AcrB, and was similar to the MIC of the same strain
with the empty pQE70 vector. This result indicated that the mutant was completely nonfunctional, as it could not increase the resistance level of the host strain to those AcrB substrates.
Table 3.1 MICs of BW25113∆acrB expressing plasmid encoded acrB gene
MIC (µg/ml)
Plasmid or mutant
Erythromycin

Novobiocin

BW25113∆acrB

4

4

pQE70

4

4

pQE70AcrB∆loop

4

4

pQE70AcrB

128

128

Normally, the drug efflux ability of AcrB can be disrupted by disrupting the substrate binding or
proton relay pathway, the folding of each subunit, the assembly of a functional AcrB trimer, or
the interaction between AcrB and its functional partners AcrA and TolC. Since the site of
mutation is distant from the substrate binding, proton relay, and AcrA/TolC docking interface,
the lack of function is more likely to be a result of disrupting subunit folding or trimerization.59,
104, 107, 109, 110, 112, 113, 152

3. 3. 3 Expression levels of AcrB∆loop and wild type AcrB
To evaluate how the truncation of the protruding loop will affect the overall structure and
stability of the protein, the expression level of the mutant was examined. If a mutation
dramatically reduced the overall stability of a protein, it could cause the mutant protein to fail the
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quality control mechanism of the cell and result in a drastic decrease of the protein abundance. In
this case, BW25113∆acrB was used to express wild type AcrB and AcrB∆loop to prevent the
interference from intrinsic AcrB expression. Membrane vesicles were extracted and then
analyzed by immunoblot. The same samples were diluted 10 and 100 fold to further compare the
expression levels of the two proteins in the cell (Figure 3.3). The densities of the blotting bands
were very similar for both proteins, indicating AcrB expression levels in two strains are fairly
close.

Figure 3.3Comparison of the expression levels of wild type AcrB and AcrB∆loop. A. Western blot
analysis of membrane vesicles extracted from BW25113∆acrB expressing the wild type AcrB or
AcrB∆loop. Each sample was diluted 1, 10 and 100 fold.

3.3.4 Structural study of AcrB∆loop by circular dichroism
Next, circular dichroism was used to characterize AcrB∆loop and wild type AcrB structures in
detail. AcrB∆loop and wild type AcrB were first purified by Ni-NTA beads. The mutant protein
can be purified following the same protocol as the wild type AcrB with comparable yield (Figure
3.4).
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Figure 3. 4 SDS-PAGE of purified wild type AcrB (lane 2) and AcrB∆loop (lane 3) samples. Both
proteins can be purified to near homogeneity. The positions of protein molecular weight markers
were marked respectively.

Far UV CD spectroscopy provides valuable information about protein secondary structure. The
“far UV” region in the CD spectra (190nm-250nm) of the two proteins superimposed well,
suggesting deletion of the protruding loop did not change protein secondary structure. Both
proteins showed two distinct peaks of α-helices (Figure 3.5A).
Thermal stability of the proteins was also compared. When protein is heated to certain
temperature, it would slowly lose its secondary structure. In this case, the changes in α-helix
signal were monitored. The wavelength was set at 222 nm with the increase of temperature from
4 to 98 °C (Figure 3. 5B).
If the truncation of the loop does affect the folding and internal packing of the AcrB subunit,
then most likely there would be a change in the melting temperature. The change in the ellipticity
at 222nm reflected the change in protein secondary structure upon heat denaturation. Residual
helical structure maintained even when the proteins were heated to 98 ºC, which is consistent
with previous observations that helices in helical membrane proteins are very stable and a
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portion of them exist even in the unfolded stage.153 The melting curves of the two proteins
almost overlap, indicating a lack of significant difference in the thermal stability between
AcrB∆loop and wild type AcrB.
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Figure 3.5 A. Far UV CD spectra of wild type AcrB (open squares) and AcrBloop (filled
squares) superimpose well onto each other, indicating the two proteins had similar secondary
structure contents. B. Temperature denaturation curves of wild type AcrB (open diamond) and
AcrB∆loop (filled squares). The ellipticity values monitored at 222 nm against the temperature was
normalized to the reading at 4 oC. The thermal stabilities of the two proteins were very similar.

The near UV CD spectrum (260-350 nm) of both proteins was collected (Figure 3.6). The signal
of near UV CD comes from aromatic residues including tryptophan, tyrosine, and phenylanine,
which is related to protein’s tertiary and quaternary structure. When protein confirmation
changes, there is likely to be a change in the microenvironment of these aromatic residues, which
will affect their UV absorption and the CD spectrum. Also, the near UV CD is sensitive to the
intramolecular and intermolecular interaction of oligomeric proteins. The spectrums of the wild
type and mutant proteins were different, proving there is a difference in the local structure of
these residues (Fig. 3.6). This change may be at the tertiary structure or the quaternary structure
level, as both may potentially change the microenvironment of the residues.
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Figure 3.6 Near UV CD spectra of wild type AcrB (grey diamonds) and AcrBloop (black
squares).

3. 3. 5 Structural study of AcrB∆loop by limited protease digestion
Limited protease digestion is another well established method that has been used extensively to
probe a protein’s structure.154-158 A well folded protein is more resistant to protease digestion
than a poorly folded one. The pattern of the resultant peptide fragments may also reveal the
disordered portion of a protein. I compared the digestion results of AcrB∆loop and wild type AcrB
at different time points of trypsin treatment. As shown in Figure 3. 7. After 15 min of incubation,
90% of full length AcrB was preserved. Under the same experimental condition, AcrB∆loop was
digested much faster. A clear decrease of the full length protein was obvious within 5 min into
digestion, and at 15 min a large portion of the protein was digested into smaller fragments. This
result showed wild type AcrB was more resistant to trypsin digestion. This difference, again, can
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be explained by the structural differences of wild type AcrB and AcrB∆loop at the tertiary and/or
quaternary structure level. Difference in trypsin digestion rates elucidated the difference in the
accessibility of Lys and Arg to the enzyme. Two factors might cause the observed difference in
trypsin digestion rate: First, AcrB∆loop is a monomer. The inter-subunit interface in the trimeric
wild type AcrB provides better protection to potential trypsin recognition site from digestion.
Second, the tertiary structure of AcrB∆loop is different from that of wild type AcrB. Since
AcrB∆loop was digested faster, its tertiary packing might be “looser” than the tertiary structure
packing in wild type AcrB.

Figure 3.7 Limited trypsin digestion of purified wild type AcrB and AcrB∆loop. Under the current
experimental condition, wild type AcrB is highly resistant to the digestion. No apparent
degradation could be observed. AcrB∆loop is much more sensitive to digestion. Degradation of the
full length protein was apparent after 5 min of incubation. The grey arrow on the right pointed
out a compact fragment resulted from trypsin digestion of AcrB∆loop. Molecular weight marker
was on the right of the gel.
3.3.6 Structural study of AcrB∆loop by cysteine pair reporters
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To determine which factor is the cause of the digestion difference, the thiol trapping method
described in chapter II was used to examine protein tertiary structure under the native condition.
Most current protein structure characterization methods, such as CD spectroscopy and protease
digestion discussed above, require the extraction of the target membrane protein from the cell
membrane followed by purification. The sample preparation process may cause protein
oligomers to dissociate, thus cannot present protein native state in vivo. Substitution of the two
intrinsic Cys in AcrB with Ala has been shown to have no impact on AcrB activity.115 Seven
reporter cysteine pairs were introduced in the cysless AcrB (CLAcrB). All seven pairs formed
disulfide bond, and none of them affect the drug efflux activity of AcrB. The extent of disulfide
bond formation in the protein under native condition, that is, before the cell membrane was
disrupted, was probed using a blocking-reducing-labeling scheme as described in the materials
and methods section. Although the protein was eventually purified and analyzed using SDSPAGE, the blocking step helped to capture the state of the protein before it suffered from the
stress of protein purification.

First, loop deletion was introduced into the cysless AcrB (CLAcrB), the results were similar to
what had been observed in wild type AcrB. Later, 5 reporter Cys pairs were introduced in the
periplasmic domain of AcrB∆loop. If the protein tertiary or quanternary structure changed, the
distance between cysteine pairs would be affected and the change in disulfide bond formation
can be detected by the fluorescence labeling method. The extents of disulfide bond formation in
five reporter pairs were used to reflect potential structural change in AcrB∆loop. The profile of
disulfide bond formation in these reporter pairs with the AcrB∆loop mutation was shown in Figure
3.8.
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Figure 3.8 Disulfide bond formations in conformation reporters. The extents of sidulfide bond
formation were very similar in AcrB∆loop as compared to the wild type AcrB. Therefore, the
overall conformation, or tertiary structure, of AcrB∆loop is very close to that of the wild type AcrB.

The truncation of the protruding loop had no significant effect on the extents of labeling for all
reporter pairs, suggesting that the tertiary structure of AcrB in the cell membrane was not
affected by this mutation.

3.3.7 AcrB∆loop exists as a well-folded monomer
Finally, to investigate how the deletion of the loop eliminated transport activity, the oligomeric
state of AcrB was examined using blue native PAGE (BN-PAGE). BN-PAGE is a method
widely used in the determination of membrane protein oligomeric states and has been used to
confirm that wild type AcrB is a trimer.149,

150

The results of the BN-PAGE showed that

AcrB∆loop migrated as a monomer. also It has been confirmed that under the same experimental
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conditions wild type AcrB migrated as atrimer, consistent with the result in literature (Figure 3.
9).

Figure 3.9 After detergent purification, freshly prepared wild type AcrB samples migrated as a
trimer in the BN-PAGE. Under the same condition, purified AcrB∆loop migrated as a monomer.

The observation that AcrB∆loop migrated as a monomer in BN-PAGE after purification does not
completely rule out the possibility that the protein may associate weakly as a dimer or trimer in
the cell membrane, but dissociate during the process of purification and electrophoresis analysis.
To further investigate the impact of the mutation on the quaternary structure of the protein, crosslinking experiments were conducted using membrane vesicles and di(N-succinimidyl) 3,3′dithiodipropionate (DSP) as the crosslinker. DSP cross-links two -NH2 groups. Crosslinking was
performed using membrane vesicles extracted from BW25113∆acrB cells expressing wild type
AcrB or AcrB∆loop. Immunoblotting with an anti-AcrB antibody was used to detect the protein
bands after SDS-PAGE analysis. As shown in Figure 3. 10, the wild type AcrB trimer was
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clearly visible, while AcrB∆loop only migrated as a monomer. Some wild type AcrB monomers
were also visible, presumably due to the incompleteness of the cross-linking reaction. In the
absence of cross-linking, wild type AcrB also migrated only as a monomer under the same
experimental conditions. This result further confirms that AcrB∆loop exists as a monomer in the
inner membrane of E. coli.

trimer

monomer

Figure 3.10 Western blot analysis of membrane vesicles extracted from BW25113∆acrB
expressing the wild type AcrB or AcrB∆loop after chemical cross-linking.

3.3.8 Impact of expressing AcrB∆loop in a wild type E. coli strain on AcrB activity
To examine if the expression of AcrB∆loop interferes with the wild type AcrB subunit, I
transformed plasmid encoded AcrB∆loop into a wild type AcrB strain and examined the drug
susceptibility level of the resultant strain. Earlier study has shown that when another functionless
AcrB mutant, AcrBD408A, was overexpressed in a wild type E. coli strain, the drug susceptibility
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level of the strain is drastically reduced.111 D407 and D408 in AcrB are two highly conserved
acidic residues in the transmembrane domain that are critical for proton relay, which provides the
energy to drive the protein conformational change critical for the function of AcrB. The crystal
structure of AcrBD407A has been determined, which forms a trimer similarly as the wild type
AcrB.159 The exact reason that causes the observed dominant negative effect when AcrBD408A is
expressed in the wild type E. coli strain remains elusive. AcrBD408A could potentially interrupt
the normal function of genomic AcrB in the wild type strain through competing for binding with
AcrA and TolC, or co-assembling with the genomic AcrB. In order for AcrB to function properly
all three subunits in an AcrB trimer need to be active.

The MIC of the wild type strain BW25113 transformed with plasmids encoding wild type AcrB
or AcrB∆loop were shown in Table 3.2. BW25113 transformed with the empty vector pQE70 was
used as a control. Other than several established AcrB substrates, a non-AcrB substrate
kanamycin was also included as a control for nonspecific effect. Expression of membrane
proteins may cause stress in the cell and lead to a non-specific reduction of MIC. The MIC for
kanamycin was monitored as a control for this non-AcrB specific effect. The expression of
AcrB∆loop causes a small change of MIC at 2 folds or less for all substrates and kanamycin. This
result indicates that the expression of AcrB∆loop does not specifically affect the function of the
genomic AcrB.

Table 3.2 Minimum inhibitory concentration of BW25113 expressing plasmid encoded acrB
mutant genes.
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MIC (µg/ml)
Plasmids
Erythromycin

Novobiocin

pQE70

128

128

pQE70AcrB∆loop

64

64

pQE70AcrB

128

128

Folding of membrane proteins is an intriguing and yet poorly understood biological process.160 In
terms of α-helical membrane proteins, the research community has acquired a decent
understanding of the identification of transmembrane helices and the prediction of their topology
in the membrane. However, how membrane proteins achieve their tertiary and quaternary
structures remains largely elusive. Here, we demonstrated, using AcrB as an example, that for
proteins in which a soluble domain contributes significantly to inter-subunit interactions, a three
stage oligomerization pathway is more likely to be the case, as recognition between folded
domains is required prior to oligomerization. For proteins containing only transmembrane
domains, folding and oligomerization may happen co-translationally with membrane insertion
following a two-stage model.

3.4 CONCLUSION
AcrB and its homologues are major players in the efflux of antimicrobials out of Gram-negative
bacteria. The structural and functional unit of AcrB is a homotrimer. The assembly process of
obligate membrane protein oligomers, including AcrB, remains elusive. It is not clear if an
individual subunit folds into a monomeric form first followed by association (three-stage
pathway), or if association occurs simultaneously with subunit folding (two-stage pathway). To
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answer this question, the feasibility of creating folded monomeric AcrB mutant was investigated.
The existence of folded monomers in the cell membrane itself would be an evidence of a three
step pathway. A monomeric AcrB mutant, AcrB∆loop, was created through the truncation of a
protruding loop that appeared to contribute to the stability of AcrB trimer. AcrB∆loop expressed at
a similar level as wild type AcrB. The secondary structure content and tertiary conformation of
AcrB∆loop were very similar to that of the wild type AcrB. However, when expressed in an acrB
deficient strain, AcrB∆loop failed to complement its defect in drug efflux. Results from Blue
native polyacrylamide gel electrophoresis (BN-PAGE) and cross-linking experiments indicated
that AcrB∆loop existed as a monomer. The expression of this monomeric mutant in a wild type E.
coli strain did not have a dominant negative effect, suggesting the mutant could not efficiently
co-assemble with genomic AcrB. AcrB∆loop is the first monomeric mutant reported for the
intrinsically trimeric AcrB. The structural characterization results of this mutant suggest the
oligomerization of AcrB might occur through a three-stage pathway involving folded monomers.

Copyright © Meng Zhong 2013
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CHAPTER IV. INVESTIGATION OF MUTATIONS THAT RESTORE P223G ACRB
ACTIVITY
4. 1 INTRODUCTION
AcrB and its homologues are the inner membrane component of the Resistance-NodulationDivision (RND) family transporters in Gram-negative bacteria. AcrB forms a tripartite pump
system with membrane fusion protein AcrA and outer membrane TolC.161 In the AcrAB-TolC
complex, AcrB plays a dominant role in determining substrate specificity and drives the
operation of the complex.61, 62, 162 A broad range of structurally unrelated antibiotics, detergents,
organic solvents and dyes are substrates of the AcrAB-TolC pump.161 Hence, the pump plays a
major role in Gram negative bacterial drug resistance. The energy necessary to drive the active
transport of substrates against their concentration gradient by AcrAB-TolC efflux pump comes
from the proton motive force. Protons flow across the cytoplasmic membrane through a pathway
in the transmembrane domain of AcrB, which drives the conformational rotation that enables the
uptake of substrates from the outer leaflet of cytoplasmic membrane or periplasm and the
subsequent efflux of these substrates through TolC.163 In the process of substrate efflux, each
AcrB monomer rotates through three comformations, access, binding, and extrusion.62, 119
Several groups have successfully solved the AcrB crystal structure.61, 62, 108, 119 AcrB consists of
12 transmembrane (TM) domain and two large periplasmic loops which spans 70 Å in the
periplasm. Mutations at the TM domains, D407A, D408A, K940A, and T978A disrupted the
electrostatic network and disabled the pump.163, 164 It was believed the TM domains were only
responsible for the proton translocation.162 The two loops served as the linkers between TM helix
1 and TM helix 2 and TM helix 7 and TM helix 8, repesctively. Based on the structure and
functionality, the periplasmic region is divided in to a porter domain and a TolC-docking
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domain.165 (Figure 4.1) Exchange of AcrB and AcrD periplasmic loops altered the substrate
preference of the proteins, suggesting that residues important for substrate specificity
determination reside in the porter domain.65 Further mutational studies and AcrB-ligands
cocrystallization identified a deep binding pocket.66, 117, 166, 167 Depending on where they interact,
substrates were divided into two groups: groove binder and cave binder.67, 168 Using the BodipyFL-maleimide labeling method, Nikaido et al. elucidated the full substrate pathway in vivo.68, 69
Substrates first bind to the lower entrance of the cleft region, then go through the hydrophobic
binding pocket, finally to the AcrB funnel. Because the top part of the protein fits with the
periplasmic tip of TolC, this region of the protein is widely believed to be the TolC docking
domain. In each of the AcrB monomer, a hairpin like loop inserts into the neighboring chain
helps stabilize the whole trimer structure.58, 169
My group has studied the role of protruding hairpin loop extensively.170 AcrB is only functional
at its trimeric state. Deletion of the loop led to stability and activity loss of trimeric AcrB.
Further characterization showed mutation of proline 223 to glycine had the biggest impact on
drug tolerance. AcrBP223G existed as a weakly associated trimer in vivo.170 Here we conducted
random mutagenesis studies on AcrBP223G and identified nine mutants with restored protein
activity. The mutants were characterized from four aspects: protein expression level, trimer
stability, AcrA/TolC-AcrB interaction, and substrate binding.

4. 2 MATERIALS AND METHODS
Cloning, expression and purification of AcrBP223G and its mutants
Plasmid pQE70-AcrB was used as the template in the construction of AcrBP223G.170 The Quick
Change mutagenesis kit (Agilent Technologies, Santa Clara, CA) was used to create AcrBP223G.
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Complementary primers used for the construction of AcrBP223G are as follows: 5’CTCGGTGGTACGGGGCCGGTGAAAGGCCAAC-3’

and

5’-

GTTGGCCTTTCACCGGCCCCGTACCACCGAG-3’. Additional site-directed mutations were
created using the same method with primers accordingly. Protein coding sequences in all
plasmids used in this study were confirmed by DNA sequencing. (Eurofins MWG Operon, AL)
AcrB and its mutants were expressed in an E. coli strain deficient in gene acrB (BW25113ΔacrB)
and purified as described.21

Drug susceptibility assay of AcrB mutants
AcrB activities were studied by a drug resistance assay. The minimum inhibitory concentrations
(MIC) of different strains were measured as described.115 Briefly, E. coli strain deficient in gene
acrB (BW25113ΔacrB) was used as the host cell. Plasmids encoding different AcrB mutants
were used to transform BW25113∆acrB as well. Freshly transformed cells were plated on LBagarose plates containing 100 μg/mL ampicillin and 50 μg/mL kanamycin. The same ampicillin
and kanamycin concentrations were used throughout the study when noted. A single colony was
used to inoculate a LB media supplemented with ampicillin and kanamycin. The exponentialphase cultures of different strains were diluted to an OD600nm unit of 0.1 using LB broth. 2 µL of
this culture was added to LB-agar plate containing the indicated concentration of antibiotics. The
plates were incubated with shaking at 37oC overnight and the MICs were recorded the next
morningBW25113∆acrB strains transformed with plasmid-encoded wild type AcrB (WTAcrB) or
AcrBP223G were used as the positive and negative controls, respectively. Each experiment was
repeated at least three times.
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Random mutagenesis of AcrB and mutants screening
Random mutagenesis of AcrB was achieved by two methods, hydroxylamine hydrochloride
treatment and error-prone PCR. Chemical mutagenesis by hydroxylamine hydrochloride was
performed as described with some modifications.171 Plasmid pQE70-acrBP223G was incubated in
44 mM potassium phosphate buffer (pH 6.0), 5 mM EDTA and 0.46 M hydroxylamine
hydrochloride at 70°C for 40 mins. To quench the reaction, Tris-HCl (pH 8.0) and EDTA were
added to the mixture to final concentrations of 90 mM and 9 mM, respectively. DNA was
purified by gel extraction kit (Qiagen, CA) and later used for transformation.
Error prone PCR was carried out using GeneMorph II EZClone domain mutagenesis kit (Agilent,
CA). First, 500 ng of pQE-AcrBP223G was amplified by Mutazyme II DNA polymerase with two
pairs of primers. Primer RM1 (5’-ATGCCTAATTTCTTTATCGATCGC-3’) and primer RM2
(5’-AACGGCGTGGTGTCGTATGG-3’) were used to generate mutations in the first
periplasmic loop of AcrB. Primer RM3 (5’-CGTTGATCCTGACTCCAGCTC-3’) and RM4 (5’ATCGACCAGCTCTCGTACAG-3’) were used for the second periplasmic region of AcrB. PCR
products were separated and quantified using agarose gel, purified by gel extraction kit. Next,
500ng PCR products were used as mega-primers to amplify AcrBP223G using EZClone reaction.
DpnI was added to digest DNA template at 37ºC for 1 hour. PCR products from the second step
were purified by gel extraction kit.
E. coli BW25113∆acrB was electroporated with purified hydroxylamine mutagenesis and errorprone PCR mutagenesis of plasmids pQE70-AcrBP223G. 1 mL LB broth was added, and the
culture was shaken at 37ºC for 1 hr without addition of selective antibiotics. Then the
electroporated cells were plated on LB agar plates containing 100 µg/mL ampicillin, 50 µg/mL
kanamycin, and 16-32 µg/mL erythromycin. Plasmids were extracted from colonies that were
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able to grow on the erythromycin plates and retransformed into BW25113∆acrB strain. Drug
susceptibility of each mutant was tested. Those who showed both increased activity were sent to
DNA sequencing (Eurofins MWG Operon, AL).

Blue Native PAGE analysis of AcrB mutants
BN-PAGE was performed as described.149 Briefly, purified protein samples were mixed with
blue native loading buffer to reach a final concentration of 0.02M 6-aminoocaproic acid, 1%
dodecylmaltoside, 5% glycerol, 0.1% Coomassie brilliant blue G-250, pH 7.0. Protein samples
were loaded to a 4-15% polyacrylamide gradient gel (Bio-rad, CA). The electrophoresis was
performed using a running buffer (50mM Tricine, 7.5mM imidazole, 0.02% Coomassie brilliant
blue G-250, pH 7.0) at 150mA, in the 4°C refrigerator for 4 hours. The protein bands were
visualized after Coomassie Blue stain. Band intensity was quantified using the software ImageJ.

AcrA-AcrB, TolC-AcrB interaction assay
pQE70 histidine-tagged AcrB and its mutations were engineered into BW25113∆acrB strain to
study in vivo interaction of AcrB, AcrA and TolC. Co-purified AcrA and TolC after crosslinking
with AcrB-His on Ni-NTA beads were quantified by immunoblot. DSP crosslinking and copurification were performed as described with modifications.172 Briefly, BW25113∆acrB
harboring pQE70-acrB-his and mutant plasmids were cultured overnight in 100 mL LB
supplemented with ampicillin and kanamycin. Cells were harvested, washed with 5 mL 50 mM
Na-phosphate buffer (pH 7.2) twice. The pellet was resuspended in 5 mL Na-phosphate buffer
containing 4 mM cross-linking agent Dithiobis(succinimidylpropionate) (DSP) (Pierce), and
incubated at 37ºC for 30 mins. Tris was added to a final concentration of 50 mM to quench the
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reaction. Cell membrane vesicles was collected and extracted with 25 mM Tris buffer, 0.2M
NaCl, 2% Triton X-100 (pH=8.0) for 2 hrs on ice. Soluble fractions were incubated with NiNTA resins for 45 mins on ice. 10 bed volumes of 10 mM and 50 mM imidazole were used to
wash impurities off the resin. Bound AcrB-His were then eluted with 25 mM Tris buffer, 0.2 M
NaCl, 0.03% DDM, 0.5 M imidazole (pH 8.0). Dithiothreitol (DTT) was added to a final
concentration of 50 mM to the samples in order to break crosslinks. Finally, the samples were
analyzed by SDS-PAGE and immunoblotted with AcrA antibody and TolC antibody.

Analysis of expression levels of AcrB mutants by immunobloting
Freshly transformed colonies of BW25113ΔacrB strain containing plasmid-encoded wild type
AcrB, AcrBP223G and mutants were used to inoculate LB medium containing ampicillin and
kanamycin. Cells were harvested after overnight culture and ruptured using French Press in 10
mM HEPES-KOH buffer (pH 7.5) and 0.5 mM PMSF. Unbroken cells were removed by lowspeed centrifugation and the membrane vesicle was collected after ultracentrifugation at 150,000
g for 1 hour at 4°C. The pellet was resuspended in 10 mM K-HEPES (pH 7.5) buffer containing
2% (wt/vol) SDS for solubilization of inner membrane proteins. Then after adding SDS-Loading
buffer the samples were separated on 8% SDS-PAGE and immunoblotted using polyclonal rabbit
anti-AcrB antibody.

Fluorescent labeling
Bodipy-FL-maleimide labeling was conducted following the published method.68 Briefly,
BW25113ΔacrB cells harboring plasmids encoded AcrB mutants were cultured overnight at
37ºC. 10 mL culture were harvested by centrifugation at 4,000×g for 5 min, washed twice using
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10 ml of buffer A (50 mM potassium phosphate, 0.5 mM MgCl2, pH 7.0), and finally
resuspended in 5 mL of the same buffer containing 0.4% glucose and 6 µM Biodipy-FLmaleimide. Final cell density was adjusted to OD660 of 3.5. The mixture was shaken at room
temperature for 1 hr. Next, Cells were harvested by centrifuge, washed with 5 ml buffer A with
0.4% glucose, and then washed again with 5 ml buffer A. AcrB was then purified following as
described with some modifications. Cells were lysed by sonication and centrifuged at 16,000×g
for 15 minutes. Buffer B (50 mM sodium phosphate, 0.2 M NaCl, pH 8.0) containing 10 mM
imidazole 2% DDM was used to solubilize the pellets for 2 hours on ice. The samples were then
collected by centrifugation at 16,000×g for 20 minutes. The supernatant was incubated with NiNTA beads at 4°C for 2 hrs. Resins were then washed with buffer B containing 50 mM
imidazole, and 0.03% DDM. Finally the protein was eluted with buffer B containing 500 mM
imidazole, and 0.03% DDM (pH 8.0).
Samples after purification were resolved by SDS-PAGE. Fluorescence signal were collected by
Typhoon Phosphorimager at the excitation wavelength of 488 nm. The gel was then stained with
Coomassie blue stain and imaged under white light. Bands from both gels were quantified by
ImageJ and relative labeling content was calculated.

4.3 RESULTS AND DISCUSSION
4. 3. 1 Random mutagenesis screening of repressor mutants that can restore AcrBP223G
activity
P223G mutation decreases AcrB oligomer stability and compromises efflux activity.170 In this
study, random mutagenesis and positive screening were used to identify mutations that recover
AcrB activity caused by P223G mutation. This could potentially help us identify residues and
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regions which are important for AcrB oligomerization and improve our understanding about the
mechanism of the AcrAB-TolC pump.
We used LB agar plate containing erythromycin to screen for high activity colonies. The reason
erythromycin was used as the screening substrate was that the difference of MIC between WT
AcrB and AcrBP223G is significant. MIC of erythromycin of AcrBP223G was 8 µg/mL. The
erythromycin concentrations in our screenings were 16 µg/mL and 32 µg/mL.
Here, we used two methods to introduce random mutations into the gene of AcrBP223G, chemical
mutagenesis and error-prone PCR. Using hydroxylamine hydrochloride chemical mutation, we
were only able to identify two mutations, T199M and D256N, which showed higher
antimicrobial resistance. Error-prone PCR was also used to achieve uniform spectrum of
mutation with equivalent mutational rates. Two pairs of primers, RM1/RM2 and RM3/RM4 were
designed, so that we could confine the random mutations to two periplasmic regions: residue 30
to 332 and residue 494 to 889. We focused our mutation studies in the periplasmic region, since
it is likely that the periplasmic domain play a more important role in substrate binding,
trimerization, and interacting with AcrA/TolC.
Two random mutagenesis methods were used to search for mutations that could restore
AcrBP223G activity. Hydroxylamine hydrochloride treatment showed a low mutational rate. The
reason was that the method is biased, as it would only result in transition from C to T and G to
A.173 In this way, the method itself limited the possibilities of some codon transition. Compare to
chemical mutation, error-prone PCR has several advantages. First, the method largely reduced
mutational bias. Second, mutational rate can be controlled by modification of buffer condition.
Third, primer design could help us control the mutational sites. Despite all the advantages, due to
the limitations of codon similarities, the method still wasn’t completely random. With this design,
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we identified nine mutants in AcrB periplasmic loop region with increased susceptibility to
erythromycin, T199M, A209V, D256N, G257V, M662I, Q737L, D788K, P800S, and E810K.
To ensure that the increased activity did not come from bacterial strain evolution or mutations in
the plasmid vector, all mutations were constructed by site-directed mutation, retransformed into
BW25113∆acrB strains. Five AcrAB-TolC pump substrates were tested to confirm the mutants
drug susceptibilities, erythromycin, novobiocin, tetracycline, tetraphenylphosphonium, and
rhodamine 6G. MICs of the nine mutants were shown in Table 4. 1. All of the mutants showed
increased MIC comparing to AcrBP223G for all five AcrB substrates. Locations of these mutations
were mapped onto AcrB structure. (Figure. 4.1)
Table 4.2 showed the conservations of these nine residues in AcrB and 13 homologues. Although
overall the sequence of AcrB is highly conserved in Gram-negative bacteria, only three residues
here were conserved. This is a reasonable observation since mutation of highly conserved sites
might by itself cause function loss. Highly conserved residues are likely to be structural or
functional related.
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Table 4. 1 Conservation in inner membrane component of RND type efflux pump of amino acid
residues who restored AcrBP223G activity.
Organism

Protein

199

209

256

257

662

737

788

800

810

E.coli

AcrB

T

A

D

G

M

Q

D

P

E

E.coli

AcrD

T

S

D

G

V

I

Y

S

G

E.coli

AcrF

T

V

D

G

V

A

I

F

Y

P. Aeruginosa

MexB

T

A

D

G

M

A

W

F

Y

H. pylori

AcrB

D

V

I

G

V

Q

E

R

P

Y. pestis

AcrB

T

I

D

G

V

A

W

F

Y

V. cholera

AcrB

T

E

N

G

V

A

W

F

Y

K. pneumonia

AcrB

T

A

D

G

V

A

W

F

Y

AdeB

L

R

T

N

P

D

G

Q

R

A. tumefaciens

AmeB

T

Q

G

A

I

D

N

S

S

P. Putita

TtgB

T

A

D

G

M

Q

D

P

E

C. jejuni

CmeB

G

V

N

E

G

M

N

T

V

B. pseudomallei

AmrB

A

H

G

G

N

M

E

K

I

N. gonorrhoeae

MtrD

A

N

S

N

V

G

V

T

T

A.baumannii

To figure out by which means these mutations increase AcrBP223G activity, we characterized the
mutants from four aspects: 1) protein expression level; 2) oligomer stability; 3) AcrA/TolC
interaction; 4) drug binding.
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Table 4. 2 MIC (µg/mL) of BW25113∆acrB harboring the corresponding plasmids. Drugs tested
were Erythromycin (Ery), Novobiocin (Nov), Rhodamine 6G (R6G), Tetraphenylphosphonium
(TPP), and Tetracycline (Tet).
plasmids

MIC (µg/mL)
Ery

Nov

Tet

TPP

R6G

128

320

2.56

320-640

>640

8

40-80

0.64

20-40

40-80

128

160

2.56

320-640

>640

pQE70-AcrB

64

80

1.28

40-80

>640

pQE70-AcrB

32-64

160-320

2.56

320

>640

pQE70-AcrB

64

160

2.56

80-160

>640

pQE70-AcrB

64-128

80

1.28

160

160

pQE70-AcrB

64

160

2.56

160-320

>640

pQE70-AcrB

128

160

2.56

160-320

160-320

pQE70-AcrB

64

80

1.28

40-80

>640

pQE70-AcrB

128

160

2.56

160-320

>640

pQE70-AcrB
pQE70-AcrB

P223G

pQE70-AcrB

P223G/T199M
P223G/A209V
P223G/D256N
P223G/G257V
P223G/M662I

P223G/Q737L

P223G/D788K
P223G/P800S

P223G/E810K
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TolC Docking
Domain

Porter Domain

Transmembrane
Domain

Figure 4. 1 Structure of AcrB (created using protein data bank file 1IWG by Pymol). Proline 223
at the protruding loop was marked in yellow. Mutations were marked in red.

4. 3. 2 Expression Levels Of AcrBP223G Mutants
To determine the effects of additional mutations on AcrBP223G expression level, we extracted
membrane vesicles from BW25113∆acrb expressing AcrB mutants, and analyzed with
quantitative western blot. (Figure. 4. 2)
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Figure 4.2 Western blot analysis of membrane vesicle extracted from BW25113∆acrB
expressing AcrBP223G and mutants.

Eight of the nine mutations, T199M, A209V, G257V, M662I, Q737L, D788K, P800S, E810K
showed no significant difference in expression level when comparing to AcrBP223G. Interestingly,
one of the mutations, D256N drastically increased AcrB level, approximately by 20 fold. Also,
as revealed in figure 4.3, cells expressing AcrBP223G/D256N grow much slower than AcrBP223G. The
growth rates of all other mutants were similar to that of WT AcrB and AcrBP223G. Previous result
has shown that the expression level of AcrBP223G is comparable with that of WT AcrB. However,
the trimer stability of AcrBP223G in vivo was much lower than WT AcrB. Introduction of D256N
increase the overall amount AcrB number, therefore more active form of AcrB trimer could have
provided more efficient drug extrusion and increased pump activity. D256N is the only mutation
that increased AcrB expression level drastically. Gene expression is related to several global
cellular parameters, such as gene and plasmid copy number, abundance of tRNA and ribosomes,
and growth rate.174 Our group has shown that when expressing in a low copy number plasmid
pBAD, AcrB expression level could be raised by three fold. In this case, we speculate the growth
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differences between mutants are due to the tRNA abundance. The relative content of tRNA of
amino acid Asp is twice as high as that of Asn. The real-time codon frequency of “GAT” (Asp)
is three times higher than “AAT” (Asn).175 The lower abundance of tRNA may contribute to the
lower growth rate of AcrBP223G/D256N and higher expression level. This observation has also been
verified by Rand et al. using medium with iron, glucose, and nitrogen limitations.176 The upregulation of AcrB is inversely proportional to cell growth rate. Additionally, the feedback
mechanism induced cell’s self-defense system could also stimulate AcrB expression and
promotes higher drug resistance.174

2.0

OD600

1.5

1.0

0.5

0.0

0

1

2

3

4

5

6

time/hour
Figure 4.3 Cell density OD600 of AcrBP223G (black) and AcrBP223G/D256N (Grey) in five hours. The
start culture cell density for both strains was 0.100.

4. 3. 3 BN-PAGE Analysis Of AcrB Mutant Oligomerization States
To evaluate the impacts of the mutations on AcrB oliogomerization states, we used BN-PAGE to
study AcrB mutant trimer stability. BN-PAGE is a widely used technique in characterizing
protein complex from biological membrane, homogenates of cell and tissue, and studying
protein-protein interaction. The technique has been used extensively in studies of MDR
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transporter oligomerization.177, 178 Freshly purified AcrB mutants were separated by BN-PAGE.
(Figure 4. 4 A & B) Protein band intensities in the gel were quantified using ImageJ and trimer
percentage was calculated using the following equation:
Trimer% = =

IT
IT + I M

IT = intensity of trimer band, IM = intensity of monomer band
Both gels used AcrBP223G as a control. After the calculation, trimer percentage of all mutants
were normalized by that of AcrBP223G and showed in Figure 4. 4C.

A)

B)
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Figure 4. 4 A) & B) BN-PAGE analysis of purified AcrB constructs. Positions of monomer and
trimer bands were marked. AcrBP223G was loaded into both gels as control for quantification. C)
Trimer percentage of mutants normalized by trimer percentage of AcrBP223G. The experiment
was repeated three times, average value and standard deviation were shown.

The majority of AcrBP223G existed as monomer which makes it incompetent to perform AcrB
function. In five of the mutants, AcrBP223G/T199M, AcrBP223G/A209V, AcrBP223G/D256N, AcrBP223G/M662I,
AcrBP223G/D788K showed approximately 1.5 to 2 fold increase in trimer percentage. The trimer
percentage of AcrBP223G/E810K was increased by 1.3 fold.

4. 3. 4 In Vivo AcrA-AcrB Interaction
The majority of mutations occurred at the TolC docking domain of AcrB. To verify if these
mutations have any impact on AcrA/TolC-AcrB interaction, DSP crosslinking and copurification
were performed. Images of Western blot membrane and gel after Coomassie blue staining were
showed in Figure 4. 5. Coomassie blue gels were used to quantify AcrB. Ratio of intensity of
AcrA or TolC bands to AcrB bands were compared between WT AcrB, AcrBP223G, and mutants.
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In each case, BW25113∆acrB transformed with pQE70 vector were used as a negative control to
confirm that the signal was not from non-specific interaction of AcrA and TolC with Ni-NTA
resin. No signal could be visualized for negative control, suggesting AcrA and TolC could not
retain on Ni-NTA resin without cross-linked with AcrB. AcrBP223G/T199M and AcrBP223G/G257V, and
AcrBP223G/P800S showed higher AcrA signal than AcrBP223G. It is possible that these mutations
improved AcrA/AcrB interaction, which could help stabilize the AcrAB-TolC tripartite complex.

P223G/M662I

P223G/G257V

P223G/D256N

P223G/A209V

P223G/T199M

P223G

pQE70

WT AcrB

A)

90

P223G/E810K

P223G/P800S

P223G/D788K

P223G/Q737L

P223G

pQE70

WT AcrB

B)

Figure 4.5 A) Top: Western blot analysis of co-purified AcrA after DSP crosslinking from
BW25113∆acrB expressing WT AcrB, pQE70, AcrBP223G, AcrBP223G/T199M, AcrBP223G/A209V,
AcrBP223G/D256N, AcrBP223G/G257V, and AcrBP223G/M662I. Bottom: Coomassie blue staining of copurification samples after DSP crosslinking. Each lane is in accordance to AcrA western blot
membrane. B) Top: Western blot analysis of co-purified AcrA after DSP crosslinking from
BW25113∆acrB expressing WT AcrB, pQE70, AcrBP223G, AcrBP223G/Q737L, AcrBP223G/D788K,
AcrBP223G/P800S, and AcrBP223G/E810K. Bottom: Coomassie blue staining of co-purification samples
after DSP crosslinking. Each lane is in accordance to AcrA western blot membrane.

To examine if these mutations affect AcrB interaction with other components in the pump, DSP
crosslinking was used to study the interaction between AcrA and AcrB in vivo. First, much less
AcrA was copurified with AcrB∆loop than with WT AcrB (data not shown), suggesting AcrA
prefers interacting with trimeric AcrB. However, there was no difference between the level of
AcrA copurified with WT AcrB and AcrBP223G. This, along with MIC test, further proved that
instead of existing as monomer in vivo, AcrBP223G existed as a loose trimer which is partially
active. Four of the mutants, T199M, A209V, G257V, and P800S, lead to higher AcrA copurification than AcrBP223G. AcrA existed as an oligomer in vivo.105 These results indicate that
oligomeric AcrA has a higher affinity towards these mutants. The interaction with AcrA may
help strengthen AcrB trimer.

4. Bodipy-FL-maleimide labeling of AcrBP223G/M662I
Of all mutations, AcrBP223G/M662I is especially interesting. This is the only mutant that resides in
AcrB porter domain. It is unlikely that this mutation could have any effect on AcrA or TolC
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interaction. Studies have shown that conversion of Phe664 and Phe666 to alanine drastically
decreased MICs.66 Nikaido and coworkers have used Bodipy-FL-maleimide labeling method to
prove that Phe664 and Phe666 were at the substrate pathway.61 Therefore, we speculate that Met
662 was involved in substrate binding. To prove the hypothesis, we introduced a cysteine as Met
662, and did Bodipy-FL-maleimide labeling. (Figure 4. 6) There were two cysteines in WT AcrB,
none of which is in substrate binding pocket. Thus, WT AcrB was used as negative control,
while AcrBF664C was used as positive control. AcrBM662C could be labeled by Bodipy-FLmaleimid, suggesting Met662 is accessible to AcrB substrate. It is likely that Met662 is in the
drug extrusion pathway. However, AcrBM662C stained less strongly than AcrBF664C, which may
indicate substrate interaction at this site is much weaker.

A)
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120kDa
90kDa
B)
Figure 4. 6 A) Structure of AcrB from a different angle (created using protein data bank file
1IWG). Met 662 was highlighted in red. B) Top: covalent label of WT AcrB, AcrBM662C, and
AcrBF664C by 6 µM Bodipy-FL-maleimide. Bottom: Coomassie blue staining of the
corresponding gel after Bodiphy-FL-maleimide labeling.

Only one mutation, M662I, happened at AcrB substrate binding pocket. As we know, the drug
binding site of AcrB is highly phenylalanine rich.66 Drugs mainly interact with the protein
through hydrophobic interaction. Conversion from Met to Ile increased the hydrophobicity,
which may increase the mutants-ligand affinity.179 Also, AcrB is more stable in its trimeric states
with this mutation, suggesting that interaction with substrates could help hold the oligomer
together. This ligand-induced oligomerization has been observed in several receptor proteins.180,
181

Three residues were identified at the inter-subunit interface in an AcrB trimer (Table 4). Ala209,
Gln737, Glu810 and the residues within 6Å of each amino acid in the neighboring chain were
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marked in Figure 6. Residues close to Ala 209 and Gln 737 were both hydrophobic. Thus,
mutations to valine and leucine increase the hydrophobic interaction between chains and
strengthen the trimer. Percentage interface assecible surface area (ASA) of Glu 810 is much
lower than the other two residues. The mutation might have a minor impact on the association
between chains of AcrBE810K. However, Glu 810 is exposed, which makes it possible to be
related to AcrA or TolC interaction.
Table 4.3 Interface property of Ala 209, Glu 737, and Gln 810. Interface between each AcrB
subunit calculated using online server PROTORP
Residue

Residue

Interface

% Interface

Number

Name

ASA

ASA

209
737
810

ALA
GLN
GLU

31.24
43.94
9.53

1.15
1.61
0.35

A)
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Segment

5
17
20

B)

C)
Figure 4. 7 Zoom in view of neighboring residues of amino acids Ala 209 (A), Gln 737 (B) and
Glu 810 (C) at interface between AcrB monomers. The residues at the interface were shown in
green, neighboring residues were marked in cyan. The three chains in AcrB trimer were marked
in red, blue and yellow, respectively.

4. 4 CONCLUSION
AcrB and its homologous are the inner membrane components of the major multidrug transporter
in Gram-negative bacteria. It assembles with AcrA and TolC to form a tripartite pump system.
AcrB recognizes and exports a broad range of functionally and structurally unrelated substrates,
and therefore decreases the drug susceptibility of the bacteria. AcrB harvests the proton motive
force to drive the conformational change required by function and determines the substrate
specificity of the pump. AcrB exists and operates as a homotrimer in vivo. Previous mutational
studies showed when a Pro (P223) at the inter-subunit interface was replaced by a Gly, the trimer
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stability was reduced, leading to drastically compromised protein activity. Using hydroxylamine
treatment and error prone PCR, random mutagenesis was performed and nine mutants were
identified that restored the activity loss in AcrBP223G. The mechanism of activity restoration was
analyzed based on current understanding of AcrB function. Nine mutants were identified with
higher efflux activity. The mechanisms of restoration were evaluated and summarized from four
aspects (Table 4.4). We found that while some mutations recover the function of AcrBP223G
through directly increase the cellular abundance of AcrB trimer, others work indirectly through
affecting substrate binding or AcrA-AcrB interaction.
Table 4.4 Summary of effects of mutations on protein expression, trimer stability, AcrA
interaction, and substrate binding.
Mutation

T199M

A209V

D256N

G257V

M662I

Q737L

D788K

P800S

E810K









Expression level
Trimer percentage



AcrA interaction













Substrate affinity

Copyright © Meng Zhong 2013
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CHAPTER V. HETEROLOGOUS EXPRESSION OF H. PYLORI ACRB IN E. COLI
5. 1 INTRODUCTION
In 1982, Helicobacter pylori (H. pylori) was first identified from the stomach of patients with
gastritis and peptic ulceration in Western Australia. It is a unipolar, spiral-shaped gram-negative
bacterium, about 0.5-1.0 µm in width and 2.5-4.0 µm in length. At least 50% of the world’s
population is infected by H. pylori.182 Infection by H. pylori causea chronic gastric inflammation,
which slowly develops into peptic ulcer and duodenal ulcer.183 Recently, it has been established
that infection with H. pylori is associated with atrophic gastritis, leading to a higher occurrence
of gastric cancer.184
Routine H. pylori diagnosis can be done by testing blood antibody, stool antigen, carbon urea
breath, and endoscopy.185-187 These tests do not need microbial culture. Because H. pylori culture
is time consuming, labor intensive and expensive, it is not practical to be used as a diagnosis
technique. However, it is sometimes required to culture the bacterium in research labs and for
epidemiologic purpose. For instance, antibiotic susceptibility, bacterium metabolism, growth
factor studies have to be performed in plate or broth culture. The growth of H. pylori requires a
micro-aerobic environment with high humidity.188 Normally, H. pylori is incubated in 30-37ºC
CO2-rich shaker. Subtle change in environment, such as addition of antibiotics, glucose and lipid,
nutritional deficiency, pH change, abnormal temperature may induce the formation of coccoid.189
Coccoid is a viable, metabolically active but non-cultivable form of H. pylori. To prevent
coccoid growth, numerous efforts have been made to optimize H. pylori culture. It has been
shown when particular supplements were added to medium, H. pylori growth can be improved
and accelerated.190 The supplements can be whole animal whole blood, serum, corn starch, egg
yolk emulsion, and charcoal. Nevertheless, growth of H. pylori takes 3-5 days with the optimum
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condition, which is much longer comparing to the growth of other bacterium species. Moreover,
cultivation of H. pylori increases the risk of exposing the researcher to a pathogenic organism.
Therefore, the alternative path involving heterologous expression has been widely employed in
studies of H. pylori proteins.191, 192
Long before the discovery of H. pylori, H2-receptor antagnoists has been successfully used to
cure patients with ulcer gastritis.193 Later, acid pump inhibitor has been used in clinical
treatment.194 Both drugs decrease gastric acid secretion of parietal cells in the stomach. However,
due to the spread of multidrug resistance, it is becoming more and more difficult to eradicate H.
pylori infection. Since 1990s, several antibiotics have been prescribed routinely for gastric
disease treatment. Today, tetracycline, metronidazole, amoxicillin, clarithromycin, bismuth, and
H+/K+-ATPase inhibitors are commonly used. Two or three antimicrobials are generally needed
to completely eradicate the bacterium.195 Unfortunately, an effective approach to cure H. pylori
in all patients has not been developed. According to geographical distribution, drug resistance is
usually caused by variable mechanisms.
Triple antimicrobial therapy (proton pump inhibitor, amoxicillin, and clarithromycin) are
recommended for clinical eradication of H. pylori infection in many countries. When the cocktail
therapy was first introduced in 1990s, the successful rate is over 80%.196 However, in a recent
summary, only 18% of the hospital reported over the 85% successful H. pylori eradication rate
due to multidrug resistance. Several factors contributed to antibiotic resistance in H. pylori,
including point mutation, enzyme inactivation, and drug efflux. Using RT-PCR, site-directed
mutagenesis study, and efflux pump inhibitor, the link between RND efflux pump system and
MDR in H. pylori is emerging.197 However, so far, no other research group has explored the role
of the AcrA-AcrB-TolC efflux system in H. pylori. Due to the restrictions in the growth
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conditions, H. pylori is much more difficult to culture than E. coli. Hence, I tried to
heterologously express H. pylori AcrB in E. coli system using recombinant DNA techniques.
Different growth conditions and different vectors were evaluated.

5.2 MATERIALS AND METHODS
Construction of plasmids
The genes encoding H. pylori AcrB and AcrA were amplified from Helicobacter pylori 26695
genomic DNA (ATCC, VA). The primers used for the PCR reactions were listed in table 5.1.
Table 5.1 Primers used for the amplification of AcrB and AcrA from H. pylori
Primers

Sequence

HPacrBFW

5’-ATTCCATATGTATAAAACAGCGATTAATCGTCC-3’

HPacrBRV

5’-AACCCTCGAGAGTTTTTTGGTTTTGATAAAACC-3’

HPacrAFW

5’-AGCATATGATACGAAAAATTTTAATAG-3’

HPacrARV

5’-TGAAGCTTATTTCGTTTGGATAAACC-3’

After amplification, PCR product containing H. pylori AcrB gene was digested using NdeI and
XhoI. Product containing H. pylori AcrA gene was treated with NdeI and HindIII. Digestion
products were separated by agarose gel electrophoresis and extracted from gel extraction kit.
Purified DNA fragments were inserted into pET-22b (New England Biolabs, MA) and pBAD-33
vector (Addgene, MA).

Preparation of competent cell
Three kinds of competent cells were prepared.198 For E. coli BW25113∆acrB preparation, first
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E.coli BW25113∆acrB was streaked on a LB plate containing 50 µg/mL kanamycin, and
incubate at 37ºC overnight. A single colony was used to inoculate 3 mL LB medium and grow at
37ºC overnight. A 200 mL LB media culture inoculated with 2 mL overnight BW25113∆acrB
culture was shaken vigorously till OD600 gets to 0.4. No selection marker was added at this step.
Cells was cooled and centrifuged at 3,000 rpm for 15 mins at 4ºC. The pellets were resuspended
in 12 mL of cold 0.1 M CaCl2, and incubate on ice for 45 mins. Cells were collected by
centrifuge at 3,000 rpm for 15 mins. Supernatant was discarded and cells were resuspended in
3.2 mL cold 0.1M CaCl2 containing 15% glycerol. Competent cells were aliquoted into cold
Ependorff tubes, frozen in liquid nitrogen, and stored at -80ºC. E. coli BW25113∆acrB harboring
pBAD33-HPacrB or pET22-HPacrB competent cells were prepared the same way with addition
of chloramphenicol and ampicillin to the LB agar plate, respectively.

Transformation, co-transformation and colony screening
1 µL 50 ng/µL plasmids was added to 60 µL competent cell, and incubate on ice for 30 mins.
The plasmid-cell mixture was heat-shocked at 42ºC for 1 min, followed by immediate incubation
on ice for 5 mins. 1 mL LB medium was added to the cell. The cells were incubated at 37ºC for
45 mins, and plated on LB agar plates containing antibiotics.
For co-transformation, pBAD33-HPacrB/pET22-HPacrA and pBAD33-HPacrA/pET22-HPacrB
were each transformation into BW25113∆acrB competent cells, respectively. Ampicillin,
kanamycin and chloramphenicol were all added in the LB plates. In addition, 8 µg/mL
novobiocin or erythromycin was added to the plates. The colonies that are able to grow in
substrate containing plates were further analyzed.
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Drug susceptibility assay
AcrB activity was monitored using a drug susceptibility assay as described in chapter 2.

Western blot analysis of AcrB expression in active colony
Western blot analysis was performed as described in chapter 2.

Plasmid loss
Active colonies were first cultured in LB media containing ampicillin, kanamycin and
chloramphenicol overnight. 5 µL of overnight culture were used to inoculate 5 mL LB medium
containing only kanamycin. The cultures were shaken at 37°C for 24-96 hours continuously. 1
mL culture were taken out at 24, 36, 48, 72, and 96 hrs, and diluted 10,000 times. 10 µL cultures
were plated on LB agar plate with kanamycin and incubated overnight. 10 colonies were picked
from each plate and cultured in LB medium with kanamycin. After the growth, each culture of
the colonies was diluted with LB medium containing ampicillin and chloramphenicol. Colonies
that failed to grow in the presence of ampicillin and chloramphenicol were studied.

5. 3 RESULTS AND DISCUSSION
5.3.1 Sequence Alignment Of AcrB From H. pylori and E. coli
AcrB is highly conserved in Gram-negative bacteria. Previously, Srikumar and co-workers
showed when expressing in E. coli strain, MexB from Pseudomonas aeruginosa increased drug
resistance of E. coli AcrB deficient strain.199 This result indicates that AcrB from a different
organism expresses and functions in E. coli. I used online server T-coffee to align amino acid
sequences of AcrB from H. pylori and E. coli. The results demonstrated H. pylori AcrB was 86%
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similar to E. coli AcrB (Figure 5. 1). The high similarity score offered potential for heterologous
expression of H. pylori AcrB in E. coli.
Ecoli
Hpylori

MPNFFIDRPIFAWVIAIIIMLAGGLAILKLPVAQYPTIAPPAVTISASYP
MYKTAINRPITTLMFALAIVFFGVMGFKKLSVALFPKIDLPTVVVTTTYP
* : *:*** : ::*: *:: * :.: **.** :*.* *:*.::::**

Ecoli
H
pylori

GADAKTVQDTVTQVIEQNMNGIDNLMYMSSNSDSTGTVQITLTFESGTDA
GASAEIIESKVTDKIEEAVMGIDGIKKVTSTSSKNVSI-VVIEFELEKPN
**.*: ::..**: **: : ***.: ::*.*... :: :.: ** .

Ecoli
Hpylori

DIAQVQVQNKLQLAMPLLPQEVQQQGVSVEKSSSSFLMVVGVINTDGTMT
EEALNDVMNKISSV-RF--DDSNIKKPSINKFDTDSQAIISLFVSSSSVP
: * :* **:. . : :: : : *::* .:.
::.:: :..::.

Ecoli
Hpylori

QEDISDYVAANMKDAISRTSGVGDVQLFGS-QYAMRIWMNPNELNKFQLT
ATTLNDYAKNTIKPMLQKINGVGGVQLNGFRERQIRIYADPTLMNKYNLT
:.**. .:* :.: .***.*** * : :**: :*. :**::**

Ecoli
Hpylori

PVDVITAIKAQNAQVAAGQLGGTPPVKGQQLNASIIAQTRLTSTEEFGKI
YADLFSTLKAENVEIDGGRIVN------SQRELSILINANSYSVADVEKI
.*:::::**:*.:: .*:: .
.* : **: ::. *. :. **

Ecoli
Hpylori

LLKVNQDGSRVLLRDVAKIELGGENYDIIAEFNGQPASGLGIKLATGANA
-----QVGNHVRLGDIAKIEIGLEEDNTFASFKDKPGVILEIQKIAGANE
* *.:* * *:****:* *: : :*.*:.:*. * *: :***

Ecoli
Hpylori

LDTAAAIRAELAKMEPFFPSGLKIVYPYDTTPFVKISIHEVVKTLVEAII
IEIVDRVYEALKRIQAISPN-YEIRPFLDTTSYIRTSIEDVKFDLILGAI
:: . :
* :::.: *. :*
***.::: **.:*
*: . *

Ecoli
Hpylori

LVFLVMYLFLQNFRATLIPTIAVPVVLLGTFAVLAAFGFSINTLTMFGMV
LAVLVVFAFLRNGTITLVSAISIPISIMGTFALIQWMGFSLNMLTMVALT
*..**:: **:*
**:.:*::*: ::****:: :***:* ***..:.

Ecoli
Hpylori

LAIGLLVDDAIVVVENVERVMAEEGLPPKEATRKSMGQIQGALVGIAMVL
LAIGIIIDDAIVVIENIHKKL-EMGMSKRKASYEGVREIGFALVAISAML
****:::******:**:.: : * *:. ::*: :.: :* ***.*: :*

Ecoli
Hpylori

SAVFVPMAFFGGSTGAIYRQFSITIVSAMALSVLVALILTPALCATMLKP
LSVFVPIGNMKGIIGRFFQSFGITVALAIALSYVVVVTIIPMVSSVVVNP
:****:. : * * :::.*.**:. *:*** :*.: : * :.:.:::*

Ecoli
Hpylori

IAKGDHGEGKKGFFGWFNRMFEKSTHHYTDSVGGILRSTGRYLVLYLIIV
R--------HSRFYVWSEPFFKALESRYTKLLQWVLNHKLIIFIAVVLVF
:. *: * : :*:
:**. : :*. .
:: :::.

Ecoli
Hpylori

VGMAYLFVRLPSSFLPDEDQGVFMTMVQLPAGATQE-RTQKVLNEVTHYY
VGSLFVASKLGMEFMLKEDRGRFLVWLKAKPGVSIDYMTQKS--KIF--** :: :* .*: .**:* *:. :: .*.: : ***
::

Ecoli
Hpylori

LTKEKNNVESVFAVNGFGFAGRGQNT--GIAFVSLKDWADRPGEENKVEA
QKAIEKHAEVEFTTLQVGY-GTTQNPFRAKIFVQLKPLKERKKEHQLGQF
. :::.* *:. .*: * **. . **.**
:* *.: :
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Ecoli
Hpylori

ITMRATRA-FSQIKDAM-VFAFNLPAIVELG---TATGFDFELIDQAGLG
ELMRVLRKELRSLPEAKGLDTINLSEVTLIGGGGDSSPFQTFVFSHSQEA
**. * : .: :* : ::**. :. :*
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Ecoli
Hpylori
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Ecoli
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* :::::::

Ecoli
Hpylori
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*******
** :*:.:**.. **::* :
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Ecoli
Hpylori
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VGKNATLLIDVANEE-RKKGLNIQEAILFAGKTRLRPILMTTIAMVCGML
.*** *:::.*::
*:* .: ** * * : ********::*:: *::

Ecoli
Hpylori

PLVISTGAGSGAQNAVGTGVMGGMVTATVLAIFFVPVFFVVVR------R
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**.:::* *:. :..:* .: **:: : **::::****: ::
:

Ecoli
Hpylori
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** :::: :
.

Figure 5.1 Sequence alignment of AcrB from E.coli and H. pylori using online alignment server
T-COFFEE

5.3.2pMal-HP AcrB And pBAD33-HP Did Not Confer Drug Resistance To BW25113∆acrB
Drug susceptibility test was conducted using BW25113∆acrB strains transformed with pMal-HP
acrB or pBAD33-HP acrB (Table 6.2). None of the strains showed increased activity for any
drug tested comparing to negative control. This result indicated that either H. pylori AcrB cannot
be expressed in E. coli or cannot functionally replace E. coli AcrB. Two vectors were tested here.
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The main difference between pMal-pIII vector and pBAD 33 vector is the copy number. pMalpIII is a high copy number vector generally leading to high protein expression yield. But some
proteins, especially membrane proteins, are reported to be toxic when expressed at high level. An
alternative low copy number vector pBAD33 was also used. However, neither high nor low copy
number vectors yielded any colonies with increased drug resistance when transformed into
BW25113∆acrB.

5. 3. 3 Co-transformation Of H. pylori AcrB And AcrA Into BW25113∆acrB Strain
The efflux pump required all three components, AcrB, AcrA and TolC, to properly assemble to
be functional. AcrB from H. pylori might not be compatible with E. coli AcrA. The sequence
similarity of E. coli AcrA and H. pylori AcrA was much lower than that of AcrB (Figure 5.2). I
co-transformed both AcrB and AcrA from H. pylori into BW25113∆acrB. This time I directly
plated transformed cells on LB agar plates containing kanamycin, ampicillin, chloramphenicol
and specific antibiotic substrates. Any colonies that could grow on these plates would harbor the
high drug tolerance. Two colonies, HPA/B-1 and HPA/B-2, were able to grow on LB agar plates
containing novobiocin after two days’ incubation at 37ºC. These were the only two colonies that
were ever obtained to grow on agar plates that contained both substrate and antibiotics. No other
transformation effort was successful. I characterized these two colonies to determine the
mechanism of increased drug resistance.
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Figure 5.2 Sequence alignment of AcrA from H. pylori (HP) and E. coli (Ecoli) with online
server T-COFFEE.

5. 3. 4 Restriction Enzyme Treatment Of HP A/B-1 And HP A/B-2
First, to clarify whether the resistance was from H. pylori AcrB expression, I used restriction
enzyme digestion to verify the plasmids and Western blot analysis to examine AcrB expression.
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Two vectors with ampicillin and chloramphenicol resistance gene, respectively, were used in this
study. Thus, the plasmids extracted were a mixture of pBAD-HPacrB and pET22b-HPacrA
Enzymatic digestion using NdeI/XhoI and NdeI/HindIII were used to verify the plasmids (Figure
5. 3).

1

2

3

4

5

6

3kb
1kb

Figure 5.3 Restriction enzyme digestion of plasmids extracted from HPA/B-1 and HPA/B-2.
From left to right: 1 kb protein ladder, 100 bp protein ladder (New England Biolabs, MA),
HPA/B-1 digested with NdeI/XhoI, HPA/B-2 digested with NdeI/XhoI, HPA/B-1 digested with
NdeI/HindIII, and HPA/B-2 digested with NdeI/HindIII. The positions of 3 kb and 1 kb bands
were marked, respectively.

In both colonies, a band of approximately 3kb showed up when treated with NdeI/XhoI, which
was in accordance to the size of H. pylori AcrB. When treating with NdeI/HindIII, the DNA was
excised mainly into two fragments of approximately 5 kb and 1.2 kb in size. The 5 kb band was
consistent with the vector size. The band around 1.2 kb was consistant with the size of H. pylori
acrA gene. The difference in the intensity of the band was due to the efficacy of the treatment.
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The restriction enzyme digestion results indicated that plasmids of H.pylori acrB and acrA did
exist in both colonies.

5. 3. 5 Western Blot Analysis Of AcrB Expression In HPA/B-1 And HPA/B-2
Next, Western blot was used to examine the protein expression level of H. pylori AcrB in the
membrane vesicle. Two kinds of E. coli AcrB antibodies were used, antibody one was raised
against full sequence E. coli AcrB and antibody two recognizes the last 14 amino acids of E. coli
AcrB. It was first used by Nikaido et al. and displayed a strong affinity to E. coli AcrB.
According to the sequence alignment result, the 1032-1045th amino acids of E. coli and H. pylori
AcrB are quite different (Figure 6.1). As a result, the peptide antibody was not expected to
recognize H. pylori AcrB. Membrane vesicles from both colonies were extracted and
immunoblotted (Figure 6.4). BW25113ΔacrB expressing E. coli AcrB, pMal-pIII HPacrB,
pBAD33 HPacrB, both pET22b HPacrA and pBAD33 HPacrB (inactive colonies) were used as
controls.

107

Figure 5. 4 Western blot analysis of membrane extract from different AcrB strains with AcrB
antibody (top) and peptide antibody (bottom). From Left to right: 1) BW25113 strain; 2) HPA/B1; 3) HPA/B-1 with 1 mM IPTG; 4) BW25113∆acrB with HPacrA and HPacrB plasmids,
inactive colonies; 5) BW25113∆acrB with pBAD33 HPacrB 6) BW25113∆acrB with pMal
HPacrB; 7) BW25113∆acrB with pBAD33 HPacrB in the presence of 3.2 µg/mL novobiocin; 8)
purified E. coli AcrB.

Only in the active colonies, an extra band can be detected by E. coli AcrB antibody. In some of
the Western blot results with full length antibody, two bands were detected. Only the lower band
was proved to be related to AcrB (data not shown). No bands showed up in those colonies with
low drug resistance. This implied the MIC difference between colonies was result from the extra
bands. At the same time, this band cannot be recognized by peptide antibody, indicating this
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band is not E. coli AcrB. MoreoverAcrB substrate novobiocin (3.2 µg/mL) was added to induce
additional protein expression. However, no induction was observed.

In the original design of the gene, a poly-histidine tag was introduced at the end of H. pylori
AcrB. Protein purification was attempted taking advantage of the tag. Unfortunately, no protein
could be obtained. This suggested the band on the western blot membrane, which was previously
assumed to be H. pylori AcrB was possibly some other proteins.

5. 3. 6 MIC Analysis Of HPA/B-1 And HPA/B-2 After Plasmids Loss
A plasmid loss method was used to probe the mechanism behind the observed decrease of drug
susceptibility in the two colonies. First, the colonies were cultured for several days in the
absence of selective markers to stimulate the growth of bacterial strains harboring no exogenous
plasmids. Cultures were then plated onto LB agar plates containing only kanamycin. Single
colony was picked to ensure the homogeneity of the culture. Colonies who cannot survive in
chloramphenicol and ampicillin were selected. Next, drug susceptibility assay were performed
for the colonies with no plasmid (Table 5.2). Since the substrate of H. pylori AcrB is still
unknown, multiple antibiotics have been tested, including erythromycin, novobiocin, nalidixic
acid, tetracycline, and neomycin. BW25113∆acrB containing only H. pylori AcrA plasmid or
AcrB plasmid were used as negative controls. The MIC of the colony without plasmids was the
highest among all strains, suggesting the drug resistance of HP A/B-1 and HP A/B-2 was solely
from the bacterial strains. During the culturing period, introduction of foreign antimicrobials
stimulated the evolution of bacterial strains. However, HPA/B-1 and HPA/B-2 showed no
enhanced drug tolerance to tetracycline, which is an E. coli AcrB substrate. The observation and
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Western blot result confirmed that there was no E. coli AcrB contamination in HP A/B-1 and
HPA/B-2. Furthermore, the neomycin MICs of HPA/B-1, HPA/B-2, and plasmid loss strain
were increased to larger than 64 µg/mL, which greatly exceeded the reported MIC of E. coli
straining expressing AcrD, 12 µg/mL. Therefore, I speculated that it was not AcrD that affected
the drug resistance either. It was reported AcrF level was elevated by 80 folds in ∆acrAB strain
[ref]. It is possible that the high drug susceptibility was the effect of the AcrF. Since tetracycline
is substrate of AcrF. The result that the bacterial strain cannot extrude tetracycline proved that
the AcrF was not the determine factor in HPA/B-1 and HPA/B-2. In conclusion, the reason
caused enhanced susceptibility in HPA/B-1 and HPA/B-2 was still unknown. The Western blot
analysis result using full length AcrB antibody suggested the higher drug tolerance might come
from the elevated expression of another protein with a sequence similar to AcrB.

Table 5. 2 Drug susceptibility of BW25113∆acrB expressing different plasmids.
Plasmids

nalidixic acid

erythromycin

novobiocin

tetracycline

neomycin

HPacrA

<1.25

<4

32

<1.25

>64

HPacrB

<1.25

32

16

<1.25

>64

HP A/B-1

10

128

>256

<1.25

>64

HP A/B-2

10

128

>256

<1.25

>64

No plasmid

10

128

>256

<1.25

>64

WT E.coli AcrB

5

128

>256

10

>64
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5. 4 CONCLUSION
Due to the technical difficulties in culturing H. pylori, heterologous expression of proteins in a
foreign host such as E. coli became a convenient approach in protein engineering. Expression of
H. pylori AcrB and AcrA in E. coli was attempted. Under the conditions tested, AcrB from H.
pylori failed to express in E. coli. In the two colonies with high drug tolerance, the increased
drug susceptibility was resulted from induced evolution during long culturing time. Addition of
antibiotics in the culture stimulated the expression of an unknown protein which is similar to
AcrB in protein sequence. This protein was unlikely to be neither AcrD nor AcrF.

Copyright © Meng Zhong 2013

111

CHAPTER VI. SURA STRUCTURAL FLEXIBILITY AND ACTIVITY—INSIGHT
INTO MECHANISM OF PERIPLASMIC MOLECULAR CHAPERONE FUNCTION
6.1 INTRODUCTION
Gram-negative bacteria cells have two layers of membranes. The outer membrane of the gramnegative bacteria consists of lipoproteins, lipopolysaccharides, phospholipids, and proteins. The
outer membrane proteins (OMPs) family is large. There are more than sixty OMPs in Gramnegative bacteria. Most of these proteins form porins, mainly for transportations of substances in
and out of cell.200 All porins share a β-barrel structure assembled by multiple anti-parallel βstrands. The center of porins is a hydrophilic pore. As a result, in general porins serve as the
major channels in the outer membrane for the translocation of small hydrophilic compounds. The
size of the central pore in porins is normally quite small. In E. coli only moleculessmaller than
600 Da can pass through the channel.201
OMPs are first synthesized in the cell cytoplasm. Later the nascent protein is recognized by
signal recognition particles and released from ribosome. After it is translocated through the inner
membrane by the Sec machinery, the N-terminus signal peptide is digested by the N-signal
peptidase.202 Then the β-barrel protein presursors are delivered through the periplasmic space
and finally inserted into the outer membrane. Due to the high hydrophobicity of the protein
sequence, periplasmic molecular chaperones are required to assist the OMP folding process and
prevent them from aggregation.76
So far, three major periplasmic molecular chaperones have been discovered in Escherichia coli.
They are SurA, Skp, and DegP.76 They share redundant chaperone activities in helping folding
and maturing of OMPs. According to the current understanding, among the three chaperones,
SurA is the primary chaperone that is involved in most OMPs’ biogenesis. Those OMP
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intermediates that fall off the SurA pathway are saved by Skp and DegP.203 Recently Zhao and
Coworkers studied the kinetics of OMPs interaction with the three chaperones. Their hypothesis
is that because of the much faster kinetics of OMP interaction with SurA and Skp than with
DegP, SurA and Skp may function at the early stage of OMP biogenesis, while DegP acts at a
later time.77 It has also been found that OMPs density dropped drastically in SurA deficient strain,
while little has been affected in the Skp and DegP deficient strain.80,

204, 205

Two potential

explanations have been proposed for the drastic change of OMP density. First, in SurA deficient
E

strain, σ transcription factor is induced, which subsequently down regulates mRNA level of
several OMPs and leads to a decrease of OMP synthesis rate.204-207 Second, without SurA, large
amounts of nascent OMPs in the periplasm cannot be stabilized and thus aggregate.80,

208

Furthermore, depletion of SurA leads to an increased sensitivity to hydrophobic drugs and
detergents. However, no direct evidence has been discovered to show correlation between a
change of OMP density and outer membrane permeability.209, 210
SurA was first identified as an essential gene in Escherichia coli for stationary phase survival.207
Crystal structure of SurA showed four domains: an N- terminus domain with the first 150 amino
acids, two peptidyl prolyl isomerase (PPIase) domains of approximately 100 residues each, and a
C- terminus domain. The N, C-terminal domains and the first PPIase domain assemble into a
core structure, with the second PPIase segment forms a satellite domain about 30 Å
away.82Deletion of the two PPIase domains has been shown to have no impact on SurA
chaperone activity. A truncated SurA construct containing only the N-terminal and C-terminal
(NCt) domains is sufficient to restore SurA activity in a surA gene knockout strain in vivo.209 The
mechanism of interaction between SurA and OMPs has been the subject of many studies.8183,211,212

However, how SurA recognizes and binds to nascent OMPs still remains unclear. It is
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generally acknowledged that peptides containing an A-X-A fragment would preferentially
interact with SurA, in which A is an aromatic and X is a random residue. Such fragments appear
in a high frequency in OMPs. Using phage display, Mckay and coworkers identified several
peptides that showed strong affinity towards SurA. Through an isothermal calorimeter study, two
of the peptides have been shown to compete with unfolded OMPs to bind with SurA. However,
the co-crystallization of SurA and these peptides demonstrated that both peptides interacted with
the first PPIase segment of SurA, which is known to be irrelevant to the chaperone function.213 In
terms of the SurA-OMP interaction, neither the binding site(s) nor potential structural
rearrangement during the interaction has been elucidated. Herein, we conducted extensive
mutagenesis studies to identify critical residues and site(s) on SurA for its activity. In addition, I
limited the structural flexibility of SurA through the introduction of four individual disulfide
bonds. I found that SurA was highly tolerant to mutations and not likely to undergo large scale
conformational change while conducting its function cycles.

6. 2 MATERIALS AND METHOD
Cloning, Protein Expression and Purification.
SurA has been expressed in both periplasm and cytoplasm. For cytoplasmic SurA expression,
surA gene lacking the signal peptide sequence was amplified from the genomic DNA of E. coli
strain K-12 with primer csurAFW and csurARV and cloned into vector pET22b in frame
between NdeI and XhoI sites. For periplasmic SurA, full length surA gene was amplified using
primer psurAFW and psurARV and cloned into vector pMal-pIII in frame between NdeI and
EcoRI sites. A polyhistidine tag was introduced into the C-terminus of both proteins to facilitate
purification. pMal-pIII SurA N-C was amplified from constructed pMal-pIII SurA using
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overlapping PCR. First, psurAFW and P2, P3 and psurARV were used to amplify SurA N- and
C- domain, respectively. Later, psurAFW and P4 were used to add linker and poly-histidine tag
to amplified SurA N-domain. Finally, psurAFW and psurARV were used to connect SurA Nand C- domains. Site directed mutagenesis was conducted following the manufacturer’s manual
using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, USA). All
primers used were listed in table 6.1. All sequences were confirmed by DNA sequencing
(Operon, USA).

Table 6.1 DNA primers used for the construction of cytoplasmic SurA, periplasmic SurA and
periplasmic SurA N-C.
Primer

Sequence

csurAFW

5’-TTAACATATGGCACCACAGGTAGTCGATAAAGTCG-3’

csurARV

5’-TTAACTCGAGGTTGCTCAGGATTTTAACGTAGG-3’

psurAFW

5’-TTAACATATGAAGAACTGGAAAACGCTGCTTC-3’

psurARV

5’-ATAGAATTCAGTGATGGTGGTGATGATGAGAACCACCGTTG-3’

P2

5’-ATGATGATGATGGCTTCCGTTCAGCTCAGTGCTG-3’

P3

5’-CACCACCATCACAGTGGT CGTAATGTCGATAAAACCGAC-3’

P4

5’-CGACCACTGTGATGGTGGTGATGATGATGATGGCTTCCGTTC-3’

For SurA expression, plasmids were used to transform E. coli BW25113∆surA strain. Cells were
grown at 37°C in LB medium supplemented with 100 μg/mL ampicillin and 50 µg/mL
kanamycin to an OD600 of 0.6, and then induced with 1 mM isopropyl-Dthiogalactopyranoside (IPTG). Cytoplasmic SurA was purified as described.212 For
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periplasmicSurA, the periplasmic fraction was prepared by osmotic shock and later purified
using metal affinity chromatography as described (pMal Protein Fusion and Purification System
manual, Qiagen literature, Qiagen Inc., Chatsworth, CA). A phosphate buffer (25 mM Naphosphate, 10% glycerol, 200 mM NaCl) supplemented with 20 or 250 mM imidazole was used
in the washing and elution steps, respectively. Purified SurA was dialyzed against the phosphate
buffer to remove excess imidazole. The same phosphate buffer was used throughout the study
unless otherwise noted.

Purified proteins were analyzed using SDS-PAGE with a 12%

homogeneous polyacrylamide gel and visualized after Coomassie Blue stain.

Protein

concentrations were determined using the BCA protein assay.
OmpF gene was amplified from E. coli genome without N-terminus signal peptide by PCR. PCR
product was digested with NdeI and HindIII, and inserted into pET22b vector. A poly-histidine
tag was added at the C-terminus of the protein. The protein was expressed under IPTG (1mM)
induction for 4 hours at 37ºC. Cells were harvested and lysed by sonication. The supernatant was
discarded and the pellet was dissolved using 30 mM Tris buffer, 100 mM NaCl, 8 M urea
(pH=8.0). The soluble part was incubated with urea pretreated Ni-NTA resin for 45 mins. Next, a
buffer containing 30 mM Tris, 100 mM NaCl, and 8 M urea supplimented with 10mM or 40mM
imidazole was used to wash the resin. Finally, a buffer containing 20 mM NaAc-HAc and 8 M
urea buffer (pH=4.0) was used for protein elution. After elution, Tris was added immediately to
adjust the pH to 8.0.
Expression level of SurA
Freshly transformed colonies of BW25113ΔsurA containing plasmid-encoded SurA were used to
inoculate LB medium supplemented with ampicillin and kanamycin. After cultured at 37°C for 6
h, cells were harvested and subjected to osmosis shock as mentioned above in the purification of
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periplasmic SurA. The supernatant containing periplasmic SurA was analyzed using SDS-PAGE
on a 12% gel, and then transferred to a polyvinylidene difluoride membrane (Millipore, Bedford,
MA) for Western blot analysis using a polyclonal rabbit anti-SurA primary antibody and
analkaline phosphatase-conjugated anti-rabbit (Abcam, Cambridge, MA) secondary antibody,
and then protein-antibody conjugates were visualized using nitroblue tetrazolium chloride and 5bromo-4-chloro-3’-indoyl phosphate p-toluidine (Sigma-Aldrich, St. Louis, MO) as substrates.

SurA activity assay
surA gene knockout E. coli strain (BW25113ΔsurA) was used as the host cell.
BW25113∆surAstrains harboring plasmids encoding wild type (WT) surA (pMal-SurA) or the
empty vector pMal-pIII were used as the positive and negative controls, respectively. Plasmids
encoding different SurA mutants were used to transform BW25113ΔsurA as well. SurA activities
in different strains were tested using two methods, a drug susceptibility assay and an OMP
expression level assay.

Drug susceptibility assay
A single colony was used to inoculate a LB media supplemented with 100 μg/mL ampicillin and
50 μg/mL kanamycin. Exponential-phase cultures of different strains were diluted to OD600nm
of 0.1 using LB broth. 10 µL of this culture was used to inoculate 1 mL LB media containing the
indicated concentration of novobiocin. The cultures were incubated overnight at 37°C. The next
morning, the minimum inhibitory concentration (MIC) was determined as the lowest
concentration that inhibited the growth of the bacteria. Each experiment was repeated at least
three times.
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FimD and OmpA expression level assay
Different strains of E. coli cells were grown in LB media, at 37ºC to an OD600nm of 0.8. Outer
membrane fractions were extracted as described with some modifications.214 Briefly, cells were
collected by centrifugation, lysed using French press, followed by ultracentrifugation at
100,000g for 1.5 h. The pellet was resuspended in buffer A (50 mM Na-phosphate, 100 mM
NaCl, 1% N-lauryl sarcosinate, pH 7.5) and incubated at 4ºC for 1 h. The outer membrane
fraction was then further isolated by ultracentrifugation at 100,000g for 1.5 h. The pellet was
then resuspended in a denaturing buffer B (4 M urea, 2% SDS, 50 mM Na-phosphate, 100 mM
NaCl, pH 7.5, 10 mM EDTA) and sonicated for 5 min. All samples were centrifuged for 5 min at
16,000g and the soluble component was analyzed using SDS-PAGE. Next, proteins on the gel
were transferred to a polyvinylidene difluoride membrane and detected using Western blot as
described above except that an anti-FimD antibody (a kind gift from Dr. Luis Angel Fernandez)
was used as the primary antibody.

Circular Dichroism (CD) Spectroscopy
CD Spectra were collected using a JASCO J-810 spectrometer (JASCO, United Kingdom) with 1
nm bandwidth. Blank scans were performed using phosphate buffer. Spectra were then corrected
for background by subtracting the blank scan.

Fluorescence Spectroscopy
Fluorescence emission spectra were collected using a Perkin Elmer LS-55 fluorescence
spectrometer (PerkinElmer, Waltham, MA) at 4°C. Tryptophan emission of SurA was monitored
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at an excitation wavelength of 280 nm. Blank scans were collected and subtracted from the
spectra.

Protease Accessibility Assay
A trypsin to SurA molar ratio of 1:200 was used in the experiments. The reaction was performed
in phosphate buffer at room temperature for the indicated period of time, and then
phenylmethylsulfonyl fluoride (PMSF) was added to a final concentration of 2 mM to stop the
reaction. SDS loading dye was then added and the samples were immediately heated at 95°C for
5 min before analyzed using SDS-PAGE.

Fluorescent labeling
SurA Cys pair mutants were freshly expressed in BW25113ΔsurA as described above. Cell was
o

harvested by centrifuge at 4,000g for 20 min at 4 C and then resuspended in ice cold Buffer A
(30 mM Tris buffer, 20% sucrose, 1 mM EDTA). After incubated for 10 min on ice, cells were
o

collected using centrifugation at 8,000g for 20 min at 4 C. Cell pellet was resuspended again in
ice cold water containing 5 mM MgSO4 and 1 mM PMSF. 10 mM iodoacetamide (IAM) was
added to block all the free thiol groups. Periplasmic extraction was then separate from the cell
debris through centrifugation and applied to a Ni-NTA column. All subsequent wash and elution
buffers contained 5 mM IAM. After purification, maleimide (MAL) and SDS were immediately
added to protein samples to final concentrations of 50 mM and 4% (w/v), respectively. SurA and
its mutants were then precipitated, reduced using DTT and labeled using a thiol specific
fluorescence probe fluoroscein-maleimide (Sigma-Aldrich, St. Louis, MO) as described.58
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Quantification of levels of disulfide bond formation
Extent of disulfide formation was quantified as described.58 Briefly, I included IAM during the
protein purification process to prevent the formation of disulfide bond during protein purification.
After purification, Ireduced the disulfide bond in the sample using DTT and then labeled the
sample using excess fluorescein-maleimide. To quantify the extent of disulfide bond formation, I
included two internal control samples: for the positive control sample, I did not add IAM during
protein purification. Therefore, all Cys in the protein was labeled after reduction (100% labeling).
For the negative control, IAM was used during protein purification, but the sample was not
reduced using DTT before labeling. Therefore, there should not be any labeling (0% labeling).
The extent of disulfide bond formation could then be calculated as a ratio of (Isam-Ineg)/(Ipos-Ineg),
in which Isam, Ineg, and Ipos were band intensities of the sample, and negative and positive controls,
respectively.

Fluorescence polarization study of SurA and OMPs interaction under macromolecular
crowding condition
SurA was incubated with FITC with a ratio of 1:2 in 20 mM PBS buffer (pH=7.4) at room
temperature for 1 hr. Tris-HCl was added to quench the reaction for 0.5 hr. Excessive dyes were
dialyzed overnight. The concentration of the protein was determined by Bradford assay.
Fluorescence polarization based titration was performed on a Perkin-Elmer LS-55 ﬂuorescence
spectrometer (Perkin-Elmer, Waltham, MA) at 20 ºC. FITC-SurA was first diluted into 400 µL
Tris buffer to a final concentration of 2 µM. Purified OmpF was added into FITC-SurA,
fluorescence polarized was recorded. The excitation and emission wavelengths of FITC-SurA
were 479 and 515 nm, respectively.
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6.3 RESULTS AND DISCUSSION
6.3.1 Identification of residues critical for SurA function
The aim of our research is to identify amino acids that are important to SurA chaperone function.
Potential residues critical for function could be identified through sequence alignment. SurA is
highly conserved in most Gram-negative bacteria.213, 215-217I aligned the sequence of SurA from
E. coli with its homologues from six different organisms using the online sequence alignment
tool T-coffee (Figure 6. 1).218

Figure 6.1 Sequence alignment of SurA from E. coli (EC) with homologues from Pantoea
ananatis (PA), Pseudomonas stutzeri (PS), Zymomonas mobilis (ZM), Vibrio vulnificus (VV),
and Nitrobacter hamburgensis (NH). The numbers indicate positions of the starting and ending
residues in the sequence of E. coli SurA. Asterisks, colons and periods indicate identical,
conserved and semi-conserved residues, respectively.
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The majority of conserved amino acids resided in SurA N, P1, and C-terminal domains. Since
SurA chaperone activities are proved to be independent from the PPIase domains, our mutations
were focused on conserved residues in N- and C-terminal domains (NCt). In these two domains,
4 residues are invariable, and 48 residues are conserved, which is 26% of total amino acids in
NCt module. All the the invariable and conserved residues were mappedonto the crystal structure
of SurA. The focus of our study was SurA chaperone function. Residues that contributed to intramolecular interactions and were mostly likely to be important for maintaining the structural
integrity of SurA were eliminated from our mutational studies.

Mymutation studies were

focused on conserved residues that were exposed to the surface, whose side chain appeared not
to be making critical intra-molecular interaction. Drug susceptibility assay of BW25113ΔsurA
containing plasmids encoding different SurA mutants was used as an initial tool to examine the
effect of the mutations. The same strains containing plasmid encoded wild type (WT) SurA or
the empty vector were used as the positive and negative controls, respectively. Twenty three
residues were mutated individually, and only one mutation, Val-37 to Gly, showed a dramatic
decrease of SurA activity (Table 6. 2).
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Table 6.2 Novobiocin MIC of BW25113∆surA expressing plasmid encoded surA mutants.
Mutants
BW25113
pMal-pIII
V32G
V37G
D41K
V42C
M114G
Y120A
Y125A
Y128A
Q131G
I132G
E135G

MIC
(µg/mL)
128
16
64
16
128
128
128
128
128
128
128
128
128

Mutants
Y398A
N403A
K405A
E408A
W413G
Q415A
E416A
R418G
Y422A
I425A
M136G
Deletion of L153-Q163

MIC
(µg/mL)
128
128
128
64
128
128
128
128
128
128
128
128

6.3.2 SurAV37G has decreased expression level and structural stability
To determine what caused the reduction of

MIC level in SurAV37G, I first examined the

expression level of the mutant as compared to that of the WT SurA in BW25113∆SurA (Figure 6.
2).
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Figure 6.2 SurA expression levels in different strains. Western blot analysis of osmotic fluid
from BW25113, BW25113ΔsurA, and BW25113ΔsurA containing plasmid-encoded WT SurA,
SurAV37G and SurAV37G/A30C/I425C (SurAV37G CC).

An anti-SurA antibody was used. The

molecular masses of bands in the molecular mass marker were marked on the left of the gels.

It appeared that SurA was not stable in vivo, since a large amount of SurA degraded fragments
could be observed. In the case of SurAV37G, only fragments were observed. Full length SurA
could barely been detected. It was likely that the mutation drastically decreased the stability of
the protein, which led to insufficient amount of SurA in the periplasm to carry out the chaperone
function.
To further compare the structure and stability of WT SurA and SurAV37G, I characterized both
proteins purified from the cytoplasm. Studies have shown that SurA purified from the cytoplasm
has the same structure and function as those purified from the periplasm.82
I first examined the structure of SurAV37G and WT SurA by CD. Far-UV CD spectra of
SurAV37G and WT SurA superimposed well, suggesting both proteins had similar secondary
structure. Both proteins are approximately 50% alpha-helical, which is consistent with solved
SurA crystal structure (Figure 6. 3A).
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Figure 6.3 Characterization of SurAV37G (grey) and WT SurA (black). A) Far-UV CD spectra.B)
Tryptophan emission spectra. Excitation wavelengths were 280 nm.

I also compared tryptophan fluorescence spectrum of WT SurA with that of the mutant (Figure 6.
3B). The fluorescence of SurAV37G was slightly higher than WT SurA, indicating that the local
microenvironment was different, possibly a consequence of mutation. In summary, the data from
CD and fluorescence spectroscopy indicated that while the secondary structure compositions of
the two proteins were very similar, there was some change in the global structure as revealed by
the fluorescence difference.
The low level of full length SurAV37Gin vivo suggested that the mutation affected SurA stability.
To further examine protein stability, Iperformed limited trypsin digestion on both SurAV37G and
WT SurA using purified proteins (Figure 6. 4). Protease digestion hasbeen used extensively in
studies of protein stability and rigidity.156-158 SurAV37G and WT SurA were treated with trypsin
and the progress of digestion was monitored over time using gel electrophoresis. Approximately
90% of SurAV37G was digested within 5 min while 60% of WT SurA remained intact after 30
min of trypsin treatment. The mutation did decrease SurA stability drastically.
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Figure 6.4 Limited trypsin digestion of purified WT SurA and SurAV37G. Typsin and protein
molar ratio is 1:200. Wild-type SurA was highly resistant to protease digestion, 63.3% remained
after trypsin treatment for 30 min. SurAV37G was more sensitive to trypsin digestion, with less
than 10% of SurAV37G left after 5 min. The molecular masses of bands in the molecular mass
marker were marked on the left of the gel.

6.3.3 V37G mutation affects the anti-parallelβ-sheet network of the N- and C-termini
A close examination of SurA structure showed that Val-37 locates in an N-terminal β strand,
which was involved in a three stranded anti-parallel β sheet involving the last few amino acids at
the C-terminus (Figure 6. 5B). Our hypothesis is that the β-sheet locks the N- and C-termini
together and thus plays an important role in stabilizing SurA tertiary structure. A mutation to Gly
might have disrupted the formation of the β-strand and/or its interaction with the neighboring
strands, and therefore destabilized the three-stranded β sheet. To examine if Val-37 to Gly
affected the local structure of the β sheet, I introduced a pair of Cys to monitor the formation of
disulfide bond (Figure 6. 5C).
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Figure 6.5 Structure of SurA. A. SurA N- (blue) and C- domain (red). Residues that are replaced
by Cys to introduce disulfide bond were highlighted, A30-I425 (1), V42-I70 (2), V89-I137 (3),
and V146-A410 (4). B. The same structure as in A, but rotated 90 degree along a vertical axis.
The black oval indicated the location a three-stranded antiparallel β-sheet formed by two stands
from the N-terminus and one strand from the C-terminus. C. A zoom in view of the β-sheet. Side
chains of Ala30, Val37, and I425 are shown in ball-and-stick model.

I introduced two Cys at positions 30 and 425 in SurA sequence as a reporter Cys pair. According
to the crystal structure of SurA, these two cysteines should be close enough to form disulfide
bond. If the Val-37 to Gly mutation caused a significant change of the β-sheet structure, then the
distance between the reporter Cys pair would be affected. Since disulfide bond formation is very
sensitive to distance, I should be able to see a difference in the level of disulfide bond formation.
I have developed an effective thiol trapping and fluorescent labeling protocol as reporters for
protein structural change.58 Using this method, I found that in SurAA30C/I425C, disulfide bond
formed completely between A30C and I425C (Figure 6. 6A).

127

However, when Val37Gly mutation was introduced to create SurAA30C/I425C/V37G, the extent of
disulfide bond formation was estimated to be approximately 50% (Figure 6. 6B). Therefore,
Val37Gly did affect the local structure of the β-sheet.

Figure 6.6 Characterization of SurAV37G/A30C/I425C (SurAV37G CC). A. Fluorescent image (F) and
Commassie Blue (CB) stain of SurAA30C/I425C (SurA CC) after fluorescent labeling. Lane1 and
lane3 were positive and negative controls, which were used to quantify the extent of disulfide
bond formation (see text). B. Fluorescent image (F) and Commassie Blue (CB) stain of
SurAA30C/I425C (SurA CC), SurAV37G CC, and WT SurA after fluorescent labeling. WT SurA was
used as a control to confirm the absence of non-specific labeling under the current experimental
condition.

6.3.4 Function loss in SurAV37G can be restored by a disulfide bond
When Ala30Cys/Ile425Cys mutations were introduced into SurAV37G, the disulfide bond
partially formed. I speculate that the disulfide bond may have stabilized SurA structure, and thus
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partially compensated for the function loss caused by V37G mutation. To examine if this was
actually the case, I performed drug susceptibility assay of SurAV37G/A30C/I425C. Consistent with our
expectation, MIC of SurAV37G/A30C/I425C toward novobiocin increased to 256 µg/mL, indicating
that the disulfide bond did improve SurA stability and activity (Table 6. 1). Furthermore, to
confirm that this increase of activity was actually caused by the formation of a disulfide bond, I
also measured the MIC of SurAV37G/A30C/I425C toward novobiocin in the presence of 5 mM DTT,
and found that the MIC reduced to a level comparable to SurAV37G (Table 6. 3). Under the same
condition, 5 mM DTT had no effect on the MIC of SurAV37G or wild type SurA. If the disulfide
bond improved the stability of SurA, there should be more full length SurA in the periplasm.

Table 6. 3 Novobiocin MIC of BW25113∆surA expressing plasmid encoded surA mutants.
Mutation

MIC (µg/mL)

A30C/I425C

256

A30C/I425C/V37G

256

A30C/I425C/V37G + 5 mM DTT

16

V37G + 5 mM DTT

16

WT SurA + 5 mM DTT
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I measured the expression level of SurA in BW25113∆surA containing plasmid-encoded
SurAV37G/A30C/I425C and SurAV37G (Figure 6. 2). Similar to SurAV37G, SurAV37G/A30C/I425C was
partially degraded in vivo. However, there was still a significant fraction of full length protein in
the case of SurAV37G/A30C/I425C, which was clearly sufficient to maintain the wild type level SurA
activity. Using quantitative Western blot analysis, I estimated that there were approximately
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1,500 molecules of SurA per cell in BW25113 strain (Fig 5. 7).

Figure 6.7 Quantitative western blot analysis of SurA expression level in BW25113∆0052 strain
expressing different plasmids. Western blot analysis of osmotic fluid from BW25113ΔsurA
containing empty pMal-pIII, plasmid encoded WT SurA, SurAV37G, SurAV37G/A30C/I425C
(SurAV37G CC), 30 ng, 90 ng, 270 ng, 810 ng, 2430 ng purified SurA (lane 1-lane 9).

When BW25113∆surA was transformed using the plasmid created in this study that encoded
wild type SurA, under basal expression condition there were ~3,500 molecules of SurA per cell.
However, this increase of SurA expression level did not further increase the MIC of the strain as
compared to that of the BW25113. When BW25113∆surA was transformed with plasmid
encoding SurAV37G/A30C/I425C, the copy number of full length SurA was approximately 1,000.
However, the MIC of the strain was twice the level of the wild type strain or surA knockout
strain transformed with plasmid encoded wild type SurA. This result revealed that E. coli need as
little as 1,000 or fewer SurA per cell for normal SurA activity and maintaining membrane
integrity. It is not clear why the MIC of BW25113∆surA containing SurAV37G/A30C/I425C was twice
as much as the MIC of the same strain containing wild type SurA. I have also tested the MIC of
BW25113∆surA containing SurAA30C/I425C and it was also twice as much at that of the wild type
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strain (Table 6. 3).

As an alternative method to examine the activity of SurA, I measured the expression level of
FimD in BW25113∆surA expressing plasmid encoded WT SurA, SurAV37G, or
SurAV37G/A30C/I425C (Figure 6. 8). Studies have shown that the FimD expression level in the outer
membrane depends on the function of SurA.219 Consistent with the MIC assay, while the levels
of FimD in cells containing WT SurA or SurAV37G/A30C/I425C were similar, the expression level in
cells without SurA or SurAV37G were significantly lower.

A)

OmpA
B)
Figure 6.8 FimD and OmpA expression levels in different strains. Western blot analysis of outer
membrane vesicles extracted from BW25113ΔsurA strain containing the empty vector (/) or
plasmids encoding WT SurA, SurAV37G, or SurAV37G CC. Anti-FimD and anti-OmpA primary
antibody were used. The positions of FimD and OmpA were marked by an arrow, respectively.
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6.3.5 Mutational Studies Of Hydrophobic Residues
Interaction between SurA and OMP precursors in the periplasm is reversible and non-covalent in
nature. The interaction between SurA and OMPs is poly-specific, in which SurA interacts with
various OMP precursors with different sequences and possibly various partially folded structures.
Therefore, I expect SurA to function according to one or both of the following mechanisms: 1)
The recognition and binding between SurA and OMPs rely heavily on hydrophobic interactions.
Hydrophobic interaction has been shown to play critical roles in poly-specific binding scenarios,
such as in the interaction between multidrug transporters and regulators and their array of diverse
substrates.110, 116 It has also been proposed as a major player in SurA-OMP interaction.217, 218 2)
The structure of SurA is very flexible and therefore can adapt to bind to different substrates. To
investigate the role played by hydrophobic interactions in SurA-OMP interaction, I mutated all
aromatic residues in the NCt domain individually and examined the effect of such mutations on
SurA function. Aromatic residues have bulky hydrophobic moieties that are usually abundant at
sites of low specificity binding.220 There are one Trp (W413), five Tyr (Y120, Y125, Y128,
Y398, Y422), and one Phe (F406) in the NCt domain (Figure 6. 9).
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Figure 6. 9 Structure of the SurA NCt domain showing the side chains of aromatic residues.

I replaced each residue individually with Ala. When introduced into BW25113∆surA, none of
these mutations caused a significant decrease of MIC values. In addition, I have mutated Y120,
Y125, and Y128 simultaneously to create a triple mutant SurAY120A/Y125A/Y128A. This
triple mutant has similar activity as WT SurA as well. These results suggested that none of the
aromatic residues investigated in this study played a dominant role in OMP binding. OMPs
might interact with SurA at multiple sites.

6.3.6 SurA structure flexibility is not required for its chaperone function
I next examined the relationship between SurA function and its structure flexibility. I have
shown earlier that a pair of Cys placed at positions 30 and 425 formed disulfide bond and the
formation of the disulfide bond had no negative impact on the function of SurA. To investigate if
disulfide bond introduced into other locations of SurA affect its activity, I introduced three
additional cysteine pairs strategically placed at different locations in the NCt domain (Figures 6.
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6A). According to SurA crystal structure, the distances between the α carbons of each Cys pair
are within 6 Å, which allows the formation of disulfide bonds.24 As shown in Figure 5. 10, Lanes
1 and 3 were positive and negative controls for the quantification of disulfide bond percentage.
The extents of disulfide bond formation were calculated as described in Experimental and
showed in Table 6. 4. Formation of disulfide bond was close to completion in all three pairs of
Cys. Next, I tested the activity of these mutants using the drug susceptibility assay and found that
they had similar activity as the WT SurA (Table 6. 5).

Figure 6.10 Secondary structure scheme of the NCt domain of SurA with theposition of
disulfide bonds shown. Arrows and rectangles denote β-strandsand α-helices, respectively
(Top).Fluorescent image (F) and Commassie Blue (CB) stain of three SurA cysteine pair mutants
after fluorescent labeling (Bottom). Lane1 and lane3 were positive and negative controls, which
were used to quantify the extent of disulfide bond formation
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Table 6.4 Percentage disulfide formation in Cys pairs as revealed by the percentage of
fluorescence labeling
Cysteine pair

Disulfide bond%

A30C-I425C

95.1±4.4

V42C-I70C

98.1±4.9

V89C-I137C

96.5±2.1

V146C-A410C

97.4±6.3

Table 6.5 Novobiocin MIC of three additional cysteine pair SurA mutants
Mutations

MIC (µg/mL)

V89C/I137C

128

V42C/I70C

128

V146C/A410C

128

Many chaperones, such as HSC70 and SecB, have been shown to undergo conformational
changes upon binding with their substrates.

221, 222

Here I introduced a disulfide bond at four

different locations in the functionally relevant NCt domain. To our surprise, while all four
disulfide bond formed in vivo, none of them had a negative impact on SurA function. Therefore,
SurA does not seem to undergo global conformational changes during its operation. Moreover,
SurA may function more effectively with a rigid structure, as one disulfide bond containing
mutant, SurAA30C/V425C, was even more active than the wild type SurA. However, the exact
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mechanism that caused the increase of MIC of cells containing this SurA mutant remains to be
determined.

6.3.7 Outer Membrane Protein Level In Different Strains Containing SurA Mutations
SurA affects bacterial drug susceptibility by changing the outer membrane permeability. The
outer membrane permeability is generally considered to be related to OMP level. However, there
is no direct evidence indicating that a reduced OMP level is associated with compromised cell
permeability. A reduced OMP level and decreased drug tolerance were observed simultaneously,
whether there is a connection in between remains unknown.

Western blot analysis was performed to examine OmpA level in strains containing different
SurA mutants. It has been demonstrated in a previous study that the two PPIase domains P1 and
P2 could be deleted without changing SurA function in maintaining outer membrane integrity.
Therefore, in this study, the SurA N-C construct was used. The antiparallel β-sheet has been
shown to be important to SurA stability in vivo. A SurA mutant, SurA10delN-C, has been identified
to confer poor drug tolerance when introduced into surA gene knockout strain [cite Brent’s
thesis]. However, Western blot analysis showed that the level of SurA10delN-C was comparable to
that of WT SurA. It is most likely that deleting the last ten amino acids caused SurA misfolding,
which eventually leads to defective cell membrane. This was the first AcrB mutant that has been
discovered with proper expression level and no activity. The discovery offered possibility to
establish the relationship between SurA chaperone activity and cell permeability.

OmpA expression level was compared in four mutants, BW25113∆surA strain expressing WT
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SurA, pMal-pIII vector, SurA10delN-C, and SurAM2-9 (Figure 6.11). SurAM2-9 was an active SurA
mutant identified in a separate study.223 First, MICs of novobiocin of the four strains were
measured (Table 6. 6).
Table 6. 6 Novobiocin MIC of SurAM2-9 and SurA10delN-C
Plasmids

MIC (µg/mL)

WT SurA

128

pMal-pIII

16

SurAM2-9

128

SurA10delN-C

16

SurA10delN-C

SurAM2-9

pMal-pIII

WT SurA

Figure 6. 11 OmpA expression level in BW25113∆surA strain expressing WT SurA, pMal-pIII
vector, SurAN-C, SurAM2-9

BW25113ΔsurA transformed with the empty vector pMal-pIII exhibited a lower OmpA level in
the outer membrane than cells expressing WT SurA. This finding is in agreement with published
result. However, OmpA level was supposed to increase in SurAM2-9 since it has the wild-type
MIC level. My results proved the opposite. The mutant with the lowest MIC, SurA10delN-C, had
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the highest OmpA level among the three mutants. The observation implied that there might not
necessarily be a connection between SurA chaperone activity and cell permeability. OMP levels
might not be directly correlated with membrane permeability. It is possible that SurA could also
be related to the biogenesis of some other components in cell membrane.

6.3.8 Interaction of SurA and OMPs under macromolecular crowding condition
An easy, sensitive, and convenient method to study SurA and OMPs binding is highly desirable.
Mckay and coworker used ITC to investigate the interaction. However, this method requires
large amount of proteins. here a fluorescence polarization based method was established in the
study of SurA and OMPs interaction. First, OmpF was titrated into FITC-SurA, fluorescence
polarized signal was collected. To prove the signal change does not result from non-specific
binding, titration of BSA to SurA was used as a control (Figure 5.12). Kd of OmpF to SurA is
1.23±0.16 µM.
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fluoroscence polarization

OmpF
BSA
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Protein concentration/µM

Figure 6. 12 Fluorescence polarization titration of OmpF (Black) and BSA (Red) into FITC
labeled SurA.
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The primary location of SurA activity is in the periplasm, which is filled with macromolecules
such as proteins and sugars. It is often important to evaluate the chaperone function in the
macromolecular crowding environment. I investigated whether the crowding condition affect
SurA-OMP interaction. Two macromolecular crowding reagents were used, Ficoll and Dextran.
The addition of Ficoll and Dextran increased the viscosity of the solutions. Consequently, the
signal change was much smaller. However, it seemed that the crowding condition had little effect
on the binding affinity between the two proteins. The Kds of SurA and OmpF in PB buffer, PB
buffer containing 30% ficoll, and 30% Dextran were 4.59, 5.13, 3.29 µM (Figure 6.13) OmpF is
dissolved in 8M urea, titration into PB buffer cause precipitation. The difference of Kd in Figure
6.12 and 6.13 might be resulted from the inaccurate concentration in buffer condition. In
summary, a simple method was established to examine SurA and unfolded OMPs interaction.
And this method can be used to measure the interaction under a crowding condition that
resembles the real situation in the periplasm.

PB buffer
30% Ficoll
30% Dextran

fluorescent polarization
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Figure 6. 13 Fluorescence polarization titration of OmpF in phosphate buffer (black) with the
addition of 30% Ficoll (red) and 30% Dextran (blue) into FITC labeled SurA.

139

6. 4 CONCLUSION
SurA is the primary periplasmic molecular chaperone that facilitates the folding and assembling
of the outer membrane proteins of Gram-negative bacteria. Deletion of SurA in Escherichia coli
leads to a decrease in outer membrane density and an increase in bacterial drug susceptibility. In
this study, the roles of structural flexibility and stability of SurA on its function were examined.
Through mutagenesis studies, a single V37G mutation was first identified that drastically
decreased the in vivo function of SurA. Further characterizations indicated that this mutation
disrupted the interaction between two anti-parallel β-sheets located at the N- and C- terminus of
SurA, respectively, which decreased the stability of the protein. SurA has no intrinsic cysteine.
The loss of activity in V37G could be restored through the introduction of a pair of cysteine and
the subsequent formation of a disulfide bond, which stabilized the interaction between the βsheets and therefore the structure of SurA. To further investigate the mechanism of SurA
function, I introduced four additional cysteine pairs distributed at different locations into the
SurA structure and confirmed that they all formed disulfide bonds. Next, the function of SurA
was examinedand the presence of disulfide bond was found to have no observable impact on
SurA function. These results indicated that the drastic decrease of structural flexibility, as a result
of disulfide bond formation, has little effect on SurA activity. Therefore, the function of SurA
appears to not require large scale conformational change. Additionally, the investigation of OMP
level and cell permeability further suggested that SurA affected cell permeability possibly by
other mechanisms other than by OMP abundance.

Copyright © Meng Zhong 2013
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CHAPTER VII. SITE SPECIFIC AND REVERSIBLE PROTEIN IMMOBILIZATION
BY A DNA BINDING FUSION TAG

7.1 INTRODUCTION
Protein immobilization is the crucial first step for many applications including the construction
of biosensors and protein microarrays, development of immunoassay methods, and employment
of enzymes in biotechnology procedures.224-227 Protein immobilization methods can be
categorized as nonspecific and site-specific. Normally, nonspecific immobilization is achieved
by physical adsorption or direct chemical reactions with amine, carboxyl, or thiol groups in the
protein.228,

229

It is difficult to control the extent of immobilization and orientation of the

immobilized proteinsince there is usually more than one single functional group in the target
protein. In addition, chemical modification of functional groups within a protein might change
protein structure, leading to protein function loss. This effect has been demonstrated by the
decrease of protein activities upon immobilization in many cases.230,

231

On the other hand,

physical adsorption is facilitatedbythe van der waals, electrostatic and hydrophobic
interactions.232 However, suchinteractions are weak, which can cause protein leaching.
A procedure that can produce a homogenous, stable, and active protein layer on a specific
surface is highly desirable. Affinity tags and fusion proteins are widely used in order to achieve
site-specific and oriented protein immobilization. After being modified with specific binding
domains and tags, proteins can be captured by the corresponding affinity matrixes.

Poly-

histidine tag (histag) is a popular choice and has been used in the immobilization of proteins on
the nickel nitrilotriacetic acid (Ni-NTA) resins.233-235 However, there are several limitations of
the binding specificity of the Ni-NTA resin. At least threeE. coli endogenous proteins has
showed certain degree of affinity to the resin.236 Also, if a protein is rich in histidine, it could
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interact with the resin nonspecifically; therefore compete with the target protein and complicate
the immobilization procedure. Other fusion domains have also being used to immobilize target
proteins, including the glutathione S-transferase, maltose binding protein, chitin binding protein,
streptag and metal binding peptide .237-239
Compared to protein, oligonucleotides are easier to be modified and specifically immobilized
due to its simpler structure and chemical composition.For example, DNA microarray is awellestablished and commercialized routine technique. It has been used extensively to direct the
assembly of proteins. In most of these studies, a ssDNA-target protein conjugation was first
created whichthen was attached to a matrix modified with the complementary strand of the
ssDNA.239-243These DNA-protein conjugates have been obtained through direct covalent links244249

,a biotin-streptavidin bridge250, or the expressed protein ligation251.RNA-protein fusions have

also been constructed for site specific protein immobilization252,

253

.However, there could be

some negative impacts on protein activity caused by the chemical modification in formation
process of the DNA/RNA-protein conjugate. In a more recent study, protein capture by a DNA
functionalized matrix was accomplished through the coiled-coil association of an engineered pair
of heterodimeric leucine zippers. One helix of the zipper was chemically linked to the DNA, and
the other helix was expressed as a fusion tag to the protein.254
To prevent the negative effects of chemical modification to the target protein, Iinvestigatedthe
incorporation ofa DNA binding protein as the fusion tag to direct the immobilization of the
protein of interest. Recently Gang and coworkers had shown that surface-bound DNAs could
serve as anchoring sites to immobilize DNA binding proteins.255Herein, I constructed a fusion
protein containing an N-terminus super-folder green fluorescent protein (sfGFP) and a Cterminus single-strand DNA binding protein (SSB). In this work, sfGFP was used as a reporter
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group to facilitate convenient characterization of immobilization, while SSB facilitated high
affinity binding toward single-stranded DNA.

The fusion protein sfGFP-SSB retained the

properties from both domains, being fluorescent and binding to single stranded DNA. In this
work, I have also demonstrated that SSB could be used as a fusion tag to facilitate fast and
convenient protein immobilization through the coupling with an ssDNA modified surface.

7.2 MATERIALS AND METHODS
Cloning, Protein Expression and Purification
The SSB and sfGFP gene was amplified by PCR. For SSB, the E. coli genomic DNA was used
as the template. The gene encoding sfGFP was obtained from Theranostech Inc. (Albuquerque,
NM, USA). The PCR products weregel purified, digested and inserted into similarly digested
pET28a expression vector to generate plasmid pET28a-SSB and pET28a-sfGFP, which
introduced a histag at the N-terminus of the proteins. Next, the gene of sfGFP was cloned into
the plasmid pET28a-SSB to generateplasmid pET28a-sfGFP-SSB. All sequences were
confirmed by DNA sequencing (Retrogen, CA, USA).
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Figure 7.1 Vector map of sfGFP-SSB, pET28a vector was used. Gene encoding sfGFP and SSB
were inserted between BamHI/NdeI and BamHI/XhoI restriction enzyme sites, respectively.

Plasmids pET28a-sfGFP-SSB, pET28a-sfGFP and pET28a-SSB were used to transform E. coli
strain ER2566 for protein production. The cells were grown at 37°C in LB medium containing
100 μg/mL kanamycin to an OD600nm of 0.6, and then induced with 1mM IPTG. Three hours
after induction, the cells were harvested by centrifugation at 7,000rpm for 10 min. The cell
pellets were resuspended in a binding buffer (100 mM Tris-Cl, 0.5 M NaCl and 10% glycerol,
pH 8.1) and lysed by sonication on ice for 10 mins with 10s on-off intervals. The cell debris was
removed by centrifugation at 12,000rpm for 15 min. DNaseI was added to the cleared lysate to
digest DNA at room temperature for 30 min. The cleared lysate was incubated with Ni-NTA
resin (Qiagen, Huntsville, AL) with shaking at room temperature for 45 min and afterward
loaded to an empty column. The resin was then washed witha buffer containing 100 mM Tris-Cl,
0.5 M NaCl, 10% glycerol and 50 mM imidazole (pH 8.1). Finally the protein was eluted with a
buffer containing 100 mM Tris-Cl buffer, 0.5 M NaCl, 10% glycerol and 500mM imidazole (pH
8.1). Purified sfGFP-SSB, sfGFP and SSB weredialyzed extensively against the binding buffer to
remove excess imidazole.
The purified proteins were analyzed using the SDS-PAGE with a 10% homogeneous
polyacrylamide gel and visualized with Coomassie Blue stain. Protein concentrations were
determined using the Bradford protein assay.

Fluorescence Spectroscopy
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Fluorescence emission spectra were collected using a PerkinElmer LS-55 fluorescence
spectrometer (PerkinElmer, Waltham, MA) at 20°C.

The buffer used for all fluorescence

measurements contains 100 mM NaCl and 100 mM Tris-Cl (pH 8.1).
Fluorescence quenching titration was used to measure binding affinity between sfGFP-SSB, SSB,
and ssDNA dT37. All oligonucleotideswere obtained from Integrated DNA Technology (San
Diego, CA), including dT37, dA35,the 5’ amine-derivatized dT37 (H2N-dT37), and the 5’ thiolderivatized dT37 (RSS-dT37).

dT37was titratedinto the protein solution and the tryptophan

fluorescence weremonitored at excitation and emission wavelengths of 282and 355nm,
respectively.

Protein immobilization
H2N-dT37 was attached to the NHS-resin (Sigma-Aldrich, St. Louis, MO). The NHS-resin was
first washed with 100 mM sodium-phosphate buffer (pH 7.4),and then incubated with H2NdT37(25μmol/L) at room temperature for 2 hours. Finally, Tris-HCl buffer was added to a final
concentration of 20 mM to quench the unreacted NHS groups. The modified resin was washed 3
times with 10 times the bed volume using 100mM Tris-HCl buffer (pH 8.1).
RSS-dT37 was attached to the DVS-A activated resin (Adar Biotech LTD, Rehovot, Israel). The
resin was washed using 100mM sodium phosphate buffer (pH 7.4). RSS-dT37 was first reduced
to form free thiols using 10mM TCEP in 100mM HAc-NaAc buffer(pH 5.4), and thenincubated
with the DVS-A resinat room temperature for 2 hours in 100mM sodium phosphate buffer (pH
7.4).

The reaction was then quenched using 20mM DTT.

washedusing the same phosphate buffer.
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The DNA modified resin was

To examine site-specific protein immobilization, sfGFP-SSB or sfGFP was incubated with the
DNA modified resins for 15 minutes, in which sfGFP was used as a negative control. Then the
resin was collected through centrifugation and washed3 times with 10 bed volumes of thesame
Tris-Cl buffer each time. Protein bound to the resin was quantifiedby subtracting the amount of
protein left unbound from the total amount of protein added. After protein immobilization and
washing, the resins were also examined directly under a fluorescent microscope (Nikon Eclipse
55i, Nikon Instrument Inc., Elgin, IL).

Reversibility of protein immobilization
After sfGFP-SSB was immobilized on NHS-dT37 and DVS-A-dT37 activated resins in a Tris-Cl
buffer (pH 8.1), the effect of different pHs on protein-substrate dissociation was examined.
HAc-NaAc buffer was used for pHs 4, 4.5 and 5.0. Sodium phosphate buffer was used for pHs
5.5, 6, 6.5 and 7. Tris-HCl buffer wasused for pHs 7.5, 8, and 8.5. Sodium-glycine buffer was
used for pHs 9, 9.5, 10 and 10.5. The indicated buffer (100 mM) was added to sfGFP-SSB
modified resin and incubated at room temperature for 30 min. The fluorescence intensity in the
supernatant was determined to estimate the quantity of protein dissociated from the beads. The
effect of pH on the intrinsic fluorescence of sfGFP-SSB was characterized and adjusted for.

7.3 RESULTS AND DISCUSSION
7.3.1 Construction of fusion protein sfGFP-SSB
Aiming at developing a reversible and site specific method for protein immobilization, I
examined the prospect of immobilizing proteins through a DNA binding fusion tag. I created a
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fusion protein containing the protein of interest and a ssDNA binding module. To facilitate
convenient detection and characterization, I have chosen sfGFP as the model target protein.
sfGFP was fused with SSB at the C-terminus. Furthermore, a histag was introduced at the Nterminus of the fusion protein to facilitate convenient purification. As controls, pET28a-histagsfGFP and pET28a-SSB were also constructed.
Histag

sfGFP

SSB

Figure 7.2 The construct of the fusion protein, which contains a N-terminus histag, followed by sfGFP,
and a C-terminus SSB.

7.3.2 Purification and activity assay of sfGFP-SSB
I was able to express and purify the fusion protein as well as individual modules, sfGFP and SSB,
in high yield. Both sfGFP and SSB will be used as controls in future experiments. Figure 7.3
showed the SDS-PAGE analysis of all three proteins. The calculated molecular weights of the
proteins using amino acid sequence are 29.0 kDa (sfGFP), 22.5 kDa (SSB) and 48.1 kDa
(sfGFP-SSB).
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Figure 7.3 SDS-PAGE analysis of purified sfGFP (lane 1), SSB (lane 2) and the sfGFP-SSB
fusion protein (lane 3). The molecular weight of the three proteins are 29.0 (sfGFP), 22.5 (SSB)
and 48.1 (sfGFP-SSB) kDa. Positions of the molecular weight markers are indicated by arrows.

It is critical to prove SSB is a tetramer, which is responsible for its interaction with ssDNA. I
examined the quaternary structure of the fusion protein using the size exclusion chromatography
(Figure 7. 4). The retention time of the fusion protein is around 20.4 min, close to the second
peak of molecular weight standard (20.7 min). The shorter retention time indicated the size of
protein is slightly larger than the molecular weight of the second standard, which is 158 kDa.
Since the molecular weight of each sfGFP-SSB subunit is 48.1, this result suggests that the
fusion protein is likely to be a tetramer.

Normalized A280nm
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Figure 7.4 Size exclusion chromatography analysis of the fusion protein (black trace). The grey
trace is the molecular weight standard. From left to right, the peaks correspond to 670, 158, 44,
and 17 kDa, respectively.
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To examine the influence of fusing on properties of each individual module, I measured the
fluorescence emission as well as the ssDNA binding affinity of the fusion protein. I first
compared the fluorescent emissions of sfGFP and sfGFP-SSB. There is a red shift of the
emission peak, from 509 nm for sfGFP to 512 nm for sfGFP-SSB (Figure 7.5). The peak shift is

Fluorescent Intensity

likely due to the local environmental change with the addition of SSB at the C-terminus.
40

20

0
500

525

550

Wavelength (nm)
Figure 7.5 Fluorescent emission spectra of sfGFP (open square) and sfGFP-SSB (filled triangle)
measured with the excitation wavelength of 490 nm. The concentration of both proteins is 45
nM. The maximum emission wavelengths of sfGFP-SSB and sfGFP are 512nm and 509nm,
respectively.

Figure 7.6 shows the plots of fluorescent intensity of each protein at increasing concentrations.
Linear fitting of the plots for sfGFP and sfGFP-SSB yielded slopes of 0.752 and 1.436,
respectively. The linear range of fluorescence vs. protein concentration was from 1 nM to 1 μM.
Slopes of the two lines show that the fluorescent intensity of the fusion protein is enhanced by
approximately one fold compared to that of the sfGFP.
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Figure 7.6 Fluorescent intensity of different concentration of

sfGFP-SSB and SFGFP

concentration. Linear curve for sfGFP is Y=0.752[sfGFP]-16.205, linear curve for sfGFP-SSB is
Y=1.436[sfGFP-SSB]-8.850.

I then examined the ssDNA binding affinity of sfGFP-SSB, SSB was used as a control. Previous
studies showed that when SSB bound to dT37,the tryptophan fluorescence of the protein
decreased.256Based on the percentage of fluorescent quenching, the binding affinity between SSB
and dT37 could be determined.

sfGFP has one tryptophan, W57.

Intrinsic tryptophan

fluorescence emission of sfGFP is very small compared to that of SSB, which won’t interfere
with the SSB tryptophan fluorescence titration (Figure 7.7a).

The excitation and emission

wavelengths were 282 and 355 nm, respectively. Under our experimental condition, the intensity
of sfGFP emission was about 3% of the intensity of SSB emission. Furthermore, the addition of
dT37 had no effect on the emission of sfGFP (Figure 7.7b).
Finally, I compared the effect of dT37 on sfGFP-SSB and SSB tryptophan fluorescence (Figure
7.7c).

The fluorescence quenching curvesof the two proteins superimposed well in the

concentration range examined (between 10-9.5M to 10-7M), and matched the result from the
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literature for SSB.257 This result indicates that the ssDNA binding affinity of SSB was not
affected in the fusion protein.
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Figure 7.7 a) Tryptophan fluorescence spectra of sfGFP (grey) and SSB (black) when excited at 282 nm.
b) Tryptophan fluorescence spectra of sfGFP before (black) and after adding 3.75*10-7 dT37 (gray). b)
Fluorescence quenching of sfGFP-SSB (grey) and SSB (black) in the presence of dT37. The excitation
and emission wavelengths are 282 and 357 nm, respectively. The concentrations of both proteins are
4.2×10-7 M.

7.3.3 Cation, pH dependent sFGFP-SSB and resin binding
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Interaction between SSB and ssDNA was highly dependent on pH and cation concentration.258260

I expect the binding of sfGFP-SSB to dT37 to be sensitive to changes of pH and cationic

concentration as well. Therefore, Icharacterized their interaction at different pHs (pH 8.1 and pH
10) and NaCl and MgCl2 concentrations, aiming at identifying conditions that could enable
reversible protein immobilization. There were two major binding modes between SSB and dT37,
named (SSB)35 and (SSB)65. The subscripts refer to the length of the oligonucleotides
interactingwithone SSB tetramer (35). In the (SSB)35 binding mode, ssDNA only interacts with
two of the four SSB subunits in a tetramer. On the other hand, in the (SSB)65 binding mode, all
four subunits participate in DNA binding. The switch between the two binding modes is
sensitive tochanges in pH, temperature, andcation concentrations.

For example, when the

concentration of Na+ is less than 10mM, the main binding mode is the (SSB)35 mode. And,
(SSB)65 mode is the main binding mode when Na+ concentration is higher than 200mM. For
MgCl2, such a switch happens at a much lower Mg2+ concentration, usually the switch to (SSB)65
mode occurs at 5 mM MgCl2. I examined the effect of NaCl and MgCl2 on the ssDNA binding of
the fusion protein. I found that sfGFP-SSB behaved very much like the free SSB. ssDNA
titration experiment using dT37 showed that fluorescence quenching reached a plateau at 60% in
1 mM NaCl. While in the presence of 2.5mM MgCl2, 90% of the tryptophan emission was
quenched (Figure 7.8A).
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Figure 7.8 A) sfGFP-SSB and dT37 binding monitored as tryptophan fluorescence quenching in the
presence of 1 mM NaCl, 25 mM Tris-Cl, pH 8.1 (triangle) or 1 mM MgCl2, 25 mM Tris-Cl, pH 8.1
(diamond). The concentration of sfGFP-SSB is 1.4×10-7 M. B) sfGFP-SSB and dT37 binding at pH 6.9
with 2.5 mM MgCl2 (square) or pH 10 with 1 mM NaCl (triangle).

These results indicate that the fusion protein also has two binding modes, similar to the two
binding modes of SSB. There are two binding sites per SSB tetramer (each binding site contains
two SSB subunits). A negative cooperation exists between bindings at these two sites.260As salt

153

concentration decreases, this negative cooperation increases. This explains why the percentage
fluorescence quenching upon binding was different in the presence of 1mM NaCl or 2.5 mM
MgCl2.
Next, I examined a series of pH and cation concentrations and their combinations to identify
conditions that maximize or minimize the interaction between sfGFP-SSB and dT37. These two
conditions could be used potentially as the binding and elution conditions during protein
immobilization experiments. I found that pH6.9, 2.5mM MgCl2 was the best condition for
sfGFP-SSB and dT37 binding, while pH 10, 1mM NaCl minimized this binding (Figure 7.8 B).

7.3.4 Reversible immobilization of sfGFP-SSB on NHS- and DVS-A activated resin
To examine the binding of sfGFP-SSB with immobilized ssDNA, I first covalently attached
chemically derivatized dT37 to a solid matrix. Two kinds of chemical reactions were tested for
the attachment: amine-derivatized ssDNA to NHS functionalized resin and thiol-derivatized
ssDNA to DVS-A activated resin. After the modification, the resins were washed extensively to
remove the unreacted ssDNA. Next, sfGFP-SSB or sfGFP were incubated under the same
experimental condition in the presence of the modified resins. I used sfGFP as a negative control
to examine the effect of non-specific interaction between the protein and the beads. After
incubation, the resins were separated from excess proteins by centrifugation and washed
extensively using the binding buffer. The white color of the modified resins indicated that
nonspecific binding of sfGFP was very weak compared to the SSB facilitated specific binding
(Figure 7.9).

154

a)

b)

Figure 7.9 Protein immobilization on NHS-dT37 (a) or DVS-A-dT37 (b) resins. In each panel, the resins
in the microcentrifuge tubes were incubated with sfGFP-SSB (left) or sfGFP (right), and then washed
extensively.

Next, fluorescent microscope was used to further characterize both types of resins incubated with
sfGFP or sfGFP-SSB (Figure 7. 10). The control resins were not fluorescent, further confirming
the lack of nonspecific interaction. The amount of sfGFP-SSB immobilized was determined to
be around 2.6or 1.8 mg protein per ml of drained NHS or DVS-A activated resins.

Figure 7.10 Protein modified NHS-dT37 (a, b and c) and DVS-A-dT37 (d, e and f) imaged using
fluorescent light (a, b, d and e) or normal white light (c and f). Resins in panels a and d were treated with
sfGFP-SSB. Resins in panels b, c, e and f were treated with sfGFP.

An immobilization method that is reversible is highly desirable as it introduced an additional
level of flexibility to the process. I evaluated twoapproaches to elute the protein off the resins:
addition of the complementary dA35 oligonucleotideand change of pH/salt concentration. I first
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examined the reversibility of sfGFP-SSB interaction with the immobilized dT37 through the
addition of dA35. Binding of the two oligonucleotides generated double stranded DNA, which
did not bind to SSB. Eluted sfGFP-SSB was quantified through its fluorescence emission. In the
presence 125μM dA35, 82.4% of bound protein was eluted within the first 10 min of incubation
(Figure 7.11).

% Elution

100

50

0
0

30

60

Time (min)

Figure 7.11 Effect of incubation time on protein elution by dA35 and glycine buffer (pH=10).
82.4% and 68.4% of protein could be eluted by dA35 and glycine buffer in 10 minutes,
respectively.

156

In addition, the resin could be regenerated by the treatment of free dT37, which competitively
bound to dA35 and removed them from the resin. Addition of fresh sfGFP-SSB changed the
color of the resins from white to green again (Figure 7.12).

Figure 7.12 Reversible immobilization of sfGFP-SSB on NHS-resin. NHS-dT37 resins modified
with sfGFP-SSB (left), elutedusing dA35 (middle), and then regenerated and incubated with fresh
sfGFP-SSB (right).

To identify a more cost effective and convenient method to release the fusion protein from the
resin, I examined the effect of pH/salt concentration on the elution of the fusion protein. I found
that 68.4% of sfGFP-SSB could be eluted by the condition identified above (Na-glycine buffer, 1
mM NaCl, pH 10). To examine the reversibility of binding, the pH value of the protein eluate
was adjusted to 8.1 and mixed with fresh resins. In parallel, fresh sfGFP-SSB was added to the
resinafter pH mediated elution and re-equilibration. In both cases, sfGFP effectively bound to
the resin.
7.7 CONCLUSION
In summary, I have demonstrated that SSB could serve as a versatile fusion tag to facilitate
ssDNA-mediated protein immobilization. SSB is very stable and shows no negative effect of the
overall expression and stability of the fusion protein. The binding between SSB and ssDNA is
very tight, with nM affinity. And yet such interaction can be attenuated through the change of
pH/salt concentration, which could serve as a convenient method to elute the immobilized
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protein and regenerate the surface without denaturing the fusion protein. Compared to other
DNA- or RNA-mediated protein immobilization methods, our approach has the advantage of not
requiring additional chemical modification. And thus, an array of potential complications related
to chemical modifications is avoided, including selectivity, specificity, extent of chemical
reaction, purification of the modified protein, and protein denaturation issues.

Copyright © Meng Zhong 2013
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